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Summary 
Cellular immunity is pivotal for the control of pathogens. An impairment of cellular 
immunity, as observed after HIV infection or upon immunosuppressive medication after 
organ transplantation, increases the risk of infectious complications. This risk seems to 
depend on both the quantity and functional quality of the pathogen specific immune 
response. 
Current diagnostic approaches to monitor pathogen specific T cell responses like 
commercially available interferon- release based ELISA and Elispot assays are able to 
quantify immune responses but do not assess T cell phenotype and functionality.  
This thesis therefore concentrated on evaluation of functional and phenotypical changes in 
pathogen specific T cell responses during different stages of chronic infections. Another aim 
was to use these characteristics as biomarkers for monitoring disease activity.  
Our studies on Cytomegalovirus (CMV) infection in kidney transplant recipients revealed that 
T cell functionality during CMV primary infection and reactivation is impaired. This is 
reflected by a decreased ability to produce an array of mainly proinflammatory cytokines 
and a constrained proliferative capacity. We could show that the impaired functionality is 
linked to the expression of the inhibitory T cell receptors PD-1, TIM-3 and CTLA-4 and at least 
partly reversible via inhibitory pathway blockade. Furthermore, our data indicate that 
expression analysis of inhibitory receptors on CMV specific T cells might be able to predict 
reactivation and relapse. Interestingly, we found that the parallel loss of the co-stimulatory 
receptors CD27 and CD28 on CD4 T cells occurs rapidly after primary CMV infection and is 
closely linked to CMV serostatus. In the future analysis of CD28-CD27- CD4 T cells, especially 
in combination with anergy markers, might be used as a method for the rapid, stimulation 
independent assessment of CMV specific immunity. 
Our studies on tuberculosis infection revealed that both functional and phenotypical analysis 
of M. tuberculosis specific T cell responses allow the diagnosis of patients with active 
infection with high specificity and reasonable sensitivity. The highest diagnostic power was 
achieved by combined analysis of the T cell receptors CD27 and CTLA-4.  
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The study on HIV patients in Tanzania and Germany, which was done in collaboration with 
Dr. Schütz, provided basic insight on the impact of regular exogenous or endogenous antigen 
rechallenge on the maintenance of pathogen specific T cell responses in HIV-
immunodeficiency.  
The results of this thesis clarify that a combination of functional and phenotypical markers 
for characterisation of pathogen specific T cells allows a more precise estimate of disease 
activity in vivo. In the future, this might be used for improved immune monitoring and 
contribute to an individualised guidance of therapy. 
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Zusammenfassung 
Die zelluläre Immunantwort spielt eine essentielle Rolle bei der Kontrolle von 
Krankheitserregern. Eine Schwächung der zellulären Immunität, wie sie nach HIV-Infektion 
oder unter immunsuppressiver Medikation im Rahmen der Organtransplantation 
beobachtet werden kann, geht mit einem erhöhten Risiko für infektiöse Komplikationen 
einher. Dieses scheint sowohl von der Quantität als auch von der Qualität der Erreger-
spezifischen Immunantwort abzuhängen. Gebräuchliche diagnostische Verfahren zum 
Nachweis Erreger-spezifischer T-Zellantworten, wie die auf Interferon- Freisetzung 
basierenden ELISA und Elispot Methoden, erlauben eine quantitative Analyse der 
spezifischen Immunantwort, liefern jedoch keine Informationen über deren Phänotyp und 
Funktionalität.  
Daher lag der Fokus dieser Doktorarbeit auf der detaillierten Charakterisierung 
grundlegender phänotypischer und funktioneller Veränderungen in der Erreger-spezifischen 
Immunantwort während unterschiedlicher Stadien chronischer Infektionen. Ein weiteres Ziel 
bestand darin, diese Charakteristika als neue Biomarker zum Monitoring der Erregeraktivität 
zu evaluieren.  
Unsere Studien zur Charakterisierung der spezifischen Immunantwort gegen das 
Cytomegalievirus (CMV) bei nierentransplantierten Patienten zeigten, dass die  
T-Zellfunktionalität während CMV-Primärinfektion und Reaktivierung beeinträchtigt ist. Dies 
spiegelt sich in einer reduzierten Produktion von überwiegend proinflammatorischen 
Zytokinen und einer eingeschränkten proliferativen Fähigkeit wider. Wir konnten einen 
Zusammenhang zwischen der erhöhten Expression der inhibitorischen T-Zellrezeptoren  
PD-1, TIM-3 und CTLA-4 und einer verminderten Funktionalität nachweisen, welche durch 
deren Blockade zumindest teilweise wiederhergestellt werden konnte. Des Weiteren legen 
unsere Daten nahe, dass die Expressionsanalyse von inhibitorischen T-Zellrezeptoren auf 
CMV spezifischen T-Zellen Reaktivierungsereignisse und Rezidive vorhersagen kann. 
Interessanterweise zeigte sich, dass ein paralleler Verlust der beiden kostimulatorischen 
Rezeptoren CD27 und CD28 auf CD4 T-Zellen zeitnah nach CMV-Primärinfektion auftritt und 
eng mit dem CMV-Serostatus korreliert. Die Analyse der CD27-CD28- CD4 T-Zellen, 
insbesondere in Kombination mit Anergiemarkern könnte zukünftig als Methode zur 
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schnellen stimulationsunabhängigen Bewertung der CMV-assoziierten Immunität eingesetzt 
werden.  
Unsere Studien zur Tuberkuloseinfektion zeigten, dass sowohl die Analyse von funktionellen 
als auch phänotypischen Veränderungen auf M. tuberculosis spezifischen CD4 T-Zellen dazu 
geeignet ist, eine aktive Tuberkulose mit hoher Spezifität und guter Sensitivität zu 
diagnostizieren. Bei kombinierter Analyse der beiden T-Zellrezeptoren CD27 und CTLA-4 war 
die diagnostische Aussagekraft am höchsten.  
Die in Kooperation mit Dr. Schütz in Tansania und Deutschland durchgeführte Studie bei HIV-
infizierten Patienten lieferte grundlegende Erkenntnisse zur Bedeutung von 
wiederkehrendem endogenem und exogenem Antigenkontakt für das Aufrechterhalten 
Erreger-spezifischer Immunantworten im Kontext der Immundefizienz nach HIV-Infektion.  
Die Ergebnisse der hier vorliegenden Arbeit verdeutlichen, dass eine Kombination 
phänotypischer und funktioneller Marker zur Analyse pathogenspezifischer T-Zellen eine 
präzisere Abschätzung der Erregeraktivität in vivo erlaubt. Dies könnte zukünftig zur 
verbesserten Immundiagnostik von chronischen Infektionen genutzt werden und einen 
wichtigen Beitrag bei der individuellen Therapiesteuerung leisten.  
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1 Introduction 
1.1 The human immune system 
The human immune system functions to protect the organism from invading pathogens and 
to eliminate degenerated and carcinogenous cells. It consist of the innate and the adaptive 
immune system, which work together to keep up the integrity of the body. 
1.1.1 The innate immune system 
The first line of defense consists of physical (skin and mucosa), chemical (pH value of skin 
and gastrointestinal passage, antimicrobial enzymes and peptides) and microbacterial 
(symbiotic bacteria which compete with pathogenous bacteria) barriers, which prevent the 
majority of pathogens from entering tissues and the blood system. The few pathogens which 
overcome these barriers are attacked by the effector cells of the innate immune system, 
predominantly comprising macrophages, granulocytes and NK cells. They are assisted by the 
humoral parts of the innate immune system such as the complement system, acute phase 
proteins, lectins and cytokines. Pathogens are detected via structures foreign to the body, 
such as peptidoglycan and mannose, or infected cells are unspecifically recognised by the 
lack of major histocompatibility complex (MHC) molecules, which are expressed on all 
healthy cells of the body. Long-term control of pathogen cannot be achieved by the innate 
immune system alone, and therefore requires induction of adaptive immunity. 
1.1.2 The adaptive immune system 
The adaptive immune system comprises T and B lymphocytes, as well as antibody producing 
plasma cells, which are specifically induced towards individual pathogens. Induction and 
expansion of these cells occurs in secondary lymphoid tissues, where B- and T cells 
encounter foreign antigen presented by antigen-presenting cells (APC). The cells of the 
adaptive immune system carry antigen specific receptors called T cell receptor (TCR) and  
B cell receptor (BCR). During the development of the immune system a repertoire of 
approximately 1011 T and B lymphocytes evolves, each carrying their individual antigen 
specific BCR and TCR. Many of the immature lymphocytes recognise self-antigens but are 
eliminated during the maturation process in the thymus (T cells) and the bone marrow  
(B cells). A few autoreactive cells may escape this negative selection. These cells are kept in 
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check by the mechanisms of peripheral tolerance to prevent the onset of autoimmune 
diseases. After maturation in the bone marrow, naive B cells migrate into secondary 
lymphoid tissues. Upon antigen presentation and activation by T helper cells, they 
differentiate into antibody producing plasma cells and memory B cells. During maturation in 
the thymus, T cells differentiate into T helper (CD4) T cells, cytotoxic (CD8) T cells and 
regulatory (CD4 CD25high CD127low) T cells. As with B cells, these naïve T cells home to 
secondary lymphoid tissues for potential recognition of foreign antigen. Whereas the main 
function of CD8 T cells is killing of infected or abnormal cells, CD4 T cells have a broad array 
of functions, such as activating CD8 T cells and B cells and recruiting leukocytes to the site of 
infection. Regulatory T cells are a subpopulation of CD4 T cells, which down-regulate 
immune responses and play an important role in preventing immune pathology and 
autoimmunity. CD8 T cells predominantly recognize 8-10 amino acid long peptides of 
cytosolic origin, which originate from intracellular antigens and are presented via MHC class I 
molecules on APC or infected somatic cells. CD4 T cells predominantly recognize 13-17 
amino acid long antigen-peptides of extracellular origin, which are presented by APC in an 
MHC class II restricted manner. Yet, the mechanisms of cross-presentation and autophagy 
enable the presentation of extracellular antigens in a MHC class I restricted manner and 
cytosolic antigens in a MHC class II restricted manner, respectively (JANEWAY et al., 2007). 
1.2 Antigen recognition, maturation and differentiation of T cells 
Naïve T cells remain functionally inactive until contact with their specific antigen epitope, 
which needs to be presented via MHC molecules on professional APC in the lymphoid organs 
in the presence of co-stimulatory receptors (Figure 1). Antigen mediated activation of naïve 
T cells induces proliferation and differentiation into many effector and a few central memory 
T cells. After antigen clearance further T cell proliferation is dampened by inhibitory T cell 
receptor signalling, and inhibitory cytokines secreted by regulatory T cells. Together, these 
signals mediate apoptosis of excessive effector cells and quiescence of memory T cells 
(Figure 1).  
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Continuous antigen specific stimulation of T cells leads to further differentiation into effector 
memory T cells and finally into terminally differentiated effector memory T cells (TTE). In 
contrast to naïve T cells, activation of antigen experienced memory T cells can occur 
independent of co-stimulation and is mediated not only by professional APC in secondary 
lymphoid tissues but also by antigen presenting somatic cells (JANEWAY et al., 2007). Each of 
this differentiation stages is marked by the expression of specific maturation markers (Figure 
2). Typical maturation markers comprise functionally relevant co-receptors needed for T cell 
activation (e.g. CD28, CD27) and T cell homeostasis (e.g. CD127) as well as chemokine 
receptors needed for lymph-node homing (e.g. CCR7 and CD62L) and two isoforms of CD45, 
CD45RA and CD45R0, which facilitate T cell activation. Whereas naïve T cells express all T cell 
activation markers and chemokine receptors, these molecules are lost in a stepwise fashion 
with increasing differentiation (Figure 2).  
 
 
 
 
Figure 1: Antigen presentation. Antigens are presented by antigen presenting cells (APC) as small peptides in 
the context of MHC class I and class II molecules to antigen specific CD8 or CD4 T cells, respectively. Co-
stimulatory (via CD28) and co-inhibitory signals (via CTLA-4) lead to T cell activation and inhibiton, respectively. 
Reprinted by permission from Macmillan Publishers Ltd: Nature, (APPELBAUM, 2001) 
citation), copyright (year of publication) 
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1.3 Persistent pathogens and their interplay with the immune system 
Whereas most infections are efficiently cleared after primary infection by a combined effort 
of innate and adaptive immunity, a few pathogens are able to evade clearance and establish 
livelong persistence in the host. Common pathogenic strategies to establish persistence are 
concealment in immune privileged compartments (e.g. neurons), interference with the host 
immune response, and the establishment of phases without metabolic activity and 
replication, a state termed latency.  
Cytomegalovirus (CMV) and Mycobacterium tuberculosis (M. tuberculosis) are two clinically 
relevant persistent pathogens that constantly challenge the adaptive T cellular immune 
response of the host. For both pathogens, the maintenance of sufficient amounts of antigen-
specific T cells is crucial to control infection. Whereas a fair amount of data on quantitative 
analysis of pathogen specific T cell responses exists, there is little knowledge on the 
phenotype and functionality of these cells in diverse clinical situations. Likewise, the 
dynamics of antigen-specific T cell characteristics upon chronic antigen stimulation in 
relation to rapid antigen clearance is poorly characterised and may be studied by comparing 
 
CD45RA + - - + 
CCR7 + + - - 
CD62L + + - - 
CD28 + + -/+ - 
CD127 + + +/- - 
CD27 + + +/- - 
Figure 2: Memory T cell differentiation. Expression of typical markers of differentiation in naïve T cells (TN), 
central memory T cells (TCM), effector memory T cells (TEM) and terminally differentiated effector memory T 
cells (TTE). Figure adapted from (MAHNKE et al., 2013). 
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patients with persistent infection with individuals after vaccination, where time, dosing and 
duration of antigen challenge are clearly defined. This might help to define phenotypical and 
functional differences between chronic and self-limiting infections. If different states of 
pathogen replication and disease activity could be linked to function and phenotype of the 
pathogen specific immune response, this might be of importance to improve current 
diagnostic strategies.  
To date it is still not fully understood what drives the differences in frequency and 
maintenance of antigen specific immune responses against different chronic pathogens. 
Patients with primary HIV infection suffer from a massive initial loss in CD4 T cells in general, 
and it is unclear how restoration of antigen specific CD4 T cell responses that re-emerge 
thereafter is driven. In stem cell transplant recipients it has been observed that the re-
emerging immune responses after severe lymphopenia do not necessarily resemble that of 
the stem cell source (GANDHI et al., 2003). It is therefore of great interest, to elucidate if 
restoration of antigen specific T cell responses is predominantly driven by equal expansion of 
precursor T cells or if it is driven by antigen prevalence. As the prevalence of M. tuberculosis 
is high in sub-saharian Africa but low throughout Europe, analysis of M. tuberculosis specific 
immunity in HIV infected patients might be a means to elucidate the influence of antigen 
prevalence on restoration of antigen specific responses.  
1.3.1 Cytomegalovirus infection 
Cytomegalovirus (CMV), also known as human herpesvirus 5 (HHV-5) contains a double 
stranded DNA of 230.000 basepairs and belongs to the herpesviridae family (subfamily 
betaherpesviridae). Like all herpesviridae, CMV establishes live long latency upon primary 
infection. In the western world the seroprevalence ranges from 30 to 70 percent and 
increases with age (CANNON et al., 2010; HEALTH, 2010). CMV infection occurs most 
commonly in the first three years of life via breast feeding and smear infections, and in 
young adults via sexual contacts. Primary infection in immunocompetent individuals is 
usually asymptomatic with flu-like symptoms accompanied in some cases by lymph node 
swelling and lymphopenia. CMV is transmitted via all cell-containing bodily fluids, as the 
virus is strictly cell associated (BOWDEN et al., 1995). CMV infects nearly all cell types but 
live long persistence is only established in leukocytes, with monocytes as the predominant 
reservoir. After primary infection, virus is shedded in high loads in urine and saliva with 
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prolonged shedding being observed in congenitally and perinatally infected children. 
Sporadic reactivation is self-limited and only minimal amounts of virus are shedded in this 
situation (ROSS, BOPPANA, 2005). Whereas CMV is effectively controlled by the immune 
system in immunocompetent individuals it causes serious infectious complications in 
congenitally infected infants and in immunocompromised individuals. CMV infection is the 
most common congenital infection (0.5-1% of infants infected) and primary CMV infection of 
the mother during pregnancy results in 30 to 40 percent congenital infection of the fetus. 
Eight to ten percent of infected infants are born with severe mental retardation. Another 10 
to 15 percent of children appear asymptomatic at birth but develop long-term damages, in 
particular hearing loss years after. CMV transmission from seropositive mothers has a 
significantly lower incidence and a reduced risk for fetal damage, compared to primary 
infection during pregnancy. Perinatal and postnatal infections are usually asymptomatic 
except in premature or immunocompromised infants (FOWLER et al., 1992; ROSS, BOPPANA, 
2005; STAGNO et al., 1986). 
1.3.1.1 Cytomegalovirus infection in transplant recipients 
Infection with human CMV is one of the most common infectious complications after organ 
transplantation. Clinical CMV disease is marked by fever, pneumonia, hepatitis, 
gastrointestinal complications, encephalitis or retinitis. Furthermore, CMV infection 
negatively affects graft function in the long-term (BRITT, ALFORD, 1996; FISHMAN, RUBIN, 
1998). Unlike immunocompetent individuals, where viral replication is largely contained by 
immunological control mechanisms, immunosuppressive drug treatment after 
transplantation may disrupt the balance between immunological control and viral replication 
(SESTER et al., 2001; SESTER et al., 2005). The overall risk of CMV disease post-transplant is 
mainly determined by the donor and recipient serostatus, the type of organ transplanted 
and the dosing of immunosuppressive drugs (LOWANCE et al., 1999; SMILEY et al., 1985; 
SPEICH, VAN DER BIJ, 2001). CMV seronegative transplant recipients of a seropositive donor 
are at particularly increased risk, due to the following reasons. Firstly, the lack of a pre-
existing CMV specific immunity enables a rapid, unlimited replication of the virus until a 
protective antiviral response is generated. Secondly, the induction of a protective antiviral 
immune response is impaired in the presence of immunosuppressive drugs following 
transplantation. Finally, higher initial viral loads may be transferred via the transplanted 
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organ, than in natural infection. CMV seropositive recipients of a seropositive or 
seronegative organ are at moderate risk for CMV disease post-transplant. In this situation, a 
pre-existing protective CMV specific immunity may be quantitatively and functionally 
affected by the type and dosage of immunosuppressive drugs after transplantation (KOTTON 
et al., 2013b). The use of T cell depleting antibodies for induction therapy further increases 
the risk for CMV disease in this patient cohort post-transplant (ISSA, FISHMAN, 2009).  
Minimisation of CMV infectious complications after transplantation implies the need for 
preventive and therapeutic strategies adapted to the individual risk profile of a patient. 
These measures include either antiviral prophylaxis for the first 3 to 6 month post-transplant 
or pre-emptive therapy, where antiviral therapy is guided by regular monitoring of viral load 
or antigenemia. Both approaches have led to a substantial decrease in CMV disease in the 
last decade (KOTTON et al., 2013b). Antiviral prophylaxis is strongly recommended for CMV 
seronegative recipients of a seropositive organ, as it reduces the risk of transplant 
transmitted CMV primary infection or delays primary infection to a later time point post-
tranplant, where immunosuppression is already reduced. In seropositive transplant 
recipients with pre-existing CMV specific immunity, pre-emptive therapy is a viable 
alternative to prophylaxis. The advantages of pre-emptive therapy are reductions in 
treatment costs and side effects of medication, yet one has to take into account the need of 
close monitoring scheme and the associated diagnostic costs (KOTTON et al., 2013b). An 
additional disadvantage of universal prophylaxis is the occurrence of late onset disease after 
completion of antiviral prophylaxis (KOTTON et al., 2013b). A possible but more costly 
solution to prevent occurrence of late onset disease would be a hybrid approach with 
prolonged close viral load or antigenemia monitoring after completion of prophylaxis. Yet, 
one general methodological limitation of viral load and antigenemia monitoring, is that it 
measures viral reactivation and hence cannot predict it. Whereas this is sufficient to prevent 
CMV disease it cannot prevent asymptomatic infections, which have been shown to have a 
detrimental impact on graft survival (SAGEDAL et al., 2004). 
An approach to more specifically identify patients at risk for infectious complications may 
include monitoring of CMV specific immunity. Previous work by our group suggests, that 
complementary monitoring of the individual CMV specific immunity in a pre-emptive setting 
might help to identify patients with CMV infection and/or disease and hence reduce a 
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negative impact of CMV on graft survival (SESTER et al., 2001; SESTER et al., 2005; SESTER et 
al., 2008b). Furthermore, the assessment of a patient´s CMV specific immunity after 
completion of prophylaxis might help to adjust further monitoring and treatment according 
to the individual immunocompetence (MANUEL et al., 2013).  
1.3.2 Mycobacterium tuberculosis infection 
Infection with M. tuberculosis is a leading cause of morbidity and mortality worldwide, 
accounting for nearly 1.3 million deaths annually and ranks second among deaths attributed 
to infectious diseases (WHO, 2013). Tuberculosis (TB) mortality is highest in developing 
countries, as malnutrition and HIV coinfection are major risk factors for active  
M. tuberculosis disease and sufficient medication is often not available (WHO, 2013). The 
primary route of infection is through bacteria containing droplets, which enter the lungs via 
the upper airways. M. tuberculosis resides and replicates primarily in macrophages. These 
cells are effective in targeting and killing microbes, but are reprogrammed by M. tuberculosis 
(HOUBEN et al., 2006). Upon uptake in phagosomes, M. tuberculosis halts phagosome 
maturation and uses them as their primary reservoir. After primary infection, M. tuberculosis 
is typically contained by an array of immune cells, consisting of macrophages, fibroblasts,  
B- and T lymphocytes. This formation of cells is called granuloma and prevents dissemination 
of bacteria. Inside the granuloma, M. tuberculosis can enter a state of dormancy, which 
allows persistence with little or no replication over years and decades. Reactivation of  
M. tuberculosis occurs most likely in the setting of immunosuppression, caused by a 
destabilization of granulomas. As CD4 T lymphocytes play a crucial role in sustaining 
granuloma structure and HIV leads to massive CD4 T cell depletion, HIV co-infection is a 
major promoter of M. tuberculosis reactivation, making HIV-TB co-infection one of the 
biggest challenges to global health (SESTER et al., 2010; WHO, 2013). To make matters worse, 
multidrug resistant tuberculosis is on the rise in many regions worldwide, mostly due to non-
adherence to the elaborate and costly treatment regimens (WHO, 2013). Because of the 
slow doubling time and a robust metabolism, recommended treatment comprises 6-9 month 
of therapy with a combination of four different antibiotics. Slow doubling time also impedes 
diagnostics, as culture of M. tuberculosis, which is still regarded the gold standard, can take 
up to six weeks. Sputum microscopy or PCR are more rapid but less sensitive and rely on 
patients’ ability to produce potentially infected sputum. Therefore, these approaches are 
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not suited to diagnose novel still asymptomatic infections or screen for latent infections with 
M. tuberculosis (PAI, O'BRIEN, 2008). Immunological assays are indirect methods commonly 
used for screening of a latent infection with M. tuberculosis. The classical immunological 
assay to diagnose latent tuberculosis infection is the tuberculin skin test, which is nowadays 
complemented or replaced by blood-based interferon gamma release assays (IGRAs). Both 
skin test and IGRAs detect an immune response towards mycobacterial antigens and hence 
provide indirect evidence of prior contact with M. tuberculosis by measuring a local 
inflammatory reaction (skin test) or T cellular IFN production (IGRAs) after stimulation with 
M. tuberculosis specific antigens (PAI, O'BRIEN, 2008).  
1.4 Principles of assays to determine antigen specific T cells 
Antigen specific immune responses can be either assessed serologically by measuring 
antibodies via ELISA technique, or by assessment of antigen specific T cells. Because 
antibody detection via ELISA is simple and inexpensive, it is commonly used to assess the 
infection status with a particular pathogen. Assays for assessment of antigen specific T cells 
are more laborious but allow more precise determination of antigen specific immunity even 
in situations where serology might be confounded by passive transfer of antibodies such as 
in neonates or in patients after plasma transfusion. Furthermore, in contrast to 
determination of specific antibodies, cellular immunity has been shown to correlate more 
closely with disease activity in numerous infections, especially when combined with detailed 
functional and phenotypical analyses of specific T cells (D'SOUZA et al., 2007; DAY et al., 
2006; KASPROWICZ et al., 2008; KAUFMANN et al., 2007; PENG et al., 2008; PETROVAS et al., 
2006; RADZIEWICZ et al., 2007; SCHMIDT et al., 2014; SCHMIDT et al., 2012a; SESTER et al., 
2002b; SESTER et al., 2011b; SESTER et al., 2008b; TRAUTMANN et al., 2006; URBANI et al., 
2008). 
Various assay principles exist to quantify and characterize antigen specific T cells. Most rely 
on 6-20h stimulation of whole blood or isolated PBMC with either whole antigen 
preparations or isolated peptides. Stimulation leads to induction of cytokines and cell 
activation markers on antigen specific T cells. Cytokines are secreted and can be analysed in 
the supernatant using ELISA formats (CHANG et al., 1984; TROYE-BLOMBERG et al., 1985). 
Whereas classical ELISAs cannot assign cytokine production to individual cells, this can be 
achieved by the ELISPOT technique (CZERKINSKY et al., 1988). In this assay, secreted 
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cytokines are bound locally via cytokine specific antibodies, which are pre-bound on culture 
plates. After washing and staining with a secondary antibody, antigen specific cells can be 
detected as distinct spots in the culture plate. An alternative method to quantify individual 
antigen specific T cells is intracellular cytokine analyses in combination with flow cytometry 
(SANDER et al., 1991). In this assay, cytokines induced in response to antigen specific 
stimulation are accumulated intracellularly by adding an inhibitor of cellular transport (e.g. 
Brefeldin A) during the stimulation period. After fixation and permeabilisation, cytokines are 
stained intracellularly, which enables subsequent flow cytometric analyses of specifically 
activated T cells. An additional advantage of this method is the possibility to co-stain several 
cytokines and/or additional phenotypical markers to further characterize antigen specific T 
cells (ELSON et al., 1995; JUNG et al., 1993; SANDER et al., 1991). Another approach to 
analyse antigen specific T cells is the use of peptide-HLA-multimers (ALTMAN et al., 1996; 
BROOIMANS et al., 2008; GRATAMA et al., 2001). Multimers are high affinity peptide-HLA 
complexes, which are covalently bound to a biotin backbone. Due to increased avidity, 
between 4 and 10 peptide-HLA complexes are bound to a biotin backbone. These multimers 
can be used as specific reagents to directly bind T cells with the appropriately matching T cell 
receptor, thus allowing stimulation independent analysis of antigen specific T cells. 
1.5 Antigen specific T cell assays as diagnostic tools to detect and monitor CMV infection 
periods 
As outlined above, monitoring of cellular immunity towards CMV has the potential to 
analyse individual immunocompetence in transplant recipients which may help to minimize 
infectious complications after transplantation (KOTTON et al., 2013a). Currently available 
assays to analyse CMV specific T cells rely on a 6-20h stimulation period of blood cells with 
specific antigens, where cytokines such as IFNγ, TNFα or IL-2 are induced in an antigen-
specific manner. As describe above, these cytokines may be detected using ELISA-based 
assays, ELISPOT-based assays or flow cytometric intracellular staining (FISHMAN, RUBIN, 
1998; KOTTON et al., 2013a). A large body of evidence exists that a quantitative decrease of 
specific immunity is associated with symptomatic CMV infection (KOTTON et al., 2013a; 
SESTER et al., 2001; WALKER et al., 2007; WESTALL et al., 2008). However, these merely 
quantitative approaches are not suited to predict asymptomatic episodes of viral 
reactivation. Whereas ELISA and ELISPOT are methodically limited to quantify stimulation 
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induced cytokine responses and cannot further characterise T cells in more detail, flow 
cytometric approaches are able to measure antigen specific T cells via multiple activation 
marker and cytokine co-expression and to characterise them in detail with phenotypical  
T cellular markers (JUNG et al., 1993; SANDER et al., 1991).  
1.5.1 Phenotypical and functional characterisation of pathogen specific immune 
responses 
As CMV is a livelong persistent pathogen, the interplay between CMV and the immune 
system is diverse. Despite potent immune escape mechanisms such as down-regulation of 
MHC molecules on infected cells (MOCARSKI, 2004), T cell immunity against CMV is among 
the strongest responses directed against a single pathogen and can account for up to 40 
percent of the total T cellular response (SESTER et al., 2002b). In addition, CMV seems to 
modulate T cell responses, as the CMV specific T cell pool consists predominantly of 
terminally differentiated effector T cells with distinct features of immune senescence. One 
prominent feature of terminal differentiation is a reduction in telomere length (FLETCHER et 
al., 2005; VAN DE BERG et al., 2010). Another typical feature of terminal differentiated  
T cells is the loss in the expression of CCR7, CD27, CD28, CD127, and the re-expression of 
CD45RA (DERHOVANESSIAN et al., 2009; DERHOVANESSIAN et al., 2011; VAN DE BERG et al., 
2008). This phenotype is observed on a majority of CMV specific T cells irrespective of 
reactivation episodes or CMV associated clinical symptoms. Interestingly, terminally 
differentiated T cells and CMV seropositivity have been attributed to a so called immune risk 
phenotype in the elderly, with increased overall susceptibility to infections and a decreased 
life expectancy (DERHOVANESSIAN et al., 2009). However, a detailed functional and 
phenotypical analysis of CMV specific immunity as correlate of protection from CMV 
replication and disease in the setting of organ transplantation had not been performed 
before. 
Studies on immunity towards a variety of other persistent pathogens have shown that 
chronic infections are associated with alterations in T cell functionality (D'SOUZA et al., 2007; 
DAY et al., 2006; KASPROWICZ et al., 2008; KAUFMANN et al., 2007; PENG et al., 2008; 
PETROVAS et al., 2006; RADZIEWICZ et al., 2007; TRAUTMANN et al., 2006; URBANI et al., 
2008), which predominantly manifest as a loss in multifunctionality (PANTALEO, HARARI, 
2006). Whereas T cell responses during primary infection are dominated by IFN single 
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producing cells, T cell responses in self-limiting infections after antigen clearance are 
dominated by IL-2 single producing cells. T cells in controlled persistent infections are 
predominated by multifunctional cells, whereas virus/disease reactivation is associated with 
a loss of IL-2 production and dominance of IFN single producing cells. This model is in line 
with our previous work on CMV and BKV infection, where we could correlate virus/disease 
reactivation with a decrease in IFN/IL-2 co-expressing cells (SCHMIDT et al., 2014; SESTER et 
al., 2008b). Apart from analysis of multifunctionality, the inhibitory T cell receptor PD-1 was 
shown to be overexpressed during chronic lymphocytic choriomeningitis virus (LCMV) 
infection in mice and seems to be responsible for the observed anergic phenotype with a 
loss in functionality and proliferative potential (BARBER et al., 2006). Of note, the anergic 
phenotype was shown to be reversible by inhibitory receptor blockade in vitro. In line with 
these studies in mice, we have previously shown that CMV specific CD4 T cells in renal 
transplant recipients with CMV reactivation episodes show reduced functionality. This was 
marked by a reduced proliferative capacity, a loss in IL-2 production and high PD-1 
expression, which was at least partly reversible by in vitro blockade of PD-1 signalling (DIRKS, 
2008; SESTER et al., 2008a; SESTER et al., 2008b). More recently, other inhibitory receptors 
such as TIM-3 and CTLA-4 have also been shown to be associated with viremic episodes in 
other types of chronic viral infections like HIV, HBV and HCV (BARBER et al., 2006; JONES et 
al., 2008; KASSU et al., 2010; KHAITAN, UNUTMAZ, 2011; ODORIZZI, WHERRY, 2012; VALI et 
al., 2010). Thus, apart from assessment of T cell functionality, additional phenotypical 
analysis of CMV specific T cells may be a promising approach to predict CMV reactivation 
episodes.  
1.5.2 Use of peptide-HLA-multimers as a stimulation independent approach to monitor 
antigen specific T cell immunity 
CMV antigen specific stimulation is well suited for quantitation, phenotypical and functional 
characterisation of CMV specific immunity (KOTTON et al., 2013b; MANUEL et al., 2013; 
SESTER et al., 2001; SESTER et al., 2008b; WIDMANN et al., 2008). Yet, these assays require 
relatively long assay times and the prerequisite of live and fully functional T cells. Therefore, 
test results may be impaired depending on time until processing. One approach to reduce 
assay time is the use of peptide-HLA-multimers, where synthetic complexes of peptides and 
MHC molecules are used as reagent to directly detect antigen specific T cells without the 
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need for specific stimulation (ALTMAN et al., 1996; BROOIMANS et al., 2008; GRATAMA et 
al., 2001). As this technique allows for a quantitation and phenotypical characterisation of  
T cells independent of their capability to produce cytokines, peptide specific responses might 
be enumerated more accurately in the setting of suspected T cell anergy (DAVIS et al., 2011; 
LEE et al., 1999). Furthermore, multimer technology can be combined with phenotypical 
characterisation. Indeed, analysis of PD-1 expression on CD8 T cells bound by CMV specific 
tetramers correlated with CMV disease in liver transplant recipients (LA ROSA et al., 2008). 
Of note, most multimer studies to date focus on CD8 T cells due to the poor stability of MHC 
class II multimers (DAVIS et al., 2011). Therefore analysis of total pathogen specific 
responses using the multimer technology is limited by the knowledge of the patient’s 
individual MHC status, the availability of peptide-HLA multimer combinations and the 
relative inability to analyse antigen specific CD4 T cell responses (DAVIS et al., 2011).  
1.5.3 CD28-CD27- CD4 T cells as a stimulation independent correlate of CMV specific 
immunity 
As outlined above, CMV specific T cells are predominantly of an end-stage differentiated 
phenotype showing signs of replicative senescence. One feature of this phenotype is the loss 
of CD28 and CD27 expression on both CD4 and CD8 T cells. Whereas a population of CD28-
CD27- CD8 T cells is also observed in CMV seronegative individuals, the existence of CD28-
CD27- CD4 T cells seems to be more specific to seropositive individuals (FLETCHER et al., 
2005; LOONEY et al., 1999; POURGHEYSARI et al., 2007; VAN DE BERG et al., 2008; VAN 
LEEUWEN et al., 2006; VAN LEEUWEN et al., 2004). The presence of CD28-CD27- CD4 T cells 
seems to correlate closely with CMV seropositivity, yet notably not with seropositivity 
towards other herpesviruses like HSV, EBV or VZV (DERHOVANESSIAN et al., 2011; FLETCHER 
et al., 2005). CMV induces the generation of CD28-CD27- CD4 T cells after infection, as CMV 
induced activation of plasmacytoid dendritic cells mediates the loss of CD28 and CD27 
expression on CD4 T cells via high level IFN secretion (FLETCHER et al., 2005). The close 
association of CD28-CD27- CD4 T cells with CMV infection might offer a tempting opportunity 
to exploit this notable T cell subset as a stimulation independent correlate of CMV specific 
immunity and to explore its value as a monitoring tool in the setting of organ transplantation.  
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1.6 T cell assays for diagnosis of active M. tuberculosis infection 
Direct microbiological confirmation of Mycobacterium tuberculosis infection is hampered by 
the low replication rate and the concealment of mycobacteria in locally confined granulomas 
in the lung. Consequently, diagnosis of active infection by culture may take several weeks 
and assay sensitivity is considerably poor (PAI, O'BRIEN, 2008). Diagnosis of latent infection 
with M. tuberculosis is indirectly performed by the use of immunological assays that detect 
specific T cell immunity towards mycobacterial antigens. Numerous studies on the 
commercially available ELISA based QuantiFERON-TB Gold in tube assay and ELISPOT based 
T-SPOT.TB assay have shown advantages to the classically used tuberculin skin test by their 
ability to discriminate between BCG vaccination response and actual infection with  
M. tuberculosis bacteria (LALVANI, 2007). This is due to the use of ESAT-6 and CFP-10 
proteins as stimulants. Both proteins are encoded in the region of difference 1 (RD1) of the 
M. tuberculosis genome, which is deleted from the genome of the vaccine strain Bacillus 
Calmette Guérin (BCG). Interestingly, IGRAs have been shown additionally to have a higher 
sensitivity in immunocompromised patients (SESTER et al., 2004; SESTER et al., 2003). 
Furthermore, unlike skin testing, they do not require a follow-up visit.  
IGRAs have also been extensively studied as tool to identify patients with active tuberculosis. 
However, they are not suited to specifically diagnose active TB, as they do not sufficiently 
discriminate active from latent infection (PAI et al., 2006; PAI, O'BRIEN, 2008; SESTER et al., 
2011a). Although M. tuberculosis specific CD4 T cell frequencies have been shown to be 
higher in untreated active infection than in successfully treated tuberculosis (SESTER et al., 
2011b), the considerable overlap in frequencies between these patient groups precludes 
their use to distinguish between active and latent M. tuberculosis infection, which was 
supported in a recent meta-analysis (SESTER et al., 2011a). Thus, better biomarkers are 
needed to discriminate active tuberculosis from latent infection. 
Better biomarkers are also needed for the identification of latently infected individuals at 
risk for progression to active tuberculosis. In general, tuberculosis develops only in about  
5 to 10 percent of individuals with latent infection during their lifetime. Whereas healthy 
immunocompetent individuals are at lowest risk of progression, individuals with impaired 
immunity are at considerably higher risk. The highest risk group are patients with HIV/TB co-
infection, which is an enormous challenge in regions of high tuberculosis incidence (WHO, 
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2013). Because of the variable progression risk, preventive chemotherapy of latent TB is not 
generally recommended for healthy immunocompetent individuals but highly recommended 
in situations of increased risk, such as close contact to a patient with active disease or 
relevant degree of immunosuppression (DIEL et al., 2009; DIEL et al., 2011). As prophylaxis 
ranges from three (isoniazide and rifapentine combination therapy) to nine month 
(isoniazide monotherapy) and is associated with serious side effects and treatment costs, it 
would be desirable to specifically target only those patients at need of therapy. Yet, both TST 
and IGRAs as currently used measures to estimate the individual risk of a patient to progress 
from latent to active TB only have considerably low positive predictive values.  
During the last decade some promising novel biomarkers for the diagnosis of active  
M. tuberculosis infection have been described, but none have reached application in clinical 
routine so far. Conceptually, these biomarkers may also have potential to predict latently 
infected individuals at risk for progression. One approach might be the use of novel  
M. tuberculosis antigens or peptide pools which seem to correlate with different  
M. tuberculosis infection states (DEMISSIE et al., 2006; DOSANJH et al., 2011; VINCENTI et al., 
2003). Furthermore, similar to chronic viral infections, we and others have shown that a loss 
in T cell multifunctionality can discriminate active from latent infection with high specificity 
and reasonable sensitivity (HARARI et al., 2011; SESTER et al., 2011b). In addition, studies in 
mice have indicated that a loss of the co-stimulatory receptor CD27 occurs on  
M. tuberculosis specific T cells in the lung, soon after infection and that reappearance of 
these cells in the circulation correlates with the degree of lung destruction and disease 
severity (KAPINA et al., 2007; LYADOVA et al., 2004). First studies in humans suggest that 
analysis of CD27 on M. tuberculosis specific T cells might be a potent biomarker to diagnose 
active tuberculosis (HARARI et al., 2011; NEMETH et al., 2012; SCHUETZ et al., 2011; SESTER 
et al., 2011b; STREITZ et al., 2012; STREITZ et al., 2007).  
As inhibitory T cell receptors have been shown to correlate with pathogen 
replication/disease activity in numerous chronic viral infections, expression of these 
inhibitory receptors on T cells specific for mycobacterial antigens might also correlate with 
mycobacterial replication. Hence, their combined analysis may represent promising tools for 
diagnosis of active TB or to identify latently infected individuals with an increased risk for 
progression to active tuberculosis. Up to now however, the diagnostic potential of inhibitory 
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T cell receptors, CD27 expression and cytokine profiling on M. tuberculosis specific T cells to 
diagnose active TB and to evaluate the risk for progression in latently infected individuals 
has not been analysed in a sufficient manner. In addition, it is not known whether certain 
combinations of biomarkers might be complementary and therefore suited to further 
enhance diagnostic accuracy. 
1.7 Aims of this thesis 
Chronic infections are marked by intermittent periods of reactivation, and by the inability of 
the immune system to eradicate the pathogen. A common feature of chronically active 
pathogens is the modulation of the pathogen specific immune response.  
The aim of this thesis was to investigate the phenotype and functionality of T cells in chronic 
infections and to evaluate those as diagnostic correlates of disease state and progression. 
We aimed to focus on cytomegalovirus and M. tuberculosis as two different clinically 
relevant persistent viral and bacterial pathogens to explore both common immunological 
features as well as differences to establish chronicity. To elucidate potential differences in 
phenotypical and functional dynamics of the antigen-specific immune response in chronic 
infections and those in the absence of antigen persistence, we additionally monitored 
antigen specific immune responses after influenza vaccination. Furthermore, the effect of 
pathogen prevalence on the maintenance of antigen specific responses was studied in 
healthy individuals and HIV-infected individuals who suffer from temporary T cell depletion. 
As reactivation of CMV infection is a particular complication in immunocompromised 
patients, a particular focus was placed on the characterisation of specific immunity in 
transplant recipients with reactivations and primary infections. Biomarkers that were 
typically found in transplant recipients with active CMV infection were then studied as 
potential markers to diagnose active infection with other clinically relevant pathogens.  
The following aims were specifically addressed in this thesis: 
 Does the occurrence of CMV reactivation episodes in transplant recipients correlate 
with phenotypical and functional changes in CMV specific T cell responses and are 
these alterations suitable as prognostic biomarkers to assess the risk of CMV 
reactivation and disease? 
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 Is the anergic phenotype linked to inhibitory T cell receptor expression and is it 
reversible via blockade of these receptors? 
 Can CMV specific HLA-peptide-multimers or the CD28-CD27- CD4 T cell phenotype be 
used in combination with anergy markers as rapid stimulation independent tools for 
monitoring infectious complications in transplant recipients? 
 Can biomarkers identified in active CMV infection be applied to immunity after 
vaccination or infection with M. tuberculosis? 
 Does pathogen prevalence influence the maintenance of antigen specific immunity in 
HIV infected individuals after temporary T cell depletion? 
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2 Materials and methods  
2.1 Materials 
2.1.1 Plastic materials 
Device Producer 
1.5ml tubes Brand, Wertheim 
15ml tubes Greiner, Frickenhausen  
50ml tubes Greiner, Frickenhausen 
FACS-tubes (5ml, 75x12mm) Sarstedt, Nürnbrecht 
Pipette tips Greiner, Frickenhausen 
Precision dispenser-tips (5ml, 1,25ml) Brand, Wertheim 
Single use pipettes (1ml, 2ml, 5ml, 10ml, 25ml) Sarstedt, Nürnbrecht, Corning Costar, 
Bodenheim 
Culture plates (96-wells) Greiner, Frickenhausen 
2.1.2 Technical equipment 
Device Producer 
Graduated pipettes (10µl, 20µl, 100µl, 200µl, 
1000µl) 
Abimed, Langenfeld  
Pipette tips Greiner, Frickenhausen 
Pipetboy Integra Biosciences, Fernwald 
Precision dispenser-tips (5ml, 1,25ml) Brand, Wertheim 
Neubauer counting chamber Neubauer, Marienberg 
MACSmix tube rotator Miltenyi Biotec 
Vortex-Mixer neoLab Migge Laborbedarf, Heidelberg 
Microscope Nikon, Düsseldorf 
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Device Producer 
Microscope CRX31 Olympus, Hamburg 
Sterile workbench, Clean Air Techniek Woerden, NL 
Sterile workbench, Tecnoflow Integra Biosciences, Fernwald 
Sterile workbench, Hera safe Heraeus, Hanau 
Incubator, Hera Cell Heraeus, Hanau 
Eppendorf-centrifuge, Minifuge Eppendorf, Hamburg 
Centrifuge, Megafuge 1.OR Heraeus, Hanau 
ELISA reader, Victor X4 PerkinElmer, Rodgau 
PCR cycler, Light Cycler 480 Roche, Mannheim 
Flow cytometers FACS Canto II,  
FACS Canto A and FACS Calibur 
BD Biosciences, Heidelberg 
2.1.3 Flow cytometers 
The flow cytometers listed in Table 1 were used for analysis of T cell immunity in this thesis.  
Table 1: Flow cytometers with the used configurations. 
 Laser configuration Optical filters Fluorochromes 
 Laser  Excitation 
(nm) 
Power 
(MW) 
Long pass Band pass  
B
D
 F
A
C
S 
C
an
to
 II
 
L1 
Solid state (blue) 
488 20 502 530/30 FITC 
556 585/42 PE 
655 670 LP PerCP, Per-CP-
Cy5.5 
735 780/60 PE-Cy7 
L2 
HeNe (red) 
633 16 - 660/20 APC 
735 780/60 APC-H7 
L3 
Solid state (violet) 
405 60 - 440/50 BD Horizon V450 
502 525/40 BD Horizon V500 
  
B
D
 F
A
C
S 
C
an
to
 A
 L1 
Solid state (blue) 
488 20 502 530/30 FITC 
556 585/42 PE 
655 670 LP PerCP, Per-CP-
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 Laser configuration Optical filters Fluorochromes 
 Laser  Excitation 
(nm) 
Power 
(MW) 
Long pass Band pass  
Cy5.5 
735 780/60 PE-Cy7 
L2 
HeNe (red) 
633 16 - 660/20 APC 
735 780/60 APC-H7 
  
B
D
 F
A
C
S 
C
a
lib
u
r 
L1 
Argon (blue) 
488 15 502 530/30 FITC 
556 585/42 PE 
655 670 LP PerCP 
L2 
Semiconductor diode 
(red) 
635 10 - 661/16 APC 
2.1.4 Chemicals, buffers, and media 
Chemicals Producer 
NaN3 Serva, Heidelberg 
Brefeldin A (BFA) Sigma, Deisenhofen 
BSA (bovine serum-albumin) Serva, Heidelberg 
CFDA-SE Molecular Probes, MoBiTec, Göttingen 
Acetic acid Sigma, Deisenhofen 
EDTA Sigma, Deisenhofen 
Facs Clean BD Biosciences, Heidelberg 
Facs Flow BD Biosciences, Heidelberg 
Facs Rinse BD Biosciences, Heidelberg 
Ficoll Linaris, Bettingen 
FCS (fetal calf serum) Cambrex Biosciences, Verviers, Belgien 
HSA (human serum-albumin) Baxter BioSience; Heidelberg 
L-Glutamin PAA, Cölbe 
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Chemicals Producer 
Lysis solution BD Biosciences, Heidelberg 
NaN3 Fluka, Buchs, Schweiz 
Paraformaldehyde Aldrich-Chemie, Steinheim 
PBS Linaris, Bettingen 
Penicillin/Streptomycin (P/S) PAA, Cölbe 
RPMI 1640 (cell medium) Biochrom AG, Berlin 
Saponin Sigma, Deisenhofen 
2.1.5 Buffers and cell culture media 
FACS buffer (PBS, 5% FCS, 0.5% BSA, 0.07% NaN3) 
Saponin buffer (PBS, 5% Saponin, 5% FCS, 0.5% BSA, 0.07% NaN3) 
CFDA-SE labelling solution (PBS, 0.1% HSA, 10µM CFDA-SE) 
CFDA-SE washing solution (RPMI 1640, 1% L-Glutamin, 1% P/S, 0.5% HSA) 
Culture medium (RPMI 1640, 1% L-Glutamin, 1% P/S, 5% FCS) 
2.1.6 Reagents for T cell stimulation 
All reagents used for T cell stimulation assays are listed in Table 2. The final concentration of 
reagents in the stimulatory reaction is indicated. 
Table 2: Reagents used for T cell stimulation. 
Stimulant Clone Concentration Producer 
CD28 L293 1µg/ml BD Biosciences, Heidelberg 
CD49d 9F10 1µg/ml BD Biosciences, Heidelberg 
CMV antigen n.a. 32µl/ml Bio Whittaker, Verviers 
CMV control antigen  n.a. 32µl/ml Bio Whittaker, Verviers 
CMV antigen n.a. 32µl/ml Virion, Würzburg 
CMV control antigen n.a. 32µl/ml Virion, Würzburg 
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Stimulant Clone Concentration Producer 
Staphylococcus 
aureus enterotoxin B 
(SEB)  
n.a. 2.5µg/ml Sigma, Deisenhofen 
PPD n.a. 7,33µg/ml Statens Serum Institute, Copenhagen 
ESAT-6 n.a. 10µg/ml Lionex, Braunschweig 
CFP-10 n.a. 10µg/ml Lionex, Braunschweig 
pdmH1N1 n.a. 2.5µg/ml GlaxoSmithKline, London, United Kingdom 
Begrivac (Flu09) n.a. 30µg/ml Novartis, Marburg 
Peptides: HLA:   
NLVPMVATV 
(pp65) 
A2 5µg /ml Glycotope Biotechnology, Heidelberg 
TPRVTGGGAM 
(pp65) 
B7 5µg /ml Glycotope Biotechnology, Heidelberg 
VTEHHDTLLY 
(pp50) 
A1 5µg/ml Glycotope Biotechnology, Heidelberg 
YSEHPTFTSQY 
(pp65) 
A1 5µg /ml Glycotope Biotechnology, Heidelberg 
FLKGGGGFV 
(neg. control) 
A2 5µg /ml Glycotope Biotechnology, Heidelberg 
MHC class I tetramers used in this study are listed in Table 3. All tetramers were obtained 
from Glycotope Biotechnology (Heidelberg). 
Table 3: MHC class I tetramers used for quantification of CMV specific CD8 T cells. 
MHC class I 
allele 
Peptide sequence HCMV epitope Fluorochrome Volume [µl] 
per test 
A*0101 YSEHPTFTSQY HCMV pp65 363-373 PE 4 
A*0101 VTEHDTLLY HCMV pp50 245-253 PE 2.5 
A*0201 NLVPMVATV HCMV pp65 495-504 PE 2.5 
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2.1.7 Antibodies  
All antibodies used in this thesis are listed in Table 4. All fluorochrome conjugated antibodies 
were used for flow cytometric analysis of T cells. All unconjugated antibodies were used to 
block inhibitory signalling pathways in CFDA-SE proliferation assays. All antibodies are 
directed against human antigens.  
Table 4: List of antibodies. 
Target antigen Fluorochrome Clone Ig-class Origin Producer 
CD3 APC SK7 IgG1 k mouse BD Biosciences 
CD4 APC SK3 IgG1 k mouse BD Biosciences 
CD4 FITC 13B8.2 IgG1 mouse Beckmann Coulter 
CD4 PE-Cy7 
APC-H7 
SK3 IgG1 k mouse BD Biosciences 
CD8 PerCP, V500 SK1 IgG1 mouse BD Biosciences 
CD25 PE-Cy7 M-A251 IgG1 k mouse BD Biosciences 
CD27 FITC L128 IgG1 k mouse BD Biosciences 
CD27 V450 M-T271 IgG1 k mouse BD Biosciences 
CD28 PerCP-Cy5.5 L293 IgG1 k mouse BD Biosciences 
CD45 RA FITC HI100 IgG2b k mouse BD Biosciences 
CD45 RO PE-Cy7 UCHL-1 IgG2a k mouse BD Biosciences 
CD62L PE DREG-56 IgG1 k mouse BD Biosciences 
CD69 PerCP L78 IgG1 k mouse BD Biosciences 
CD127 AlexaFluor647 HIL-7R-M21 IgG1 k mouse BD Biosciences 
CD152 (CTLA-4) PE, APC BNI3 IgG2a k mouse BD Biosciences 
CD279 (PD-1) APC MIH4 IgG1 k mouse BD Biosciences 
IFN FITC 4S.B3 IgG1 k mouse BD Biosciences 
IL-2 PE MQ1-17H12 IgG2a mouse BD Biosciences 
B*0702 TPRVTGGGAM HCMV pp65 417-426 PE 4 
A*0201 FLKGGGGFV Negative control PE 2.5 
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Target antigen Fluorochrome Clone Ig-class Origin Producer 
TIM-3 PE 344823 IgG2a mouse R&D Systems 
TNF APC MAb 11 IgG1 rat BD Biosciences 
bPD-L1 - MIH1 IgG1 k mouse eBiosciences 
bPD-L2 - MIH18 IgG1 k mouse eBiosciences 
bTIM-3 - F38-2E2 IgG1 k mouse Biozol 
bCTLA-4 - BNI3 IgG2a k mouse BD Biosciences 
Isotype (bPD-L) - P3 IgG1 k mouse eBiosciences 
Isotype (bTIM-3) - MOPC-21 IgG1 k mouse Biozol 
Isotype (bCTLA-4) - G155-178 IgG2a k mouse BD Biosciences 
“b” denotes blocking antibodies. 
2.2 Patients and controls 
Different patient and control groups were recruited for the individual parts of this thesis. 
Individuals were either analysed cross-sectionally or longitudinally over time. Characteristics 
of these groups of individuals are specified below. All studies were approved by the local 
ethics committee and all participants gave informed consent. 
2.2.1 Individuals to characterise CMV associated and CMV specific immunity  
A total of 93 healthy controls (40.58±13.33 years; 36 CMV seronegative, 57 CMV 
seropositive), 67 hemodialysis patients (54.41±14.29 years; 12 CMV seronegative, 55 CMV 
seropositive), and 81 renal transplant recipients (55.07±14.11 years; 19 CMV seronegative, 
62 CMV seropositive) were analysed in a cross-sectional manner. Among seropositive 
transplant recipients, 20 patients did not show any reactivation, and 42 were analysed at the 
time of reactivation. In addition, 12 transplant recipients (53.75±16.54 years) were included 
at the time of primary viremia.  
Longitudinal analyses comprised 46 CMV seropositive transplant recipients with (n=35) and 
without (n=11) CMV reactivation, and 10 patients with CMV primary infection. Transplant 
recipients received basiliximab induction and a standard immunosuppressive triple drug-
regimen consisting of mycophenolate mofetile, tacrolimus and steroids. T cell analyses were 
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performed in parallel with viral load at the day of transplantation until week 16 (weekly 
during the first six weeks and biweekly thereafter). Furthermore, patients were stratified 
into non-viremic patients with no detectable CMV load during the four months observation 
period (n=11), patients with low level viremia (with a single positive CMV load between 500 
and 800 copies/ml, or all patients with multiple low level CMV loads of ≤450; n=21) and high 
level viremia (at least one CMV load >800 copies/ml or multiple CMV loads >450 copies/ml; 
n=14). Antiviral therapy with valganciclovir was administered at the discretion of the 
clinicians in 13/14 (93%) patients with high level viremia, 6/21 (29%) patients with low level 
viremia, and 3/11 (27%) of patients without viremia. The rationale to start therapy was 
either ≥2 consecutive positive viral loads and/or mild clinical symptoms where CMV infection 
was a differential diagnosis.  
2.2.2 Individuals to characterise inhibitory receptor blockade on proliferation and 
cytokine expression 
Multiplex cytokine profiling was performed in a cross-sectional study design among 10 
kidney transplant recipients who were selected from a previous study that showed an anti-
PD-L1/L2-mediated restoration of proliferative responses after CMV specific stimulation of 
peripheral blood mononuclear cells (PBMC) from patients with a high percentage of PD-1 
positive CMV specific T cells (SESTER et al., 2008b). This study was now specifically 
performed to assess the cytokines involved in increased proliferative responses in such 
patients. As such, it is a cross-sectional study where subgroups of patients were explicitly 
enrolled with respect to high and low PD-1 expression on CMV specific CD4 T cells, 
respectively. All patients were seropositive for CMV and received standard double or triple 
immunosuppression. Patients with high levels of PD-1 were defined as patients with >50% of 
PD-1 expressing CMV specific T cells. These patients were viremic at the time of analysis (n=3 
with 450, 450, and 900 copies/mL, respectively) or within the last 2 months (n=2). Two of 
three viremic patients received valganciclovir at the time of blood sampling. Patients with 
low PD-1 expression did not show any evidence of viremia and served as controls. None of 
the patients had CMV disease. Three healthy non-immunosuppressed CMV seropositive 
persons were analysed as additional controls. Further characteristics of the study 
participants including drug treatment are shown in Table 5.  
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Table 5: Characteristics of healthy controls and transplant recipients. 
 Healthy controls Kidney transplant recipients 
 
PD-1 low 
n=3 
PD-1 low 
n=5 
PD-1 high 
n=5 
Years of age, mean±SD 39.4±3.5 58.7±8.8 57.1±9.6 
Gender, m/f 2/1 4/1 4/1 
years after transplantation, 
median (range) 
n.a. 6.2 (1.3-21.9) 0.7 (0.4-19.7)* 
Immunosuppression n.a. 5 5 
- Tacrolimus or cyclosporine  4 4 
- Mycophenolate mofetil or 
azathioprine 
 4 4 
- Methylprednisone  5 5 
Valganciclovir  0 2 
SD, standard deviation; *the three viremic patients were 0.40, 0.43 and 2.1 years after transplantation. 
2.2.3 Individuals to analyse CMV specific T cells using HLA-peptide-tetramers 
For assessment CD8 T cell responses using HLA-peptide-tetramers, individuals included were 
chosen based on positive CMV serostatus and positivity of at least one of the indicated HLA-
molecules A2, A1 and B7. We cross-sectionally analysed 17 healthy controls (mean age 
36.25±25.19 years) and a total of 72 immunocompromised individuals, which included 15 
patients on hemodialysis (mean age 59.58±11.98 years), 43 patients after kidney 
transplantation (mean age 58.08±12.34 years) and 14 after stem cell transplantation (mean 
age 47.76±14.15 years). Kidney transplant recipients were on a similar immunosuppressive 
regimen as those described in section 2.2.1 and patient stratification according to episodes 
of viremia was done as outlined in section 2.2.1. 
2.2.4 Individuals to characterise M. tuberculosis specific T cells  
Similar to a previous study on IFN/IL-2 cytokine profiling (SESTER et al., 2011b), we analysed 
samples from 18 patients with confirmed active tuberculosis (mean age 55.41±19.89 years), 
25 patients with a history of successfully treated tuberculosis (mean age 51.85±16.08 years), 
108 patients with latent M. tuberculosis infection (mean age 58.33±16.69 years) and 137 
individuals with immunity consistent with BCG vaccination or NTM infection (mean age 
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49.48±19.15 years). All patients diagnosed with active tuberculosis had positive cultures for 
M. tuberculosis or acid fast bacilli from one or more clinical specimens, or clinical and 
radiologic features highly suggestive of tuberculosis together with a good response to anti-
tuberculosis treatment. Patients with successfully treated tuberculosis were studied after 
treatment completion and did not show any signs or symptoms compatible with active 
tuberculosis at the time of analysis. Latent M. tuberculosis infection was defined by T cell 
reactivity towards both PPD and towards ESAT-6 and/or CFP-10 proteins. A positive immune 
response towards PPD in the absence of specific immunity towards ESAT-6 and CFP-10 is 
consistent with either BCG vaccination status or NTM infection, although BCG vaccination 
status was not consistently known and this does not firmly exclude latent infection. 
2.2.5 Individuals to characterise functional and phenotypical properties of specific 
immunity towards influenza vaccines 
This part of the study was conducted among 19 immunocompetent individuals in 
October/November 2009. Among them, ten persons (mean age 43.64±10.05 years) had 
been pre-vaccinated against seasonal influenza (Begrivac 2009/2010, Novartis, Marburg, 
Germany) about 3 weeks before (mean 18.9±7.9 days), whereas nine (mean age 37.8±15.9 
years) had not. All individuals did not have any signs or symptoms of prior contact with 
pandemic influenza A/H1N1. They received a routine vaccination using one standard dose of 
the pdmH1N1 vaccine (Pandemrix, GlaxoSmithKline Biologicals s.a., Rixensart, Belgium). 
Whole blood samples were drawn prior to vaccination with Pandemrix as well as 1, 2, and 10 
weeks thereafter. To characterize cellular immunity in acute infection, additional whole 
blood samples of seven immunocompetent individuals (mean age 49.28±11.07 years) who 
were newly diagnosed with influenza A/H1N1 infection on a clinical/epidemiological or 
virological basis were analysed. All except one individual were hospitalized due to influenza-
related symptoms and samples were collected within a median of 5 days (range 1–18 days) 
of symptom onset. 
2.2.6 HIV infected and non-infected individuals to quantify CMV and M. tuberculosis 
specific immunity  
This part of the study was conducted among 60 HIV infected individuals from Homburg, 
Germany (low tuberculosis endemic country), and 39 HIV infected patients from Mbeya, 
Tanzania (high tuberculosis endemic country). Immunocompetent HIV seronegative 
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individuals from both countries served as controls (Table 6) and were recruited from the 
same geographic regions as HIV positive patients. All individuals from Germany were 
German whites except for two HIV infected individuals of African origin. All individuals from 
Tanzania were of African ethnicity. Study participants had no signs or symptoms of active 
tuberculosis during the study period. Furthermore, a group of 34 HIV infected patients with 
active tuberculosis from Tanzania were recruited. Active disease was diagnosed by clinical 
symptoms and sputum smear testing. Bacillus Calmette-Guerin vaccination status, CD4 cell 
counts and antiretroviral therapy (ART) status was not consistently available for all study 
participants (Table 6). Patients in Tanzania were recruited and analysed by Dr. Alexandra 
Schütz and data were provided for combined analysis with German individuals. 
Table 6: Demographic and clinical characteristics of HIV-positive patients and healthy controls. 
 low tuberculosis endemicity 
(Germany)
a
 
high tuberculosis 
endemicity 
(Tanzania)
b
 
 controls HIV
+
 patients controls HIV
+
 patients HIV
+
 patients 
 n=144 n=60 n=31 n=39 n=34 
active 
tuberculosis 
no no no no yes 
age [years] 43.2±14.6 43.0±11.7 23.0±4.2 42.3±8.9 
(n=24) 
33.2±7.2 
(n=16) 
male/female 
[n] (%) 
50/94 
(35%/65%) 
46/14 
(77%/23%) 
21/10 
(67%/33%) 
9/19 
(32%/68%) 
18/16 
(53%/47%) 
HIV viral load 
[copies/ml] 
n.a. 7109±29498 
(n=55) 
n.a. 19537±49285 
(n=25) 
176648±153079 
(n=16) 
CD4 counts 
[cells/µl] 
n.a. 525±335 
(n=57) 
n.a. 506±177 
(n=25) 
214±156 
(n=28) 
Number (%) of 
patients <200 
CD4 T cells/µl 
n.a. 5/57 (9%) n.a. 0/25 (0%) 17/28 (60.7%) 
Number (%) of 
patients on ART 
n.a. 49/57 (86%) n.a. 16 (41%) 0/18 (0%) 
a
TB prevalence 5.9 (1.9-10)/100000 individuals. 
b
TB prevalence 183 (87-281)/100000 individuals; ranges 
represent uncertainty intervals (WHO). Some parameters were not determined/available for all individuals; in 
this situation the number of individuals wherein respective values were available is indicated. 
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2.3 Methods 
2.3.1 Flow cytometry 
Flow cytometry is a high throughput method, which allows sequential analysis of up to 
10.000 cellular events/second and at the same time enables characterisation of multiple 
antigens on a single cell level. Flow cytometric analysis of up to four antigens was performed 
on FACS Calibur and FACS Canto A flow cytometers, whereas the FACS Canto II cytometer 
was used for simultaneous staining of up to eight parameters. Flow cytometric data were 
acquired and analysed by Cellquest Pro, FACS DIVA 6 (both BD Biosciences), or FlowJo 
software (Tree Star, Ashland, USA). 
2.3.2 Antigen specific stimulation of T cells from whole blood samples and subsequent 
intracellular cytokine staining 
Heparinised blood samples can be stimulated in vitro with either specific peptides or whole 
protein preparations. Whereas peptides are directly integrated in and presented by the 
appropriate human leucocyte antigen molecules (MHC class I or II), proteins have to be first 
taken up and processed by antigen presenting cells. External uptake and processing leads to 
predominant MHC class II associated antigen presentation. Stimulation time may range from 
6 to 24 hours, depending on the antigens used and the cytokines analysed for readout.  
The stimulation assay used in this thesis was performed as described before (SCHMIDT, 
SESTER, 2013). Subject to the numbers of cells needed for meaningful analyses, between 
150µl and 300µl blood per staining reaction was stimulated as specified below. Heparinised 
blood samples were stimulated with specific antigens in the presence of 1µg/ml anti-CD28 
and anti-CD49d costimulatory antibodies for a total of 6 hours (37°C, 6% CO2). After 2 hours, 
brefeldin A (BFA) was added as a blocker of vesicular transport, which leads to intracellular 
accumulation of cytokines. After stimulation, blood cells were treated with 2mM 
ethylenediaminetetraacetic acid (EDTA) to disrupt cell-cell interactions. Thereafter, red 
blood cells were lysed and white blood cells were fixed for 10 min using BD-lysing solution 
according to the manufacturer´s instruction. After a washing step with FACS buffer and pre-
treatment with FACS buffer containing 0.1% saponin, cells were stained intracellularly with 
fluorochrome labelled antibodies against stimulation induced cytokines. After staining, cells 
were either analysed directly or stored overnight in 1% PFA. One notable exception from our 
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published protocol was the staining protocol that included PD-1 and TIM-3 (see Table 7). As 
antibodies towards PD-1 and TIM-3 do recognise antigens after cellular fixation, both 
antibodies had to be stained directly after EDTA treatment before the fixation step.  
2.3.2.1 Stimulation of CMV specific CD4 T cells  
For CMV specific stimulation, a lysate of CMV infected fibroblasts was used as stimulus (CMV 
antigen, 32 µL/ml). A lysate of non-infected fibroblasts was used as negative control (control 
antigen, 32 µl/ml) and Staphylococcus aureus Enterotoxin B (SEB, 2.5µg/ml) as positive 
control, respectively (Table 2). For stimulation with CMV antigen and SEB, 600µl whole blood 
each was stimulated to enable three subsequent staining reactions (Staining I-III, Table 7). 
For each reaction, ≥15.000 CD4 T cells were acquired for analysis. For negative control 
stimulations, stimulation of 450µl whole blood was generally sufficient, as staining I was 
usually omitted to save antibodies, and as the results from staining II and III could be used to 
asses and subtract unspecific T cell reactivity. The detection limit for defining a positive T cell 
response was 0.05% CD69/IFN co-producing CD4 T cells as previously established (SESTER 
et al., 2001). The combination of antibodies used in the three staining reactions including 
volumes of reagents per sample after titration are summarised in Table 7. Analyses were 
performed on a FACS Canto II (Staining I-III) and/or FACS Canto A (Staining II). 
Table 7: Staining reactions for characterisation of CMV specific T cells. 
Staining I A (surface) 
Antibody/ 
Reagent 
Fluoro-
chrome 
Volume 
[µl] 
CD4 PE-Cy7 0.50 
PD-1 APC 5.00 
TIM-3 PE 10.00 
Total volume  15.5 
Staining I B (intracellular) 
IFN FITC 0.50 
CD69 PerCP 2.00 
Saponin (5%)  1.00 
FACS buffer  46.50 
Total volume  50.00 
  
Staining II (intracellular)  Staining III (intracellular) 
Antibody/ 
Reagent 
Fluoro-
chrome 
Volume 
[µl] 
 
Antibody/ 
Reagent 
Fluoro-
chrome 
Volume 
[µl] 
CD4 APC 0.50  CD4 PE-Cy7 0.50 
CD69 PerCP 2.00  CD69 PerCP 2.00 
IFN FITC 0.50  IFN FITC 0.50 
IL-2 PE 2.00  TNF PE 0.30 
    CTLA-4 APC 1.00 
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Saponin 5%  1.00  Saponin 5%  1.00 
FACS buffer  44.00  FACS buffer  44.70 
Total volume  50.00  Total volume  50.00 
2.3.2.2 Stimulation of M. tuberculosis specific CD4 T cells  
Titered amounts of PPD (7.32 µg/ml, Tuberkulin for in vitro use (RT-50)), recombinant ESAT-
6 and CFP-10 (10 µg/ml each) were used as stimuli (see Table 2). As negative control, cells 
were stimulated with diluent (phosphate buffered saline). To provide enough T cells 
(≥15.000) for two separate staining reactions, 450µl whole blood was stimulated with each 
antigen. The staining reaction performed on all samples was Staining I (Table 8). Staining II, 
III, or IV (Table 8) was performed in addition as specified in the results section. Although 
reactivity in the control stimulations was largely negligible, the percentage of specific T cells 
was calculated by subtracting the frequency obtained by the control stimulation. The lower 
limit of detection for all antigen preparations was 0.05% CD69/IFN co-producing CD4 T cells 
as previously established (SESTER et al., 2001).  
Table 8: Staining reactions for characterization of M. tuberculosis specific T cells. 
Staining I (intracellular)  Staining II (intracellular) 
Antibody/ 
Reagent 
Fluorochrome Volume 
[µl] 
Antibody/ 
Reagent 
Fluorochrome Volume 
[µl] 
CD4 APC 0.50 
CD4 APC 0.50 
CD69 PerCP 2.00 
   
IFN FITC 0.50 IFN FITC 0.50 
IL-2 PE 2.00 CTLA-4 PE 2.00 
SAP 5%  1.00 SAP 5%  1.00 
FACS buffer  44.00 FACS buffer  46.00 
Total 
volume 
 50.00 Total 
volume 
 50.00 
  
Staining III (intracellular) Staining IV (intracellular) 
Antibody/Re
agent 
Fluorochrome Volume 
[µl] 
Antibody/ 
Reagent 
Fluorochrome Volume 
[µl] 
CD4 APC 0.50 CD4 PE-Cy7 0.50 
CD69 PerCP 2.00 CD69 PerCP 2.00 
IFN FITC 0.50 IFN FITC 0.50 
CD27 PE 2.00 CD27 PE 2.00 
   CTLA-4 APC 2.00 
SAP 5%  1.00 SAP 5%  1.00 
FACS buffer  44.00 FACS buffer  42.00 
Total 
volume 
 50.00 Total 
volume 
 50.00 
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2.3.2.3 Peptide stimulation for assessment of CMV specific CD8 T cell responses 
For stimulation of CMV specific CD8 T cells peptides comprising 8-11 amino acids with 
binding affinity to HLA-A1, HLA-A2 and HLA-B7 were used (Table 2). Cells were stimulated 
with 5µg/ml peptides in the presence of 1 µg/ml anti-CD28 and anti-CD49d antibodies. Mock 
stimulation and stimulation with 2.5 µg/mL SEB were performed as negative and positive 
controls, respectively. For each peptide, 200µl heparinised whole blood was used and 
stained post-stimulation as outlined in Table 9.  
Table 9: Staining protocol for CMV specific CD8 T cells after peptide stimulation 
Staining I A (surface)  
 
 
Staining I B (intracellular) 
Antibody/ 
Reagent 
Fluorochrome Volume 
[µl] 
Antibody/ 
Reagent 
Fluorochrome Volume 
[µl] 
CD8 PerCP 0.50 IFN FITC 0.50 
PD-1 APC 5.00 Saponin 5%  1.00 
   FACS buffer  48.50 
Total volume  5.5 Total volume  50.00 
2.3.3 HLA-tetramer staining for stimulation-independent assessment of CMV specific CD8 
T cell responses  
Depending on the individual HLA-type, one or more of the CMV specific MHC class I 
tetramers as well as the negative control tetramer were added together with 10µl PD-1 APC 
antibody to separate FACS-tubes pre-filled with 200µl whole blood. After 30 minutes of 
incubation, cells were lysed with BD lysing solution for 10 minutes and washed with 2ml PBS. 
After centrifugation, cells were incubated for an additional 20 minutes with 70µl staining mix 
(10µl CD8 FITC, 10µl CD3 PerCP, 50µl PBS). After staining, cells were washed with 3ml PBS 
and resuspended in 1% PFA. Cells were analysed immediately or stored at 4°C until analysis. 
2.3.4 Cell surface staining and phenotypical characterisation of CMV associated CD4 T 
cells  
Cell-surface expression of CD4, CD28 and PD-1 was simultaneously analysed by staining 
100µl of heparinized whole blood for 20 min in the dark (Staining I and II, Table 10). 
Subsequently, cells were treated with BD lysing solution and washed using FACS buffer. 
Thereafter cells were permeabilised for 10 minutes with saponin buffer and subsequently 
stained for 30 min in the dark using anti-CD27 and CTLA-4 antibodies (staining I, Table 10). 
CD27 may also be stained directly on the cell surface, although the presence of soluble CD27 
in whole blood from patients with chronic renal failure reduces staining efficacy 
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(unpublished observations). Samples were kept in 1% PFA at 4°C until flow cytometric 
analysis. CD28-CD27- cells were identified among CD4 T cells and analysed for co-expression 
of PD-1 and CTLA-4, which was quantified as mean fluorescence intensity (MFI). Absolute 
numbers of CD28-CD27- CD4 T cells were calculated from differential blood-counts. In 
selected experiments, CD28-CD27- CD4 T cells were co-stained for CD62L and CD45RO to 
determine their differentiation status (staining II, Table 10). 
Table 10: Staining protocol for cell surface identification of CMV asscociated CD4 T cells 
Staining I A (surface)  
 
Staining II A (surface) 
Antibody/ 
Reagent 
Fluorochrome Volume 
[µl] 
Antibody/ 
Reagent 
Fluorochrome Volume 
[µl] 
CD4 APC-H7 0.50 CD4  0.50 
PD-1 APC 5.00 CD45 RO  1.25 
CD28 PerCP-C5.5 5.00 CD62L  8.00 
CD25 PE-Cy7 1.00 CD28  5.00 
Total volume  11.5 CD27  2.50 
Staining I B (intracellular)  CD8  0.50 
CD27 FITC 4.00 CD45 RA  10.00 
CTLA-4 PE 2.00    
Saponine 5%  1.00    
FACS buffer  43.00    
Total volume  50.00 Total volume  27.75 
2.3.5 Isolation of peripheral blood mononuclear cells 
For proliferation analyses, peripheral blood mononuclear cells (PBMC) were isolated from 
whole blood samples via density gradient centrifugation using Ficoll. In short, up to 10ml 
heparinised whole blood was distributed into a 50ml tube, filled up to 35ml with PBS 0.02% 
EDTA and gently mixed. Next, samples were underlayed with 13ml Ficoll and centrifuged for 
20 minutes (1120g, no brake). The intermediate phase containing PBMC was then carefully 
transferred to a new 50ml tube using a pipette. This was followed by two washing steps with 
PBS (centrifugation at 580g and 260g, respectively). Finally cells were resuspended in 2ml 
PBS (0.1% HSA). 
2.3.6 Cell proliferation analyses using CFDA-SE dilution assay 
PBMC were prepared from 20ml heparinised whole blood via ficoll separation. Between  
1-50*106 PBMC were resuspended in 1ml PBS (0.1% HSA) and stained with 1ml CFDA-SE 
labelling solution for 10 minutes at 37°C on a MACSmix tube rotator. Labelling was stopped 
by addition of 13ml CFDA-SE washing solution. After a centrifugation step (300g, 7min), cells 
were incubated twice with CFDA-SE washing solution on a MACSmix tube rotator for 5min 
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and centrifuged after each step. Cells were resuspended in CFDA-SE culture medium at a 
final concentration of 1*104 cells/µl. 600.000 cells/well were seeded into a 96-well round 
bottom culture plate and stimulated with 32µl/ml CMV antigen, 32µl/ml CMV negative 
control (Bio Whittaker) or 2.5µg/ml SEB. For each stimulus, the following blocking antibodies 
were added in separate wells: PD-L1+PD-L2 (10µg/ml each), CTLA-4 (50µg/ml), TIM-3 
(10µg/ml), PD-L isotype control, CTLA-4 isotype control, and TIM-3 isotype control. In 
addition double blockade with TIM-3 and PD-L-1/2 and triple blockade with TIM-3, PD-L-1/2 
and CTLA-4 was performed. Cells were incubated for a total of 3 (SEB reactions) or 5 days 
(CMV antigen and CMV control reactions) at 37°C and 6% CO2. After 16-20 hours of 
stimulation, 240µl CFDA-SE culture medium was added to each well. After the end of the 
respective incubation period, 150µl supernatant of each well was sampled and frozen at  
-20°C for later analysis of secreted cytokines. The cells were transferred to FACS-tubes for 
subsequent flow cytometric staining. Cells were treated with 2mM EDTA for 15 minutes to 
disrupt cell-cell interactions, followed by washing with 2ml FACS buffer (300g, 7min). 
Staining was performed as indicated in Table 11 and cells were stored in 150µl 1%PFA at 4°C 
until flow cytometric analysis. 
Table 11: Staining protocol for stimulated CFSE labelled PBMC  
Antibody/Reagent Fluorochrome Volume [µl] 
CD4 PE 4.00 
CD8 PerCP 6.00 
CD3 APC 1.00 
FACS buffer  39.00 
Total volume  50.00  
2.3.7 Viral load analysis 
CMV DNA was determined based on current recommendations for pre-emptive monitoring 
(KOTTON et al., 2013b) and quantified from whole blood using the Cobas-Amplicor-assay 
(Roche Diagnostics). All analyses were performed as part of the clinical routine by the 
diagnostics department of Virology. The clinically relevant detection limit was 450 copies/ml. 
2.3.8 IgG-ELISA for detection of cytomegalovirus specific antibodies 
CMV specific antibodies were determined using an IgG ELISA (Euroimmun-AG). Titers <16 
RE/ml were classified as negative. 
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2.3.9 Differential blood-counts 
Differential blood counts were determined at the central laboratory of Saarland University 
Medical center according to standard procedures. The absolute numbers of lymphocytes/µl 
whole blood obtained via differential blood-counts was used for enumeration of absolute 
numbers of T cells and their subpopulations based on frequencies determined using flow 
cytometry.  
2.3.10 Multiplex assay for multiple cytokine analyses 
Simultaneous analysis of 27 cytokines was performed from stimulated PBMC using Luminex 
technology according to the manufacturer’s instructions (BioRad 27-plex, Reinach, 
Switzerland). These analyses were performed by Dr. Adrian Egli and Prof. Hans H. Hirsch as a 
collaborative project (Basel, Switzerland). 
2.3.11 Statistical analyses 
Statistical analysis was performed using GraphPad Prism-V5.02 (San Diego, CA). Mann 
Whitney-testing was used for comparisons of a single parameter between two patient 
groups. Wilcoxon matched-pairs testing was used to compare a single parameter in the 
same patient group at two different time points/clinical situations or in cellular 
subpopulations. Kruskall-Wallis test with Dunn´s post-test was used for comparison of a 
single parameter between three or more patient groups. For longitudinal analysis of a 
patient group at several time points Friedman test with Dunn´s post-test was used. 
Correlation of distinct cell populations or parameters was performed according to Spearman. 
Receiver operator characteristics (ROC) analysis was performed to analyse sensitivities and 
specificities. 
2.3.12 Data management  
Patient characteristics, clinical data, diagnostic results as well as parts of the measured data 
were managed in a specifically designed Microsoft Access database and pre-processed for 
further analysis by individual queries. These were further managed and pre-processed for 
statistical analyses by Pivot charts using Microsoft Excel software. 
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3 Results 
3.1 CMV immunomonitoring in transplant recipients 
Current immune monitoring approaches which largely focus on quantitative changes in CMV 
specific T cell responses are applicable to estimate the risk of CMV disease, but only of 
limited value to predict CMV reactivation episodes (LISBOA et al., 2012; MANUEL et al., 
2013; SESTER et al., 2001). We therefore designed a panel of phenotypical and functional 
markers and elucidated if changes in expression of these markers allow for prediction of 
CMV reactivation and relapse in longitudinally monitored transplant patients. 
3.1.1 Functional characterisation after antigen specific stimulation  
In this part of the thesis, analysis of a total of 28 CMV seropositive healthy controls, 51 
seropositive hemodialysis patients and 62 CMV infected kidney transplant recipients was 
performed. The kidney transplant recipients (KTR) were further stratified according to CMV 
infection status in patients with (n=38) and without (n=12) reactivation episode as well as 
patients with primary CMV infection (n=12). For all patients CMV specific CD4 T cells were 
quantified by determining the frequency of IFN/CD69 co-expressing cells and their 
functionality was further characterised by monitoring the co-expression of the cytokines 
TNF and IL-2. To elucidate if the CMV specific CD4 T cells show signs of anergy, we analysed 
the expression of three inhibitory T cell receptors, PD-1, CTLA-4 and TIM-3.  
3.1.1.1 Sole quantification of CMV specific CD4 T cells is valuable in patients after primary 
CMV infection, but of limited use in detecting CMV reactivation periods 
To elucidate if quantitative changes in CMV specific CD4 T cell frequencies correlate with 
CMV infection status, we compared CMV seropositive patients with and without reactivation 
episode and patients with primary viremia to patients on hemodialysis and healthy controls. 
Kidney transplant recipients during primary CMV infection showed significantly lower 
frequencies compared to hemodialysis patients and transplant recipients during CMV 
reactivation (Figure 3, p=0.0002), whereas no difference was observed between kidney 
transplant recipients with and without reactivation, hemodialysis patients and healthy 
controls. 
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3.1.1.2 Episodes of viral replication are paralleled by a loss in multifunctionality of CMV 
specific CD4 T cells  
Next, we wanted to assess if there are changes in T cell functionality depending on 
transplantation and CMV infection status. Whereas CMV specific CD4 T cells in healthy 
controls, dialysis patients and KTR without reactivation episodes were dominated by IFN-
TNF co-expressing cells (median>85.00% in all groups), a striking loss in IFN/TNF co-
expression was observed in patients with CMV primary infection (median 32.25%, p<0.0001, 
Figure 4A). This loss was mainly caused by a shift towards IFN single producing cells. 
Patients with reactivation showed only a slight loss in IFN/TNF co-expression compared to 
dialysis patients (p<0.05). Levels of IFN/IL2 co-expressing cells were generally lower 
(median<35.00% in all groups, Figure 4B), again resulting from a shift towards IFN single 
producing cells. In contrast to IFN/TNF co-expression, we observed a prominent additional 
loss in IFN/IL2 co-expressing cells during both reactivation (median=11.55%) and primary 
infection (median=6.76%), compared to healthy controls and dialysis patients (p<0.0001, 
Figure 4B).  
 
Figure 3: Frequencies of CMV specific CD4 T cells after antigen specific stimulation in transplant patients and 
controls. Frequencies of CMV specific CD4 T cells were compared between healthy controls, dialysis patients 
and kidney transplant recipients, who were stratified according to their CMV infection status. No difference in 
frequencies were observed, except for transplant recipients during primary CMV infection, who showed 
significantly lower frequencies than hemodialysis patients and transplant recipients with CMV reactivation 
(p<0.001 and p<0.01, respectively). If more than one data set per individual existed, mean values were 
calculated and displayed as a single value.  
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3.1.1.3 Longitudinal analysis reveals a viremia associated and partially reversible loss of 
CD4 T cell multifunctionality after kidney transplantation 
A total of 46 CMV seropositive kidney transplant recipients were longitudinally monitored 
pre-transplant and during the first 4 months after transplantation. Among those, 35 (76%) 
had detectable CMV viremia after transplantation with high level viremia in 14 (40%) cases. 
High level viremia was defined by at least one viral load >800 copies/ml, or >500 copies/ml 
on multiple time points and is used as a parameter to initiate antiviral therapy. Patients with 
low level viremia were only treated if additional clinical signs of CMV infection were present. 
Whereas IFN/TNF profiles in patients without reactivation and those with low level 
viremia was stable over time, a significant decrease in IFN/TNF co-expressing cells 
between month two and three post-transplant was observed in patients with high level 
viremia (p=0.001, Figure 5A). This loss was followed by a subsequent increase towards the 
end of the observation period. For IFN/IL2 co-expression, a trend towards reduced 
frequencies was observed in patients without reactivation, yet this decrease was 
significantly more pronounced in patients with high and low level viremia (p=0.09, p<0.0001, 
p<0.0001, respectively, Figure 5B). In contrast to IFN/TNF co-expression, levels of IFN/IL2 
co-expressing cells remained low throughout the end of the observation period.  
 
Figure 4: Changes in cytokine profiles according to CMV infection status. Frequencies of dual cytokine 
expressing cells IFN/TNF (A) and IFN/IL-2 (B) co-expressing cells were determined among CMV reactive CD4 
T cells. (A) IFN/TNF co-expressing cells were strikingly reduced in patients with primary infection (p<0.0001). 
(B) IFN/IL-2 co-expressing cells where reduced in both KTR during reactivation and primary infection 
(p<0.0001). If more than one data set per individual existed, mean values were calculated.  
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To elucidate if the observed dynamics in frequencies of multifunctional cells correlated with 
time of viral reactivation, results were stratified according to temporal proximity to the 
reactivation period (Figure 5C and D). In patients with high level reactivation a significant 
loss in IFN/TNF co-expressing cells was observed during the reactivation period, which 
rapidly reverted thereafter (p=0.0041, Figure 5C). In low level viremic patients IFN/TNF co-
expression remained stable even during the reactivation period (n.s., Figure 5C). Both 
patients with low and high level viremia showed a significant loss in IFN/IL2 co-expression 
during reactivation with only a slight reversion thereafter (p<0.0001 for both groups, Figure 
5D). This indicates that the ability of IFN producing CMV specific CD4 T cells to co-produce 
 
Figure 5: Longitudinal analysis reveals changes in cytokine profiles after transplantation and in relation to 
CMV viremia. CMV seropositive kidney transplant recipients were longitudinally analysed before (pre-Tx) and 
during the first four months after transplantation. Patients were stratified according to time from 
transplantation (A+B) and time from viremia (C+D). (A) Significant decrease in IFN/TNF co-expressing cells 
during the first two months after transplantation in patients with high level viremia but not in those with no or 
low level viremia. (B) Significant decrease in IFN/IL2 co-expressing cells after transplantation in patients with 
high level and low level viremia. (C) Loss of IFN/TNF co-expression occurs only during high level viremic 
episodes and reverses thereafter. (D) Loss of IFN/IL-2 co-expression occurs during high level and low level 
viremic episodes with only partial reversion. “Before viremia” refers to the analysis before the first CMV-DNA 
was positive, and “after viremia” denotes all analyses >28 days after the last positive viral load. If more than 
one data set existed, mean values were calculated. Median viral load in patients with low and high level 
viremia was 450 (IQR 50) and 2800 (IQR 6500) copies/ml, respectively.  
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IL-2 is sensitive to even low level viral replication and mostly irreversible, whereas TNF- co-
production is more stable and correlates closely with time of viremia. 
3.1.1.4 Increased expression of inhibitory T cell receptors in patients during CMV primary 
infection and reactivation  
To assess if the observed changes in CD4 T cell function during CMV primary infection and 
reactivation are associated with phenotypical signs of anergy, the expression of the three 
inhibitory T cell receptors PD-1, TIM-3 and CTLA-4 was analysed. The expression strength of 
these receptors was determined by their mean fluorescence intensity (MFI) on CMV specific 
IFN producing CD4 T cells, as illustrated in representative examples in Figure 6A-C. For all 
three receptors no difference in expression was observed between healthy controls, dialysis 
patients and kidney transplant recipients without CMV viremic episodes, yet patients with 
CMV reactivation and primary infection showed significantly increased expression levels 
(p<0.0001 each, Figure 6D-F). Expression during primary infection was generally higher than 
during reactivation, reaching significance for TIM-3 and CTLA-4, but not PD-1 expression. 
3.1.1.5 Close correlation between increased expression of inhibitory T cell receptors and 
episodes of viremia in longitudinally monitored transplant patients 
To investigate the temporal association between CMV replication and the expression of the 
three inhibitory T cell receptors, we longitudinally analysed 46 CMV seropositive kidney 
transplant recipients and 10 patients with primary CMV infection before and for a minimum 
of 4 months after transplantation. As illustrated in a representative patient without CMV 
reactivation (Figure 7, left panel) both frequencies of CMV specific CD4 T cells and MFI of the 
three inhibitory receptors remained stable over time. In a patient with reactivation (Figure 7, 
middle panel), expression of all three inhibitory receptors rapidly increased at onset of 
viremia and slowly decreased thereafter. A decrease in CMV specific CD4 T cell frequencies 
was also observed, although this succeeded the onset of viremia by several days. In a patient 
with primary infection, CMV specific CD4 T cells were detectable a few days after onset of 
viremia (Figure 7, right panel) and demonstrated a highly anergic phenotype. The expression 
of the inhibitory receptors decreased after cessation of primary viremia but increased again 
at onset of a secondary reactivation period, whereas a temporary decrease in frequency was 
observed not until several days later (Figure 7, right panel).  
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Figure 6: Increased expression of inhibitory T cell receptors during viremic episodes. Representative dotplots for the expression of PD-1 (A), TIM-3 (B) and CTLA-4 (C) are 
shown for healthy controls and kidney transplant recipients (KTR) stratified according to viremia. (D-F) Expression of all three inhibitory T cell receptors is significantly 
increased during both, CMV reactivation and primary infection. If more than one data set per individual existed, mean values were calculated. 
Longitudinal data for all 46 seropositive kidney transplant recipients were analysed in fixed 
time intervals after transplantation (Figure 8A-C) and in association with viremia (Figure 8D-
F). For PD-1 expression, an initial increase in the first month after transplant was observed in 
patients with and without reactivation episode, followed by a further increase in patients 
with high and low level viremia, whereas PD-1 expression decreased thereafter in patients 
without reactivation (p=0.0003, p<0.0001, p=0.009, respectively, Figure 8A). TIM-3 
expression was stable over time in patients with low level and without reactivation, but 
increased significantly in those with high level reactivation (p=0.0008, Figure 8B). For CTLA-4, 
expression remained stable in non-reactivating patients, yet significantly increased in low 
level and high level reactivating patients (p<0.0001, p<0.0001, respectively, Figure 8C).  
To elucidate if the observed increases in anergy marker expression correlated with viremia, 
the data were analysed in temporal association with viremia (Figure 8D-F). An increase in 
PD-1 expression was already observed prior to viremia in both low and high level 
reactivating patients (p<0.0001 each, Figure 8D). In high level reactivating patients, we 
observed a further increase during viremia followed by a decrease thereafter. TIM-3 
expression was found to be significantly upregulated during viremia in high level viremic 
patients (p<0.0001), whereas this did not reach statistical significance in low level 
reactivators (Figure 8E). In contrast to PD-1, there was no increase in expression prior to 
 
Figure 7: Dynamic changes in CMV specific immunity correlate with viral load. Typical examples of 
longitudinal data of each a CMV seropositive transplant recipient without and with reactivation episode and a 
patient with primary CMV infection are shown. Frequencies of CMV specific CD4 T cells and viral load 
[copies/ml] are depicted in the upper panel. DL denotes the detection limit for CMV specific CD4 T cells and 
CMV-DNA, respectively. Expression of the inhibitory T cell receptors PD-1, TIM-3 and CTLA-4 at each time point 
are depicted in the lower panel. 
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viremia. CTLA-4 significantly increased during viremia in both groups, but this increase did 
not precede viremia (p<0.0001, p=0.0005, Figure 8F). Taken together; TIM-3 discriminates 
best between high level and low level viremic patients, whereas PD-1 is the only marker 
which is significantly upregulated already during the pre-viremic episode. 
3.1.1.6 TIM-3 either alone or in combination with PD-1 and CTLA-4 predicts episodes of 
CMV reactivation  
To test the potential of the three markers to detect viremia in patients, we calculated the 
fold increase in anergy marker expression at onset of viremia (time of first positive viral load 
 
Figure 8: Expression of inhibitory T cell receptors correlates with time of viremia. CMV seropositive transplant 
recipients were longitudinally analysed before (pre-Tx) and during the first four months after transplantation. 
Patients were stratified according to time from transplantation (A-C) or time from viremia (D-F). (A) Increase in 
PD-1 expression in all patient groups, with highest increase in patients with high level viremia during the 
second month after transplantation. (B) Significant increase in TIM-3 expression in patients with high level 
viremia peaks during second month after transplantation. (C) Significant increase in CTLA-4 expression in 
patients with high level and low level viremia peaks between second and third month after transplantation. (D-
F) Upregulation of inhibitory T cell receptors precedes onset of viremia and peaks during viremic episodes in 
both patients with high level and low level reactivation with statistical significance for all but TIM-3 expression 
in low level viremic patients. “Before viremia” refers to the analysis before the first CMV-DNA was positive, and 
“after viremia” denotes all analyses >28 days after the last positive viral load. If more than one data set existed, 
mean values were calculated. Median viral load in patients with low and high level viremia was 450 (IQR 50) 
and 2800 (IQR 6500) copies/ml, respectively.  
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5.8±2.4 weeks after transplantation) compared to pre-transplant. For patients without 
reactivation, the mean expression between week 5 and 8 after transplantation was 
compared to that pre-transplant. As illustrated in Figure 9, fold increase in anergy marker 
expression discriminated between non-viremic and highly viremic patients (PD-1: AUC=0.74, 
p=0.022; CTLA-4: AUC=0.84, p=0.032; TIM-3: AUC=0.95, p=0.004; Figure 9A-C). Of the three 
markers, TIM-3 discriminated best with a sensitivity of 78.57% and a specificity of 100%. 
Next we assessed, if combined analysis of all three markers may further improve the 
diagnostic power and summed up the respective fold increases in expression. These 
combined analyses allowed good discrimination similar to, but not better, than the best 
marker TIM-3 individually (AUC=0.92, p=0.003, Figure 9D). As the ultimate goal of T cell 
monitoring is not to detect viremic episodes but to predict them, the same analysis was 
performed with the fold increase between baseline and the last measurement before onset 
of viremia (median 7 (IQR 4.8-12) days before onset of viremia). We now no longer saw 
significant differences in the increase in PD-1 and CTLA-4 expression between patients with 
high level viremia and without viremia (data not shown). In contrast a >1.3-fold increase in 
TIM-3 expression predicted viremia with 61.54% sensitivity and 100% specificity (AUC=0.81, 
p=0.009, Figure 9E). The combined increase of all three markers by >4-fold led to a higher 
sensitivity of 85.71% but lower specificity of 81.82% (AUC=0.85, p=0.006, Figure 9F). Thus, 
our data indicate that expression of all three inhibitory T cell receptors on CMV specific CD4 
T cells correlates closely with episodes of viremia. Analysis of TIM-3, either alone or in 
combination with PD-1 and CTLA-4 has substantial potential to predict viremia.  
3.1.2 Tetramer staining as a stimulation independent approach to characterise CMV 
specific CD8 T cells 
As demonstrated in the preceding chapter and in several publications by our group and 
others (KOTTON et al., 2013b; MANUEL et al., 2013; SESTER et al., 2001; SESTER et al., 
2008b; WIDMANN et al., 2008), CMV antigen specific stimulation is well suited for 
quantitation, phenotypical and functional characterisation of CMV specific immunity. Yet a 
technical disadvantage is the relatively long assay time and the prerequisite of live and fully 
functional T cells. One approach to limit assay time is the use of peptide-HLA-multimers 
(BROOIMANS et al., 2008; GRATAMA et al., 2001). In the following experiments we used  
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fluorochrome-labeled peptide-HLA-tetramers for ex vivo stimulation-independent analysis of 
CMV specific CD8 T cells.  
 
Figure 9: Evaluation of the diagnostic potential of inhibitory T cell receptors to detect patients at risk for CMV 
reactivation. Fold increase (FI) in expression of inhibitory T cell receptors is calculated between time of onset 
of viremia and pre-Tx. For patients without reactivation, the mean expression between week 5 and 8 post-
transplant is divided by the expression pre-transplant. ROC analysis was performed to find the threshold 
discriminating best between transplant recipients with high level reactivation and those without reactivation. 
(A-C) Of the three inhibitory T cell receptors, TIM-3 discriminates best between KTR with and without 
reactivation (PD-1: AUC=0.74, sensitivity=64.29%, specificity=90.91; CTLA-4: AUC=0.84, sensitivity=100%, 
specificity=63.64%; TIM-3: AUC=0.95, sensitivity=78.57%, specificity=100%). (D) Combined analysis of all three 
inhibitory T cell receptors does not further enhance diagnostic power (AUC=0.92, sensitivity=92.86%, 
specificity=81.82%). (E+F) Fold increase in expression was calculated between the last measurement before 
onset of viremia (median 7 (IQR: 4.8-12) days before viremia) and pre-transplant. TIM-3 and the combination of 
all three markers discriminated well between patients with and without viremic episode (AUC=0.81, 
sensitivity=61.54%, specificity=100% and AUC=0.85, sensitivity=85.71, specificity=81.82%). The threshold 
discriminating best between patients with and without reactivation is indicated by a stippled line.  
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3.1.2.1 Tetramer CD8 T cell frequencies correlate with the peptide specific immune 
response after stimulation but do not differ between patient groups 
To elucidate if CMV specific peptide-HLA-tetramers are suitable to assess the CMV specific 
immunity, we analysed 17 healthy controls and a total of 72 immunocompromised 
individuals, which included 15 patients on hemodialysis, 43 patients after kidney 
transplantation and 14 after stem cell transplantation. Individuals were chosen based on 
positive CMV serostatus and positivity of at least one of the indicated HLA-molecules A2, A1 
and B7. This precluded a priori ~40% of CMV seropositive individuals, which were negative 
for all three HLA molecules included in the tetramers used (RAHMEL, 2013).  
 
 
Figure 10: Tetramer positive CD8 T cells correlate with peptide reactive CD8 T cells and their frequencies do 
not differ between patient groups. (A-B) Close correlation between tetramer positive and peptide reactive 
CD8 T cell frequencies, determined via positive staining for tetramer-PE and IFN-FITC, respectively. (C-D) Low 
sensitivity for detection of CMV specific CD8 T cells after both, tetramer staining and peptide stimulation, but 
no significant differences in frequencies between healthy controls (HC), hemodialysis patients (HD), stem cell 
transplants (SCT) and kidney transplants (Tx). 
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Fourty-four out of 64 individuals (68.75%) showed cells reactive to HLA-A*0201 NLVPMVATV 
CMV pp65, 10/14 (71.43%) to HLA-A*0101 VTEHDTLLY CMV pp50, 12/15 (80%) to HLA-
A*0101 YSEHPTFTSQY CMV pp65 and 7/15 (46.66%) to HLA-B*0702 TPRVTGGGM CMV pp65. 
Thirteen individuals reacted to two or more (14.61%) and 14 (15.73%) to none of the 
tetramers. In 11 healthy controls and 52 of the immunocompromised patients, peptide 
specific stimulation was performed in parallel with the same peptides as included in the 
tetramers. As illustrated in Figure 10A and B, we observed a close correlation between 
frequencies of tetramer positive cells and peptide reactive cells in our study population. 
When comparing healthy controls and the three immunocompromised patients groups, no 
significant differences were observed in the frequencies enumerated by tetramers and those 
after peptide stimulation (Figure 10C and D). Yet, despite the fact that only seropositive 
individuals were included, sensitivity was variable, with tetramer positive cells being 
detectable in 84.27% of the study population and peptide reactive cells in 92.10% (Figure 
10C and D).  
 
Figure 11: PD-1 expression on tetramer cells correlates with viral load and reactivation episodes after 
transplantation. (A) PD-1 expression on tetramer positive CD8 T cells is increased during viremia. (B) Peptide 
reactive CD8 T cells show an insignificant trend towards higher PD-1 expression during viremia. (C-E) 
Frequencies of PD-1 expressing tetramer positive CD8 T cells correlate with viral load (C), PD-1 expression on 
peptide reactive CD8 T cells (D) and inversely with their functionality (E). 
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3.1.2.2 Increased PD-1 expression on tetramer cells during CMV viremia 
Similar to analysis of inhibitory T cell receptors on CMV specific CD4 T cells, we tried to 
elucidate if PD-1 expression on tetramer positive CD8 T cells might be indicative of CMV 
viremic episodes. Indeed, we observed a specific upregulation of PD-1 expression during 
viremia, compared to pre-viremic patients and patients without CMV reactivation (p=0.0052, 
Figure 11A). We saw a similar yet non-significant trend for PD-1 expression on peptide 
reactive CD8 T cells after stimulation (n.s., Figure 11B). This might be due to the smaller 
sample size, as PD-1 expression on tetramer positive and peptide reactive cells correlated 
closely (r2=0.65, p<0.0001, Figure 11C). The ratio between IFNproducing CD8 T cells after 
peptide stimulation and tetramer positive CD8 T cells after surface staining revealed a 
correlation between high expression of PD-1 and reduced functionality (r2=0.06, p=0.012, 
Figure 11D). In line with that we found a correlation between PD-1 expression levels on 
tetramer positive cells and level of viral load in patients (r2=0.83, p<0.0001, Figure 11E).  
3.1.3 CD28-CD27- CD4 T cells as a stimulation independent correlate of CMV specific 
immunity 
As currently available CMV specific tetramers allow only for analysis of CD8 T cell immunity, 
require the knowledge of patient HLA-status and represent only a small fraction of the CMV 
specific T cell immunity, we looked into alternate stimulation independent approaches to 
characterize CMV specific T cells. It is known that one prominent effect of CMV infection on 
the T cell repertoire is the loss of CD28 and CD27 expression. Whereas CD28 and/or CD27 
negative CD8 T cell populations exist in both CMV seropositive and CMV seronegative 
individuals, over 99% of the CD4 T cell population in seronegative individuals are CD28 
and/or CD27 positive ((DERHOVANESSIAN et al., 2011; VAN DE BERG et al., 2008; VAN 
LEEUWEN et al., 2004) and own unpublished data). Therefore we explored if analysis of 
CD28-CD27- CD4 T cells might serve as a reliable stimulation independent correlate of CMV 
specific immunity. 
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3.1.3.1 CD28-CD27- CD4 T cells serve as a reliable marker to define the CMV infection  status 
To address whether the occurrence and frequency of CD28-CD27- CD4 T cells may represent 
an estimate of CMV specific immune responses, CD28-CD27- CD4 T cells were quantified 
from a total of 316 samples from CMV seropositive and seronegative non-symptomatic 
healthy controls and immunocompromised patients, and compared with CD4 T cell 
frequencies identified using intracellular cytokine staining after CMV specific stimulation. 
Representative dotplots of each a CMV seropositive and seronegative healthy control person 
and kidney transplant recipient are shown in Figure 12A. As shown in a representative 
example, CD28-CD27- CD4 T cells after surface staining were largely CD62L-CD45RO+ effector 
memory cells (Figure 12B; 60.1%, IQR 37.2%, n=17) and their frequencies correlated closely 
with those of CMV reactive CD4 T cells after CMV antigen specific stimulation (Figure 12C, 
r=0.73, p<0.0001). 
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To analyse whether the presence of CD28-CD27- CD4 T cells may serve as a reliable marker 
for CMV-seropositivity, results from the 57 CMV seropositive and 36 seronegative healthy 
controls were compared using ROC analysis. As shown in Figure 12D, CD28-CD27- CD4 T cell 
frequencies were significantly lower in seronegative individuals (p<0.0001), and a 
percentage of 0.44% CD28-CD27- CD4 T cells discriminates between CMV seropositive and 
 
Figure 12: Close correlation between frequencies of CD28
-
CD27
-
 and stimulation induced CMV specific CD4 T 
cells. (A) Representative examples of CD28
-
CD27
-
 and CMV-specific CD4 T cell frequencies in each, a CMV 
seropositive and seronegative healthy control and renal transplant recipient. (B) Representative dotplots of 
CD62L and CD45RO expression patterns on CD28
-
CD27
-
 -CD4 T cells and non CD28-CD27- CD4 T cells. The 
majority of CD28
-
CD27
-
 CD4 T cells show an effector memory phenotype (60.1%, IQR 37.2%, 8 controls and 9 
transplant recipients, data not shown), which holds true for both controls and patients. In comparison with non 
CD28
-
CD27
-
 CD4 T cells, not only effector memory but also terminally differentiated memory populations are 
enriched among CD28
-
CD27
-
 CD4 T cells (3.1-fold and 20.8-fold enrichment, respectively). (C) Frequencies of 
CD28
-
CD27
-
 and CMV specific CD4 T cells in samples assessed in parallel correlate closely (r=0.73, p<0.0001). 
CD28
-
CD27
-
 CD4 T cells were assessed in 57 CMV seropositive and 36 seronegative healthy controls. (D) 
Frequencies were significantly higher in the seropositive (median 3.23%, IQR 5.45%) compared to the 
seronegative cohort (0.14%, IQR 0.19%; p<0.0001). ROC analysis revealed a detection limit of ≥0.44% CD28- 
CD28
-
CD27
-
 CD4 T cells to discriminate with a sensitivity of 93% and a specificity of 97% between CMV 
seropositive and seronegative individuals (AUC 0.98; p<0.0001). We did not consider CD28
-
CD27
-
 CD8 T cells in 
our study, as a substantial proportion of these cells were also found in CMV seronegative individuals (median 
14.7%, from 3.8-27.1%, n=6). 
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seronegative individuals with a sensitivity of 93% and specificity of 97% (AUC 0.98). Likewise, 
this detection limit also discriminates well between seropositive and seronegative 
individuals with immunodeficiency such as hemodialysis patients (sensitivity 94%, specificity 
100%, AUC=0.98) and transplant recipients (sensitivity 97%, specificity 89%, AUC=0.99; data 
not shown). Thus, CD28-CD27- CD4 T cell frequencies 0.44% may serve as a reliable marker 
to define a positive CMV infection status.  
3.1.3.2 CD28-CD27- CD4 T cells are induced after CMV primary infection 
As the presence of CD28-CD27- CD4 T cells was linked to CMV positivity, we comparatively 
investigated the evolution of CD28-CD27- CD4 T cells and CMV specific CD4 T cells in the 
context of primary infection. A total of 10 CMV seronegative recipients of a CMV 
seropositive graft with CMV primary infection were studied of which only eight had received 
CMV prophylaxis for the first 12 weeks after transplantation. Median CD28-CD27- CD4 T cell 
frequencies showed a significant increase from 0.07% (interquartile range IQR 0.25%) before 
onset of primary viremia to 2.61% (IQR 3.28%) after its resolution (p=0.002, Figure 13A), 
 
Figure 13: CD28
-
CD27
-
 and stimulation induced CMV specific CD4 T cells develop after primary CMV infection. 
(A) Significant increase in CD28
-
CD27
-
 CD4 T cell frequencies after CMV primary infection in CMV seronegative 
recipients of a CMV seropositive transplant (p<0.002, n=10). If more than one data set existed, mean values 
were calculated for each patient. (B) Typical examples of the time course of CD28
-
CD27
-
 CD4 T cells and CMV 
specific CD4 T cells in 6 patients with CMV primary infection. Onset of CD28
-
CD27
-
 and CMV reactive CD4 T cells 
may occur parallel to onset of viremia (left panels). Onset of CMV reactive CD4 T cells may precede onset of 
CD28
-
CD27
-
 CD4 T cells (middle panel). In two patients who did not receive prophylaxis due to misclassification 
of the donor CMV infection status, development of CMV specific CD4 T cells was delayed and CD28
-
CD27
-
 CD4 T 
cells remained below the cutoff (right panel). CD28
-
CD27
-
 and CMV reactive CD4 T cells are indicated by black 
and white circles and their individual cutoffs by a dotted or stippled horizontal line, respectively. Gray curves 
depict viral load (right axis, detection limit (DL) 450 copies/ml). Seroconversion (SC) is indicated by a dotted 
vertical line. Small and large shaded areas indicate duration of antiviral prophylaxis and therapy, respectively, 
with valganciclovir. Arrows indicate administration of CMV specific immunoglobulins. 
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although the time of first detection varied. Individual time courses of CD28-CD27- CD4 T cells 
and CMV specific CD4 T cell frequencies in association with CMV load are shown in Figure 
13B for 6 typical patients. The two patients in the left panels show a rapid onset of both 
CMV specific and CD28-CD27- CD4 T cells directly after onset of primary CMV viremia. In the 
middle panels, the onset of detectable CMV specific CD4 T cell frequencies preceded that of 
CD28-CD27- CD4 T cells. The right panels depict the time courses of the two patients who 
inadvertently did not receive CMV-prophylaxis. As expected, primary viremia occurred early 
after transplantation (week 4 and 5, respectively) compared to the other 8 patients (median 
week 23, from week 18 to 49, data not shown). Interestingly, these two patients developed 
comparably low levels of CMV specific CD4 T cell frequencies only late after resolution of 
primary viremia, and CD28-CD27- CD4 T cells remained below the detection limit during the 
entire observation period. Taken together, consistent with the acquisition of a positive CMV 
infection status, CD28-CD27- CD4 T cells evolve after CMV primary infection in the majority 
of transplant recipients. 
 
Figure 14: Comparison of CD28
-
CD27
-
 CD4 T cell frequencies between patients groups and their dynamics 
after transplantation. (A) Comparable frequencies of CD28
-
CD27
-
 CD4 T cells in transplant patients with and 
without reactivation episode, healthy controls and dialysis patients and markedly lower frequencies in 
transplant patients during primary CMV-viremia. Mean values are shown if more than one dataset per person 
existed. For patients with reactivation and primary infection, only datasets during viremic episodes are 
depicted. (B) Kinetics in the percentage of CD28
-
CD27
-
 CD4 T cells during the first month after transplantation 
differ between viremic and non-viremic patients. (C) Absolute numbers of CD28
-
CD27
-
 CD4 T cells show 
significant changes in both viremic and non-viremic patients. Data in panels B and C are normalized to the 
respective pre-transplant values. 
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3.1.4 CD28-CD27- CD4 T cell frequencies differ in viremic patients with reactivation and 
primary infection 
To analyse whether viremia was associated with quantitative changes in CD28-CD27- CD4  
T cells, their frequencies were compared between age-matched CMV seropositive healthy 
controls (n=38), dialysis patients (n=54), and non-viremic transplant recipients (n=20). In 
addition, viremic transplant recipients at the time of reactivation (n=42) or primary CMV 
infection were analysed (n=12; A). Of note, patients during CMV reactivation showed similar 
levels of CD28-CD27- CD4 T cells as non-viremic transplant recipients, dialysis patients and 
healthy controls (n.s., Figure 14A). In contrast, although the CD28-CD27- CD4 T cell 
population evolved in most patients after cessation of primary CMV infection , their median 
frequencies during the primary infection episode itself were significantly lower (1.63%, IQR 
2.55%, p=0.0003, see also Figure 14). To analyse dynamic changes in patients before and 
after reactivation, we longitudinally analysed a total of 46 CMV seropositive renal transplant 
patients before and in the first four months after transplantation and relative and absolute 
numbers of CD28-CD27- CD4 T cells were plotted against the pre-transplant values (Figure 
14B and C). Among those, 35 developed CMV viremia, whereas 11 remained CMV-DNA 
negative throughout this period. Of note, while kinetics in relative percentages of  
CD28-CD27- CD4 T cell frequencies exhibited significant changes in viremic patients only 
(Figure 14B, p<0.0001), absolute numbers showed some initial decline in both viremic and 
non-viremic patients (Figure 14C). This indicates that the mere quantitation of CD28-CD27- 
CD4 T cells and in particular their dynamics in absolute numbers are inappropriate to 
distinguish between patients with and without reactivation.  
3.1.4.1 Increased expression of PD-1 on CD28-CD27- CD4 T cells in patients with viremia 
To elucidate whether increased expression levels of PD-1 and CTLA-4 on CD28-CD27- CD4  
T cells are associated with viremia in CMV seropositive individuals, we analysed CD28-CD27- 
CD4 T cells for co-expression of PD-1 and CTLA-4 in 28 healthy controls, 51 hemodialysis-
patients and 69 renal transplant recipients. The latter were stratified into patients without 
viremic episodes (n=19), patients with CMV reactivation (n=41) and patients with primary 
CMV infection (n=9). Representative histograms of PD-1 and CTLA-4 expression on  
CD28-CD27- CD4 T cells as compared to remaining CD4 T cells in a control, in a patient 
without viremia, and viremic patients at the time of reactivation or primary infection are 
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shown in figure Figure 15A and B, respectively. When compared to healthy controls and 
hemodialysis-patients, both patients with reactivation and CMV primary infection showed a 
significantly higher PD-1 expression on CD28-CD27- CD4 T cells (median MFI 767, IQR 569; 
and 863, IQR 533 respectively, p<0.0001, Figure 15C). In addition, their PD-1 expression 
levels correlated with viral load (r=0.24, p=0.0007, data not shown). In contrast, whilst  
CTLA-4 expression was significantly higher in individuals during primary CMV infection 
(median MFI 595, IQR 207; p=0.03), this was not the case in those with reactivation (MFI 483, 
IQR 220; Figure 15D).  
3.1.4.2 An increase in PD-1 expression on CD28-CD27- CD4 T cells correlates with periods of 
viremia in longitudinally monitored transplant recipients 
To analyse dynamics of PD-1 and CTLA-4 expression on a single patient basis, we 
longitudinally analysed kidney transplant recipients with regard to their PD-1 and CTLA-4 
expression levels before and after transplantation. To allow for PD-1 analysis independent of 
local flow cytometer settings and of potential PD-1 expression on non-CD28-CD27- CD4  
T cells, we calculated a PD-1 expression score as a ratio of PD-1 MFI on CD28-CD27- CD4  
T cells divided by the PD-1 MFI of non-CD28-CD27- CD4 T cells, and data were plotted in 
relation to the pre-transplant values. Meaningful analysis of PD-1 and CTLA-4 co-expression 
was precluded in one patient with and one without reactivation, as their CD28-CD27- CD4  
T cell frequencies remained under the threshold of 0.44% (see Figure 15B). 
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 Of note, in patients with reactivation, a significant increase in PD-1 expression was observed 
during the first two months after transplantation, which decreased thereafter (p<0.0001, 
Figure 16A). In contrast, PD-1 expression in non-viremic patients only slightly increased, but 
changes did not reach statistical significance. The CTLA-4 expression score also showed 
significant changes over time, but this held true for both viremic and non-viremic patients 
(Figure 16B). The subgroups of low and high level viremic patients were additionally 
analysed in temporal association with viremia, i.e. before, during and after resolution of 
viremia (Figure 16C and D). Compared to pre-transplant, there was a significant increase in 
the PD-1 expression score during the reactivation episode for both high- and low level 
viremic patients, which was preceded by a strong increase prior to reactivation and followed 
by a decrease after resolution of viremia (Figure 16C, p<0.0001 respectively). In contrast, 
increases in CTLA-4 expression were less pronounced (Figure 16D). 
 
 
Figure 15: Expression profiles of PD-1 and CTLA-4 on CD28
-
CD27
-
 CD4 T cells in association with CMV-
infection status. Representative examples of PD-1 (A) and CTLA-4 (B) expression on CD28
-
CD27
-
 CD4 T cells 
(black line) in each, a CMV seropositive healthy control, a renal transplant-recipient without viremia, with CMV 
reactivation or CMV primary infection. Respective expression levels on non CD28
-
CD27
-
 CD4 T cells are depicted 
as gray lines. (C) Both transplant recipients with CMV primary infection and CMV reactivation expressed 
significantly higher levels of PD-1 on CD28
-
CD27
-
 CD4 T cells compared to healthy controls (p<0.001) and 
dialysis patients (p<0.001) and showed a trend towards higher expression compared to transplant recipients 
without viremic episodes. (D) CTLA-4 expression was significantly higher in patients with CMV primary infection 
compared to healthy controls (p<0.01). Bars indicate median expression levels. Each patient is depicted once, 
apart from some of the dialysis patients who underwent kidney transplantation and were assigned to the 
dialysis and to the respective transplant group according to viremia. If more than one data set existed, mean 
values were calculated for each patient. 
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Figure 16: PD-1 and CTLA-4 expression on CD28
-
CD27
-
 CD4 T cells in association with viremia in prospectively 
monitored transplant recipients. (A) Significant increase in PD-1 expression in the first two months after 
transplantation in patients with, but not those without CMV reactivation episode. (B) Significant changes in 
CTLA-4 expression in the first month post-transplant in both patients with and without reactivation episodes. 
(C) PD-1 upregulation precedes onset of viremia and peaks during viremic episodes in both patients with high 
level and low level reactivation. (D) Significant yet less pronounced upregulation of CTLA-4 expression before 
and during CMV reactivation episodes. “Before viremia” refers to the analysis before the first CMV-DNA was 
positive, and “after viremia” denotes all analyses >28 days after the last positive viral load. If more than one 
data set existed, mean values were calculated. Median viral load in patients with low and high level viremia 
was 450 (IQR 50) and 2800 (IQR 6500) copies/ml, respectively. Data are normalized to the respective pre-
transplant values. 
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3.1.4.3 Evaluation of the diagnostic potential of PD-1 analysis on CD28-CD27- CD4 T cells 
Although PD-1 expression dynamics may have been confounded by antiviral therapy, we 
evaluated the diagnostic potential of monitoring PD-1 expression on CD28-CD27- CD4 T cells 
to identify patients with reactivation among CMV seropositive transplant recipients. The 
increase in PD-1 expression at the time of viremia was calculated by the ratio of the 
respective PD-1 expression score at the day of first detectable viral load (5.8±2.4 weeks after 
transplantation) and pre-transplant. For patients without reactivation, the mean score 
between week 5 and 8 after transplantation was compared to that pre-transplant. ROC 
analysis revealed a ≥1.3-fold increase to be indicative of viremia with a sensitivity of 87% and 
a specificity of 60% (AUC=0.73, p=0.034, Figure 17A). Assessment of high level viremia by an 
increase of ≥1.6 was less sensitive (75%), but specificity was higher (80%, AUC=0.80, p=0.018, 
data not shown).  
 
Figure 17: Evaluation of the diagnostic potential for measuring PD-1 expression on CD28
-
CD27
-
 CD4 T cells. 
(A) The increase in PD-1 expression is significantly higher in CMV-seropositive transplant-recipients with 
reactivation compared to patients without reactivation. ROC analysis revealed a cutoff value ≥1.3 to be best 
predictive of CMV-viremia (AUC=0.73, sensitivity 87%, specificity 60%). Fold increase in PD-1 expression was 
determined as the ratio between PD-1 score at time of first positive viral load and PD-1 score pre-transplant. 
For patients without viremic episode mean PD-1 score during week 5 and 8 post-transplant was divided by the 
PD-1 score pre-transplant. (B) PD-1 score ≥3.1 at time of therapy cessation is specific for patients with 
recurrent CMV-viremia. ROC analysis revealed a PD-1 score ≥3.1 to predict recurrence of CMV-viremia with 
100% specificity and 53% sensitivity (AUC=0.66). Transplant recipients with therapy indicated CMV reactivation 
(circles) or primary infection (squares) were analysed for PD-1 expression at the end of therapy. The PD-1 score 
was determined as the ratio between PD-1 MFI on CD28
-
CD27
-
 and non-CD28
-
CD27
-
 CD4 T cells.  
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Figure 18: CTLA-4 expression is increased on TNF and IFN single producing CD4 T cells. Combined data from 
healthy controls and immunocompromised patients with and without viremic episodes reveals increased 
expression of CTLA-4 on TNF and IFN single producing CD4 T cells (p<0.0001). Compartments of TNF and 
IFN single and co-producing cells were flow cytometrically determined after CMV specific stimulation with 
subsequent ICS and analysed for CTLA-4 expression by MFI. 
We next analysed whether the PD-1 expression score after the end of therapy may predict 
additional episodes of viremia. In our center antiviral therapy is typically terminated after 
four weeks with at least two consecutive negative viral load determinations. A total of 27 
patients (18 after CMV reactivation, 9 after primary CMV viremia) were included in this 
analysis of which 15 experienced a second episode of viremia. As shown in Figure 17B, the 
PD-1 expression score at the end of treatment was significantly higher in individuals 
experiencing subsequent viremia. Interestingly, although sensitivity was low (53%), a PD-1 
score of ≥3.1 had a 100% specificity to predict a second viremic episode (AUC=0.66, p=0.032).  
3.1.5 Functional T cell anergy during viremic episodes is marked by an altered cytokine 
expression pattern and can be reversed by blocking inhibitory T cell receptors 
In the previous chapters of this thesis, both changes in inhibitory T cell receptor expression 
and cytokine profiles were shown to be associated with episodes of viremia after 
transplantation. Therefore, we analysed if inhibitory T cell receptor expression was 
associated with changes in cytokine profiles. Furthermore, we performed CFSE dilution 
assays with and without blockade of inhibitory pathways to elucidate the effect of inhibitory 
T cell receptors on CMV specific proliferation. In addition, multiplex cytokine analysis was 
performed from the supernatants to explore potential alterations in cytokine expression and 
to analyse if altered cytokine expression may be reverted by blockade of inhibitory pathways.  
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3.1.5.1 Polyfunctional T cells show lower grade of anergy compared to IFN or TNFα -only 
producing T cells  
Cells from healthy controls and immunocompromised patients with and without viremic 
episodes were co-stained with the cytokines IFN and TNF and the inhibitory T cell receptor 
CTLA-4 after CMV specific stimulation. As illustrated in Figure 18, TNF and especially IFN 
single positive cells expressed significantly higher levels of CTLA-4 than IFN/TNF co-
expressing cells (p<0.0001). This indicates that high expression of CTLA-4 might play a role in 
the loss of T cell multifunctionality. 
3.1.5.2 Patients with high expression levels of inhibitory T cell receptors show a reduced 
proliferative capacity, which can be in part restored by blockade in vitro  
As high expression of inhibitory T cell receptors was associated with a functional loss in 
cytokine production, we now assessed to which extent these receptors also negatively 
impact the proliferative capacity and if this can be reverted by blockade of the inhibitory 
pathways. Therefore we intentionally chose three transplant patients with high level 
expression of all three inhibitory receptors (PD-1, TIM-3, and CTLA-4) on their CMV specific 
CD4 T cells (MFI>median of the CMV reactivating group for each marker), five with medium 
levels (MFI<median of the CMV reactivating group for at least two of the markers) and a 
healthy control with low levels (MFI<median of the healthy control group for all markers, see 
Figure 6). The median levels of proliferating CD4 T cells were 0.95% (range 0.25-2.5%) in the 
high level group, 6.86% (1.51-37.14%) in patients with medium levels and 20.02% for the 
healthy control after 5 days stimulation with CMV antigen (data not shown). Proliferative 
responses towards SEB were similar in all individuals tested (data not shown). To assess the 
effect of inhibitory receptor blockade, we additionally performed proliferation assays with 
antibody mediated blockade of the single inhibitory T cell receptor pathways or their 
respective isotype controls, and combined blockade of the PD-1 and TIM-3 pathways or all 
three markers (PD-1, TIM-3, and CTLA-4). Of note, whereas TIM-3 and CTLA-4 were directly 
targeted by blocking antibodies, PD-1 blockade was achieved indirectly by combined 
blockade of the ligands PD-L1 and PD-L2. In all samples containing CTLA-4 or the CTLA-4 
isotype control antibodies, we observed an unspecific negative impact on proliferation, and 
both CMV and SEB stimulated samples were affected (data not shown). Therefore these 
samples were excluded from further analysis. In two patients from the medium level group, 
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no combined blockade of TIM-3 and PD-L1/2 was done, as cell numbers were not sufficient 
to perform all stimulatory reactions.  
As illustrated in representative dotplots from a patient with high anergy marker expression 
(Figure 19A), individual blockade of TIM-3 signalling led to a 1.2fold increase in proliferation 
of CMV specific CD4 T cells (Figure 19C, p=0.027). Individual blockade of PD-L1/2 led to a 
2.4fold increase in proliferation (p=0.008), which was not altered after combined blockade of 
TIM-3 and PD-L1/2 (2fold increase, p=0.016, Figure 19C). As expected, the effect of blockade 
was higher in patients with high expression levels of anergy markers (see colour code in 
Figure 19C) and highest in a patient, who was acutely viremic at time of analysis (indicated 
by asterisks, Figure 19C). Interestingly, blockade of PD-L1/2 alone led to a slight but 
significant decrease in SEB reactive proliferation of 1.05fold (p=0.004) and a non-significant 
decrease of 1.07fold in combination with TIM-3 (Figure 19E). 
In contrast to CMV specific CD4 T cell proliferation, we observed no significant effect of  
TIM-3 blockade upon CD8 T cell proliferation (n.s., Figure 19B and D). Blockade of PD-L1/2 
alone or in combination with TIM-3 led to 2.2fold and 1.6fold increases in proliferation 
(p=0.008 and p=0.031, respectively, Figure 19D). As with CD4 T cells, the effect of blockade 
was higher in patients with high levels of anergy marker expression and highest for the 
acutely viremic patient (see Figure 19D). Likewise, blockade of PD-L1/2 alone led to a slight 
but significant decrease in SEB reactive proliferation of 1.07fold (p=0.004), and a non-
significant decrease of 1.09fold in combination with TIM-3 (Figure 19F). 
Figure 19 (next page): Blockade of inhibitory receptors partly restores proliferative capacity of anergic T cells. 
CFSE dilution after antigen specific stimulation of freshly isolated PBMC was analysed in three transplant 
patients with high level expression of all inhibitory receptors on their CMV specific CD4 T cells, five with 
medium levels and a healthy control with low levels. Mean fluorescence intensities (MFI) >median of the CMV 
reactivating group for each marker was regarded as high level expression, MFI of <median of the healthy 
control group as low level expression and MFI<median of the CMV reactivating group for at least two out of 
three markers as medium expression (see Fig. 4). Representative examples of proliferating CD4 (A) and CD8 T 
cells (B) after stimulation with CMV control antigen, CMV antigen or SEB with and without blocking antibodies 
against PD-L1/2 and TIM-3 or isotype controls are illustrated (left panels) and the respective frequencies of 
proliferating CFSE-low cells indicated (right panel). Fold increase (FI) in proliferation compared to isotype 
control proliferation is illustrated for CD4 and CD8 T cells after CMV specific (C+D) and SEB stimulation (E+F). 
Patients with high and medium level expression of anergy markers are indicated in red and orange and the 
healthy control in green respectively. Asterisks indicate the single patient who was viremic at time of analysis. 
As for two patients with medium anergy marker expression PD-L1/2 single and TIM-3 single blockade but not 
combinatorial blockade was performed, Wilcoxon matched pairs test was used to test for differences between 
samples with blocking antibodies and isotype controls and Friedman test excluding those two data sets were 
performed to test for overall significance. In addition, one individual with medium level anergy marker 
expression did not show CD8 T cell proliferation in any sample and was hence excluded from analysis. b denotes 
blocking antibodies. 
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3.1.5.3 Reduced proliferative capacity of PD-1 high expressing cells can be reversed via PD-
L-blockade  
As our data from the previous chapter indicate that PD-1 is the anergy marker with the most 
pronounced effect on T cell proliferation we next performed proliferation assays with and 
without blockade of the PD-1 pathway and subsequent cytokine analysis of the respective 
supernatants. Therefore we specifically chose three healthy controls, five transplant 
recipients with low and five with high PD-1 expression on CMV specific T cells for this set of 
experiments. Representative dotplots of PD-1 expression on CMV specific CD4 and CD8 T 
cells in healthy donors and renal transplant recipients are shown in Figure 20A. Transplant 
recipients with a high percentage of PD-1 expressing CMV specific T cells (n=5; median 63.9%, 
range 53.7%-87.0%) were compared to patients with a low percentage of PD-1 expressing 
cells (n=5; median 28.7%, range from 15.9%-39.2%; Figure 20B, data refer to both CD4 and 
CD8 T cells), where the PD-1 high group was defined by having more than 50% PD-1 
expressing CMV specific T cells We observed a strong correlation between PD-1 expression 
on total unstimulated CD4 and CD8 T cells and total CD4 and CD8 T cells after stimulation 
with CMV antigen or SEB (Figure 20D). This excludes an unspecific impact of in vitro 
stimulation on PD-1 expression. Three out of the five patients with high PD-1 expression had 
concomitant CMV viremia, whereas viral load in all patients with low PD-1 expression was 
below the limit of detection (<450 copies/mL). The overall frequencies of CMV specific T cells 
in the two patient groups were not significantly different and corresponded to those found 
in healthy controls (p=0.59, Figure 20C). However, as shown in Figure 20E and F, the 
percentage of proliferating T cells after 5 days of CMV specific stimulation was lower in 
transplant recipients with high PD-1 expression (p=0.03, Figure 20F). We have previously 
shown that the low proliferative capacities of PD-1 positive CMV specific T cells can be 
restored in the presence of a combination of antibodies towards PD-L1 and PD-L2 (anti-PD-L) 
(SESTER et al., 2008b). To assess, whether this is associated with a concomitant restoration 
of cytokine production, the effect of anti-PD-L blockade on CMV specific cytokine release 
was analysed. In our group of individuals, anti-PD-L blockade led to a 3-fold increase in CMV 
specific proliferation in patients with high PD-1 expression, whereas no such effect was 
observed in controls or patients with low PD-1 expression (p=0.009, Figure 20). Data 
displayed in Figure 20B-C and F-G represent combined results for CD4 and CD8 T cells to 
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account for the fact that cytokines subsequently analysed from supernatants of stimulated 
PBMC cannot be assigned to an individual cell population. 
 
 
 
Figure 20: PD-1 as a marker of reversible functional anergy in transplant patients. (A) Representative 
examples of PD-1 expression on CMV specific CD4 and CD8 T cells are shown for a control and transplant 
recipients with low and high PD-1 expression, respectively. (B) The percentage of PD-1 expressing cells among 
CMV-specific T cells and (C) the frequency of CMV-specific T cells were determined after specific stimulation 
using flow cytometry. As with the percentage of PD-1 positive CMV specific T cells, the mean fluorescence 
intensity (MFI) of PD-1 on CMV specific T cells was significantly different among controls (median 6.4; range 
5.8-19.7), PD-1 low transplant recipients (15.4; 9.8-18.9) and PD-1 high transplant recipients (24.7; 22.3-65.7, 
p=0.01). (D) PD-1 expression on unstimulated CD4 and CD8 T cells correlated with PD-1 expression on CD4 and 
CD8 T cells after stimulation with CMV antigen or SEB thereby excluding a stimulation bias of PD-1 expression. 
(E) Representative examples of CFSE-assays from CD4 and CD8 T cells after CMV specific stimulation in 
individuals shown in panel A. (F) The proliferative potential of CMV-specific T cells was quantified as the 
percentage of CFSE-low cells after 5 days of stimulation. (G) The increase in proliferation after antibody-
mediated blockade of PD-L1 and PD-L2 was expressed as a multiple of the proliferation observed upon 
incubation with isotype controls. This increase was significantly different between PD-1 high and PD-1 low 
patients (p=0.009). Data displayed in panels B-C and F-G represent combined results for CD4 and CD8 T cells. 
Asterisks denote patients that were viremic at the time of analysis.  
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Figure 21: Cytokine release in controls and transplant recipients. Bars show median values and interquartile 
ranges of cytokines (in pg/mL) in supernatants from (A) CMV and (B) SEB stimulated cells in controls (n=3, 
white bars) or transplant recipients (n=10, black bars). The Mann Whitney test was used to compare cytokine 
expression in the two groups (p-values are indicated).  
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3.1.5.4 General screening of cytokines 
Analyzing the expression levels of 27 cytokines in supernatants of stimulated PBMC, we 
found that the cytokines IL-5, IL-7, IL-12-p70, IL-17, FGF basic, and GM-CSF did not show any 
pronounced expression after CMV specific stimulation, as a large percentage of samples 
were below or close to detection limit. Therefore, no specific role of these cytokines could 
be attributed to CMV specific cellular immunity. Conversely, the levels of four cytokines (IL-8, 
IP-10, MCP-1 and MIP-1β) were above the highest cut-off in most samples regardless of PD-1 
expression, which precluded further analysis on the effect of PD-1/PD-L blockade 
(percentages of antigen-stimulated samples above cut-off: IL-8 87.5%, IP-10 68.3%, MCP-1 
59.6%, MIP-1 79.8%). A CMV specific role of IL-8 and MCP-1 is rather unlikely as they were 
also highly expressed in samples stimulated with control antigens.  
As judged by comparative analysis of specific stimulation with the polyclonal T cell stimulus 
SEB and control antigen, the cytokines IL-1Rα, IL-4, IL-15, eotaxin, PDGF und VEGF were not 
sufficiently induced by T cells (stimulation index <10 as compared to a median SI of 70.0 for 
the remaining cytokines). Therefore, 11 of 27 cytokines with specific effects were further 
analysed.  
3.1.5.5 Cytokine profiles in kidney transplant recipients differ from that of healthy control 
persons 
The expression levels of the 11 cytokines in transplant recipients were first compared to 
those in healthy controls. In supernatants of CMV-stimulated cells, levels from 4/11 
cytokines were significantly higher in healthy controls (IL-9, IL-13, IFN and RANTES, Figure 
21A). As an example, the median CMV-induced IFN release in controls was 7369.4 pg/ml 
compared to 428.1 pg/ml in patients (p=0.028). A trend towards a higher expression was 
observed for MIP-1α and TNFα (Figure 21A). Overall, cytokine-levels in the supernatants of 
SEB-stimulated PBMC did not differ between controls and patients. A notable exception was 
IL-10, where the respective levels were higher in controls (p=0.028, Figure 21B). 
3.1.5.6 Influence of PD-1 expression on cytokine profiles in transplant recipients 
To further assess the role of PD-1 expression on CMV specific T cells, transplant recipients 
with high and low PD-1 expression were compared. As shown in Figure 1, PD-1 expression 
levels did influence the amount of cytokines released after stimulation with CMV antigen, as 
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patients with high PD-1 expression showed an overall lower cytokine-release compared to 
patients with low PD-1 expression. The difference in IL-13 expression was significant and IL-9, 
IFN and RANTES showed a trend towards lower expression (Figure 1A). After SEB 
stimulation, however, cytokine levels were in general higher and the relative difference in 
their expression levels between both groups was less pronounced (Figure 1B). 
3.1.5.7 Changes in cytokine profiles upon anti-PD-L blockade  
To mechanistically link PD-1 expression to lower cytokine expression, we investigated the 
effect of anti-PD-L on cytokine expression. As shown in Table 12, anti-PD-L blockade induced 
an increase in the levels of a variety of cytokines in CMV-stimulated samples. When the 
effect of anti-PD-L1/2 blockade was analysed in samples of transplant recipients irrespective 
of PD-1 baseline expression, cytokines with a pronounced median increase were IL-6, IL-9, 
and IFN (data not shown). Interestingly, in line with proliferative responses the anti-PD-L-
mediated increase of CMV specific cytokine-release was strongest for patients with high  
PD-1 expression compared to patients with low PD-1 expression on CMV specific T cells 
(Figure 20G; Table 12 and data not shown). Low PD-1 expression was associated with only 
moderate increase in 10/11 cytokines, whereas high PD-1 expression led to a pronounced 
increase in the levels of 9/11 cytokines, of which cytokines such as IL-6 and IFN were 
induced by more than 10-fold. Interestingly, unlike CMV specific stimulation, cytokine-
release in SEB stimulated PBMCs was largely unaffected by anti-PD-L-blockade (<3fold in all 
cytokines, Table 12). 
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Figure 22: Cytokine release in transplant recipients with high and low PD-1 expression on CMV specific            
T cells. Bars show median values and interquartile ranges of cytokines (in pg/mL) in supernatants from (A) CMV 
and (B) SEB stimulated cells in transplant recipients with low and high PD-1 expression on CMV-specific T cells 
(white and black bars, respectively, n=5 patients each). CMV and SEB stimulated samples were analysed after 5 
and 3 days, respectively. The Mann Whitney test was used to compare cytokine expression in the two groups 
(p-values are indicated).  
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Table 12: Restoration of cytokine expression after blockade with anti-PD-L1 and anti-PD-L2 blocking 
antibodies in kidney transplant patients. 
 
Numbers show mean fold increases of respective cytokines compared to isotype-treated cell cultures including 
standard deviation (SD). Increases of 3-4.9-fold; 5-9.9-fold, and more than 10-fold are indicated in yellow, 
orange, and red, respectively. CMV- and SEB-stimulated samples were analysed after 5 and 3 days, 
respectively. 
When comparing the individual impact of antibody-mediated blockade of either PD-L1 or 
PD-L2 in separate stimulation experiments, IL-6 was the only cytokine that showed a 3.1-fold 
induction after blockade with anti-PD-L1 in patients with high PD-1 expression, whereas no 
other cytokine was induced by individual blockade (data not shown). This indicates that the 
combined blockade of both PD-L1 and PD-L2 is necessary to mediate sufficient restoration of 
cytokine expression. The reversibility of PD-1 induced T cell anergy confirms our previous 
findings (see 3.1.1) that monitoring of inhibitory T cell receptors is a good correlate of CMV 
specific T cell functionality and hence valuable in identifying patients at increased 
immunological risk for viremia. 
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3.2 T cell assays for diagnosis of active M. tuberculosis infection 
Whereas novel T cell based assays for diagnosis of tuberculosis infection, such as the 
commercially available ELISA based Quantiferon TB gold in tube assay and ELISPOT based  
T-SPOT.TB assay are able to discriminate between BCG vaccination responses and actual 
infection with M. tuberculosis, they are insufficient to specifically discriminate between 
active and latent infection (HINKS et al., 2009; LALVANI, 2007; SESTER et al., 2011a). Our aim 
was therefore to identify phenotypical and functional markers of the M. tuberculosis specific 
T cell response as biomarkers with potential correlation with disease activity in vivo.  
Based on our studies on cytomegalovirus infection in chapter 3.1.1 of this thesis and 
evidence from other viral infections (PANTALEO, HARARI, 2006; SESTER et al., 2008b), 
disease activity correlates with changes in cytokine profiles of the pathogen specific T cells. 
This approach was applied to improve M. tuberculosis diagnostics. Indeed, active  
M. tuberculosis infection (A-TB) was associated with a loss of PPD specific CD4 T cell 
multifunctionality, which was not seen in successfully treated (T-TB) or latent M. tuberculosis 
infection (L-TB). A frequency of less than 56% of IFNγ/IL-2 cytokine secreting cells identified 
patients with active tuberculosis with a specificity of 100% and a sensitivity of 70%. These 
data, where I contributed with experimental analyses and supervision of a medical student 
are published and described in detail in (SESTER et al., 2011b). 
3.2.1 CTLA-4 and CD27 expression on PPD specific CD4 T cells as an indicator of active M. 
tuberculosis replication 
In addition to cytokine profiling, a loss of CD27 on M. tuberculosis specific CD4 T cells has 
been shown to correlate with active infection (STREITZ et al., 2007). As we demonstrated in 
the previous chapters, that expression of inhibitory T cell receptors correlates with disease 
activity in active CMV infection, we sought to characterise expression of these molecules on 
antigen-specific T cells of patients with active M. tuberculosis infection. Our unpublished 
preliminary data from a first series of patients indicated CTLA-4 expression on purified 
protein derivate (PPD) specific CD4 T cells may be more informative than PD-1 expression 
(data not shown).  
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Therefore we analysed the expression of the biomarkers CTLA-4 and CD27 on PPD specific 
CD4 T cells, compared their diagnostic power to cytokine profiling and elucidated if 
combination of the markers might be of added value. As with cytokine profiling, we 
performed 6h antigen specific stimulation of whole blood samples from 18 patients with 
confirmed active tuberculosis, 25 patients with successfully treated TB, 108 patients with 
latent TB infection and 137 with immunity consistent with BCG vaccination or NTM infection. 
Latent TB infection was defined by reactivity towards PPD concomitant with reactivity 
towards ESAT-6 and/or CFP-10 proteins. PPD specific CD4 T cells were enumerated via 
IFNCD69 co-expression and analysed for CD27 expression. A representative CD27 
expression pattern for each patient group is illustrated in Figure 23A. Patients with active  
M. tuberculosis infection showed significantly lower frequencies of CD27 expressing PPD 
specific cells compared to the three non-active states (p<0.0001, Figure 23B). Based on 
receiver operator characteristics (ROC) analysis, a percentage of less than 30.31% CD27 
 
Figure 23: Loss of CD27 expression on PPD specific CD4 T cells is indicative of active tuberculosis infection. 
Whole blood from all individuals was stimulated with PPD and antigen specific CD4 T cells co-expressing CD69 
and IFN were quantified and analysed for CD27 expression using flow cytometry. (A) Representative examples 
of CD27 expression on PPD specific CD4 T cells are shown for each patient group. Percentages of CD27 
expressing cells among PPD specific CD4 T cells are indicated. (B) Patients with A-TB had significantly lower 
percentages of CD27 expressing cells, than all three non-active states (p<0.0001). The stippled line indicates the 
30.31% threshold established by ROC analysis. 
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positive PPD specific CD4 T cells discriminated with 100% specificity and 83.33% sensitivity 
between patients with active TB and successfully treated TB (AUC=0.93, Figure 23B and 
Table 13). The threshold of <30.31% CD27 positive CD4 T cells was also powerful to 
discriminate patients with active TB from latently infected and BCG vaccinated/NTM infected 
individuals (91.67% and 96.35% specificity, 83.33% sensitivity, AUC of 0.91 and 0.93 
respectively, Figure 23B and Table 13). Thus, a decrease in CD27 expression on PPD specific 
CD4 T cells is highly indicative of active M. tuberculosis replication. 
As with analysis of CD27, expression of CTLA-4 on PPD specific CD4 T cells was characterised 
in a similar set of patients. A total of 40 patients with confirmed active TB, 9 with 
successfully treated TB, 45 with latent TB infection and 249 with BCG/NTM related immunity 
were tested. As illustrated by representative profiles in Figure 24A, patients with active TB 
showed significantly higher frequencies of CTLA-4 expressing PPD specific CD4 T cells than 
the three non-active states (p<0.0001; Figure 24B). ROC analysis revealed a percentage of 
>17.5% CTLA-4 expressing PPD specific CD4 T cells to be best in discriminating between 
active TB and successfully treated TB (specificity 88.89%, sensitivity 72.50%, AUC=0.84, 
Figure 24B and Table 13). This threshold discriminated tuberculosis patients similarly well 
from latently infected and BCG vaccinated/NTM infected individuals (latent TB: 91.11% 
specificity, 72.50% sensitivity, AUC=0.90; BCG/NTM: 92.77% specificity, 72.50% sensitivity, 
AUC=0.91; Figure 24B and Table 13).  
3.2.2 Combination of phenotypical and functional markers might further improve 
diagnostic power 
Compared to our previously published results on cytokine profiling (SESTER et al., 2011b), 
CD27 seems to be of higher sensitivity in discriminating active from successfully treated TB 
than the IFN/IL-2 profile (83.33% vs. 70.00% sensitivity, respectively), with both being of 
100% specificity.  
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Figure 24: Increase in frequency of CTLA-4 expressing PPD specific CD4 T cells is indicative of active 
tuberculosis infection. PPD specific CD4 T cells were analysed for CTLA-4 expression using flow cytometry. (A) 
Representative examples of CTLA-4 expression are shown for each patient group. Percentages of CTLA-4 
expressing cells among PPD specific CD4 T cells are indicated. (B) Frequencies of CTLA-4 expressing cells are 
significantly higher in patients with A-TB compared to all three non-active states (p<0.0001). The stippled line 
indicates the 17.5% threshold established by ROC analysis. 
Table 13: Analysis of CD27 and CTLA-4 allows discrimination between active M. tuberculosis infection and 
non-active states. 
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A-TB vs. T-TB A-TB vs. L-TB A-TB vs. BCG/NTM 
AUC 
Sensiti-
vity 
Speci-
ficity 
AUC 
Sensiti-
vity 
Specifi-
city 
AUC 
Sensiti-
vity 
Specifi-
city 
CD27 <30.31% 0.93 83.33% 100% 0.91 83.33% 91.67% 0.93 83.33% 96.35% 
CTLA-4 >17.50% 0.84 72.75% 88.89% 0.90 72.75% 91.11% 0.91 72.75% 92.77% 
IFN/ 
IL-2* 
<56.00% 0.84 70.00% 100% 0.87 70.00% 100% 0.87 70.00% 100% 
The respective potentials to diagnose active TB infection between the inhibitory T cell receptor CTLA-4, the co-
stimulatory receptor CD27 and the IFN/IL-2 cytokine profile were compared. Thresholds for diagnosis of active 
TB were determined via ROC analysis. *The values for the IFN/IL-2 cytokine profile are taken from a previous 
publication (SESTER et al., 2011b). A-TB, active tuberculosis, L-TB, latent infection with M. tuberculosis, BCG, 
Bacille Calmette-Guérin vaccine, NTM, nontuberculous mycobacteria. 
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In comparison, CTLA-4 is slightly more sensitive but less specific than the IFNIL-2 profile 
(72.50% and 88.89%). Indeed, CD27 seems to have the best diagnostic power of the three 
markers in discriminating A-TB from T-TB (AUC=0.93 for CD27 vs. AUC=0.84 for CTLA-4 and 
IFNIL-2, respectively). To evaluate if the combination of the markers might further increase 
the diagnostic potential, we performed parallel staining and analysis of CTLA-4, CD27 and 
IFNIL-2 in 9 patients with clinically proven active and 4 patients with successfully treated  
M. tuberculosis infection. Although sample size was low, the combined analysis of the 
IFNIL-2 cytokine profile with either CTLA-4 or CD27 did not improve the diagnostic power 
to discriminate between active and successfully treated TB compared to analysis of single 
markers (Figure 25, IFNIL-2 profiles <56% are indicated by squares). In contrast, 
combination of CTLA-4 and CD27 led to a strong increase in diagnostic power. Whereas CD27 
and CTLA-4 alone discriminated with 100% specificity but rather low sensitivity (66% and 
77%, respectively, Figure 25) between A-TB and T-TB in this subgroup of patients, the 
combination of both markers retained 100% specificity and increased sensitivity to 100%. 
Likewise the negative predictive value (NPV) increased to 100%, compared to 57% for CD27 
and 66% for CTLA-4 analysis only. Even though limited by the small number of patients 
included, the combination of these two markers may have potential as a powerful tool to 
improve immune-based diagnosis of active tuberculosis. 
3.2.3 The immunological profile in patients with latent M. tuberculosis infection at risk 
for progression to tuberculosis 
Up to now there is neither a measure to estimate the individual risk for progression from 
latent to active M. tuberculosis infection with sufficiently high positive predictive value nor 
to discriminate a de novo infection from a previous immunological well contained infection. 
As demonstrated above, all three of our analysed markers are able to discriminate between 
active and non-active states of M. tuberculosis infection. We therefore used the combined 
analysis of these markers to elucidate, whether alterations in the expression of the markers 
may also be observed in asymptomatic individuals at increased risk for active TB.  
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A total of 25 ESAT-6 and/or CFP-10 confirmed latently infected individuals with increased 
exposition risk or clinical suspicion of TB infection were recruited. Thirteen of those 
individuals were analysed in the context of TB contact tracing, 3 because of increased 
exposure risk, 3 in the context of immunosuppression and 6 due to radiological or clinical 
signs compatible with tuberculosis. Of the individuals analysed, 13/25 (52%) were below the 
threshold for active disease for all three markers, 8/25 (32%) showed a shift in either  
IFNIL-2 profile (n=7) or in CD27 expression, and 4/25 (16%) showed a shift in two of the 
markers (Figure 26). Among these, two showed a shift in their IFNIL-2 profile and CD27 
expression, one a shift in IFNIL and CTLA-4 and one a shift in both CD27 and CTLA-4 
(Figure 26, IFNIL-2 profiles <56% are indicated by squares). Of note, the patient who 
showed a shift in CD27 only displayed 57% IFNIL-2 double positive CD4 T cells which is 
close to the threshold of 56%. 
 
Figure 25: Combination of phenotypical and functional markers might further increase diagnostic potential. 
In a subset of 9 patients with A-TB and 4 with T-TB staining and analysis of CD27, CTLA-4 and the IFN/IL-2 
cytokine profile were performed in parallel. Combination of CD27 and CTLA-4 analysis improves discrimination 
between A-TB and T-TB to 100% sensitivity and specificity each. Stippled lines indicate the thresholds of 
<30.31% for CD27 and >17.5% for CTLA-4. Round dots indicate patients with >56%, square dots patients with 
<56% IFN/IL-2 co-producing cells. A-TB patients are indicated by red and patients with T-TB by green colour. 
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3.3 Phenotype and functionality of CD4 T cell immunity induced by pandemic H1N1 
vaccination differs from active influenza infection 
As described in detail in our recent publication (SCHMIDT et al., 2012a), we analysed the 
induction of antigen-specific T cells in 19 individuals before and after vaccination against the 
pandemic H1N1 strain (pdmH1N1). Part of this thesis focussed on the comparison of the 
vaccine induced phenotype and functionality of the pdmH1N1 specific immune response 
with that observed after natural H1N1 infection. As illustrated in Figure 27A and C we found 
that the pdmH1N1 specific CD4 T cells one week after vaccination consisted mainly of 
IFNIL-2 co-producing as well as IFN single producing cells and lower numbers of IL-2 single 
producing cells. Already at week two after vaccination the functional profile changed to a 
predominance of IFNIL-2 co-producing cells, followed by cells producing IL-2 and IFN only. 
This phenotype seems to be stable over time, as suggested by a similar profile 10 weeks 
after vaccination (Figure 27A and C). In contrast, acute infection with pdmH1N1 led to a 
functional profile dominated by IFN single producing cells, with markedly less IFNIL-2 co-
producers and an almost complete absence of IL-2 single producers (Figure 27B and D). 
 
Figure 26: Immunological profile in TB contacts. 25 ESAT-6/CFP-10 confirmed L-TB patients with increased 
exposition risk or clinical suspicion of TB infection were analysed for expression of CD27, CTLA-4 and the 
cytokines IFN/IL-2. 4/25 (16%) patients showed a shift towards an A-TB associated profile in 2 of the three 
markers and 8/25 (32%) in one marker. Stippled lines indicate the thresholds of <30.31% for CD27 and >17.5% 
for CTLA-4. Round dots indicate patients with >56%, square dots patients with <56% IFN/IL-2 co-producing 
cells.  
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The observed differences 
in CD4 T cell functionality could be clearly attributed to the pdmH1N1 specific immune 
response, as the functional profile of SEB reactive cells was similar in patients and vaccinees 
and stable over time (Figure 27E and F).  
 
Figure 27: Influenza-specific CD4 T cells induced after vaccination differ in the cytokine expression profile from 
T cells in acute infection. Influenza-specific CD4 T cells induced after vaccination differ in the cytokine 
expression profile from T cells in acute infection. Representative dotplots of the flow cytometric analysis of IFNγ 
and IL-2 expression in CD4 T cells after stimulation with pdmH1N1 antigen in blood samples of (A) one healthy 
individual (not prevaccinated against seasonal influenza) before and after vaccination with pdmH1N1 and (B) 
one patient with acute pandemic H1N1 influenza infection within 1 week after onset of symptoms. IFNγ/IL-2 
cytokine profiling was performed in pdmH1N1-specific CD4 T cells of (C) all 19 individuals after immunization 
with pdmH1N1 over time and (D) of seven patients with acute pandemic H1N1 influenza infection. Shown are 
the median values and IQR of absolute numbers of IFNγ single positive (black circles), IFNγ/IL-2 double positive 
(grey circles), and IL-2 single positive (white circles) CD4 T cells. Respective values after stimulation with SEB 
(positive control) are depicted for (E) the vaccination cohort (n=19) and (F) the acutely infected patients (n=7). 
Stimulation with the seasonal vaccine yielded the same results (data not shown). 
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To assess the phenotype of the induced responses, we analysed in a second staining reaction 
the expression of the T cell memory marker CD127 and the T cell inhibitory receptor CTLA-4. 
Because of low pdmH1N1 specific responses, this analysis could only be performed in 15/19 
individuals pre-vaccination (Figure 28).  
 
Figure 28: Differences in CD4 T cell phenotype after pdmH1N1 vaccination and acute infection. Induction of 
pdmH1N1 specific CD4 T cells after vaccination is associated with changes in phenotype, which are clearly 
distinct from phenotype after acute infection. Percentages of CD127 expressing IFNγ positive CD4 T cells after 
stimulation with the pdmH1N1 antigen of all tested individuals are depicted over time (A) and in patients 
during acute pdmH1N1 infection (B). CTLA-4 mean fluorescence intensities (MFI) of pdmH1N1 specific CD4       
T cells of all tested individuals are depicted over time (C) and in patients during acute pdmH1N1 infection (D). 
Each symbol represents data from one individual. Analysis was performed in all 7 patients with acute infection 
and in all 19 individuals before vaccination, and after 1 and 2 weeks. In 4 of 19 individuals, the percentage of 
reactive T cells before vaccination was too low to perform phenotypical analysis. Analysis after 10 weeks was 
performed in 11 individuals only. Bars indicate median values and IQR. Statistical analysis was performed using 
the Kruskal-Wallis test. 
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In line with a memory T cell phenotype in the absence of recent antigen encounter, almost 
all pdmH1N1 specific CD4 T cells expressed CD127 (median 97.6%, IQR 5%, Figure 28A). The 
newly generated pdmH1N1 specific CD4 T cells at week one post-vaccination, consisted to a 
higher percentage of CD127 negative effector phenotype like CD4 T cells, resulting in a 
reduced proportion of CD127 positive cells (median 80.0%, IQR 12.1%, p<0.0001, Figure 28A). 
This shift in memory/effector phenotype was only transient, as at week two already 91.1% 
(12.3%) of pdmH1N1 specific cells (re-)expressed CD127 and reached pre-vaccination levels 
at week ten (median 98.0%, IQR 6%, Figure 28A). CTLA-4 mean fluorescence intensities (MFI) 
on pdmH1N1 specific CD4 T cells showed an inverse relationship, as they increased from pre-
vaccination levels to peak levels at week one (median 5311, IQR 2204) and declined 
thereafter to almost pre-vaccination levels at week ten (Figure 28C, p<0.0001). In contrast to 
this peak, CTLA-4 expression levels during acute pdmH1N1 infection were about 2.2fold 
higher than peak levels post-vaccination (median 11479, IQR 6405, Figure 28D, p=0.0005). 
Likewise CD127 expressing cells were significantly reduced to 43.8% (6.79) compared to pre-
vaccination (p=0.0003, Figure 28B).  
Similar to our results on CMV and M. tuberculosis infection, we observed a pro-inflammatory 
effector response in acute pdmH1N1 infection, whereas vaccination with pdmH1N1 antigens 
led to a protective multifunctional response of predominantly memory phenotype. 
3.4 Pathogen prevalence may determine maintenance of antigen specific T cell 
responses after HIV infection 
One serious issue in HIV infection is the weakened immune response to numerous 
pathogens, resulting in an increase in opportunistic infections, reduced vaccination 
responses and low sensitivity in T cell based diagnostic assays. In the following part of the 
thesis, we assessed whether the increased turnover of CD4 T cells in HIV infection favours 
the maintenance of immune responses towards antigens that are regularly encountered 
over those with no or only limited antigen rechallenge and might therefore be linked to 
antigen prevalence.  
To model differences in antigen rechallenge we analysed specific immunity in latent  
M. tuberculosis infection in healthy controls and HIV patients in a high (Tanzania) and a low 
prevalence country (Germany). We compared this with specific immunity in CMV infection, 
where continuous endogenous antigen rechallenge is present.  
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Data from Tanzanian patients were provided by Dr. Alexandra Schütz and Prof. Dr. Andreas 
Meyerhans who collaborated in this part of the project. 
3.4.1 A low prevalence and frequency of PPD specific immunity is a particular feature of 
HIV related immunosuppression in tuberculosis low endemic regions 
To test if HIV related immunodeficiency may affect cellular immunity toward mycobacterial 
antigens, PPD reactive CD4 T cells were assessed in 60 HIV infected individuals and 144 age 
matched HIV seronegative healthy controls from Germany. Typical dot plots of antigen 
specific CD4 T cells are shown in Figure 29A. The percentage of individuals with detectable  
T cell immunity towards PPD was significantly lower in HIV positive patients (20%) as 
compared to healthy controls (52.7%, P<0.0001, Figure 29B). In line with these results, HIV 
positive patients showed a significantly lower frequency of PPD specific CD4 T cells (median 
0.008%, ≤0.001–2.08%) as compared to immunocompetent individuals (median 0.05%, 
≤0.001–3.76%; p<0.001). Interestingly, this was not due to a general loss of immunity 
 
Figure 29: Decreased prevalence and frequency of PPD reactive CD4 T cells in HIV
+
 patients from Germany. 
(A) Representative dot plots after purified protein derivative (PPD), cytomegalovirus (CMV) and SEB 
stimulation, where antigen-reactive CD4 T cells are defined as CD69 and IFN coexpressing cells. PPD, CMV and 
SEB reactive CD4 T cells were assessed in healthy controls and HIV positive patients without active tuberculosis 
from (B) Germany and (C) Tanzania. (D) In addition, HIV positive patients with active tuberculosis are shown. 
They are from the same endemic region as individuals in panel (C), who serve as controls for this group. Median 
frequencies are indicated by bold lines, the dotted line represents the detection limit for antigen-reactive CD4 
T cells (0.05%). CMV specific T cell frequencies are displayed for CMV seropositive individuals. Significant 
differences were observed between PPD reactive T cell frequencies in Tanzanian HIV infected individuals with 
and without active tuberculosis (p<0.0001, compare panel C and D), whereas CMV or SEB reactive T cell 
frequencies did not differ (p=n.s.). TB, tuberculosis. 
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towards recall antigens, as both groups did not differ in CMV reactive or SEB reactive T cell 
frequencies (p=0.20 and p=0.30, respectively, Figure 29B). 
3.4.2 A high antigen prevalence is associated with a sustained PPD specific immunity in 
HIV infected individuals from a tuberculosis high prevalence region 
The observed loss in PPD specific immunity in HIV-positive individuals may be due to a 
considerably low antigenic challenge in a low endemic region such as Germany. To assess 
the effect of a higher extent of exogenous challenge with M. tuberculosis, PPD reactive  
T cells were analysed in a group of 39 HIV infected patients from a high prevalence country. 
Notably, in this setting, the percentage of patients with detectable PPD specific immunity 
was higher (64.1%) as compared to HIV positive patients in a low endemic region and 
indistinguishable to HIV seronegative healthy controls (51.6%, p=0.34). Likewise, median 
frequencies of PPD reactive CD4 T cells did not differ between HIV positive individuals and 
controls from endemic regions (0.09%, ≤0.001–1.91% and 0.06%, ≤0.001–0.99%, respectively, 
p=0.29, Figure 29C). Moreover, the two groups did not differ in their frequencies of reactive 
T cells towards CMV and SEB (p=0.22 and p=0.17, Figure 29C). Together this indicates that an 
increased extent of mycobacterial exposure in a high endemic area may contribute to the 
maintenance of specific immunity in HIV infected individuals. Of note, differences in sex did 
not have any confounding effect on our results observed in low and high endemic regions. In 
Germany, the percentages of both male and female HIV infected individuals with positive 
PPD responses was lower as respective controls (45.7% female controls vs. 14.3% female HIV 
infected individuals, p=0.04; 66.0% male controls vs. 21.7% male HIV infected individuals, 
p<0.0001). Likewise, overall results in Tanzania were not confounded by sex (60.0% female 
controls vs. 63.2% female HIV infected individuals, p=1.00; 47.6% male controls vs. 77.8% 
male HIV infected individuals, p=0.23). Moreover, there was no significant difference in the 
percentage of PPD positive responses in patients with and without antiretroviral therapy 
(ART) (Germany: p=1.00, Tanzania: p=0.74). To assess the effect of active tuberculosis on 
PPD specific immunity in HIV infected individuals, a total of 34 patients with active 
tuberculosis were recruited from the same high endemic region. In this group, both the 
prevalence of a specific response (88.2%) as well as their median frequencies (0.9%, ≤0.001–
5.2%) were significantly higher as compared to HIV infected patients or healthy controls 
without active tuberculosis (P<0.001, Figure 29D). PPD specific T cell frequencies did not 
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show any correlation with CD4 T cell counts/ml (r=0.03, p=0.89) or viral load (r=0.02, p=0.96). 
Likewise, although most patients with tuberculosis were treatment naive, their PPD specific 
T cell frequencies were still higher as compared to respective HIV infected patients without 
tuberculosis (p=0.017). Thus, differences in these parameters are unlikely to contribute to 
the increased frequency of PPD reactive T cells in patients with active tuberculosis. As 
expected, tuberculosis in HIV infected individuals did not have any effect on the frequencies 
of CMV reactive or SEB reactive CD4 T cells (p=0.10). Notably, however, CMV reactive T cell 
levels in patients with active tuberculosis were slightly higher as compared to HIV 
seronegative controls (p=0.03). 
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4 Discussion 
Adaptive immunity is important for pathogen control and its loss results in uncontrolled 
pathogen replication and disease. In this thesis, phenotypical and functional characterisation 
of specific immunity towards clinically relevant persistent pathogens such as CMV and  
M. tuberculosis as well as vaccine antigens was performed. A more terminal effector 
memory differentiation state was found to be a common determinant for pathogen 
chronicity, which was indicated by the loss of CD27 on PPD specific and a parallel loss of 
CD28 and CD27 on CMV specific T cells. Furthermore, a loss of multifunctionality and an 
increase in the expression of anergy markers such as PD-1, TIM-3 and CTLA-4 was found to 
correlate with disease activity. We postulate that a meaningful combination of these 
biomarkers might help to assess the risk of pathogen and disease reactivation and 
progression and may in future play an important role in guidance of therapy initiation and 
duration. 
4.1 CMV immunomonitoring in transplant recipients 
Cytomegalovirus is a clinically relevant persisting pathogen, which is immunologically well 
controlled in immunocompetent individuals, yet may cause severe clinical symptoms in 
immunocompromised patients (FISHMAN, 2007; FISHMAN, RUBIN, 1998; GANDHI, KHANNA, 
2004). It is well known that the risk of CMV complications after solid organ transplantation is 
determined by the level of immunosuppression and the transplanted organ (FISHMAN, 
RUBIN, 1998; SMITH et al., 2001; SPEICH, VAN DER BIJ, 2001). CMV complications in renal 
transplant recipients are largely restricted to the first three month post-transplant, whereas 
heart and lung transplant recipients are at prolonged risk to suffer from infectious 
complications (FISHMAN, RUBIN, 1998; LOWANCE et al., 1999; ZAMORA, 2004). Furthermore, 
seronegative recipients of a seropositive organ are at increased risk of infectious 
complications, as they have to establish a protective immune response under the influence 
of high levels of immunosuppressive drugs (SMILEY et al., 1985). CMV specific T cells have 
been proven critical for CMV control and we and others have shown that a quantitative loss 
of CMV specific immunity correlates with CMV disease in transplant patients (KOTTON et al., 
2013a; SESTER et al., 2001; WALKER et al., 2007; WESTALL et al., 2008).  
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Most immune-based assays to analyse cell-mediated immunity towards CMV such as the 
commercially available IFN release assays based on ELISA or ELISPOT assays are able to 
quantify immune responses but do not assess T cell phenotype and multifunctionality. 
Whereas this might be helpful to determine the onset of a CMV specific immune response in 
CMV seronegative recipients of a seropositive organ (MANUEL et al., 2013), these assays are 
not well suited to predict episodes of viral reactivation or CMV-relapse after cessation of 
antiviral therapy in transplant patients with pre-existing CMV specific immunity (KOTTON et 
al., 2013b).  
In this thesis functional and phenotypical changes of CMV specific T cells were shown to 
correlate with clinical events and the occurrence of CMV reactivation episodes in 
longitudinally monitored kidney transplant patients. Furthermore, the diagnostic potential of 
the identified markers of T cell anergy to predict the risk of viral reactivation was evaluated.  
4.1.1 Function and phenotype of CMV specific immune responses are interrelated and 
correlate closely with episodes of viremia after transplantation 
Previous studies by our group and others indicated that quantitative changes in CMV specific 
T cell frequencies correlate with CMV disease but not with CMV reactivation per se (SESTER 
et al., 2001; WALKER et al., 2007; WESTALL et al., 2008). This was supported by data from 
this thesis, as we observed no quantitative differences in CMV specific T cell frequencies 
between patients with and without reactivation episodes but reduced frequencies in 
patients with acute primary CMV infection, which is in line with the newly initiated induction 
of CMV specific immunity (Figure 3). In contrast to this, the presented data clearly 
demonstrate a loss of multifunctionality of CMV specific CD4 T cells not only in patients with 
CMV primary infection but also in those with reactivation episodes. CMV specific T cells lose 
the ability to co-produce the cytokines IL-2, TNF and IFN and show an impaired 
proliferative capacity. Interestingly, co-production of IFNand TNF seems to be far more 
robust than IFNIL-2 co-production. IFN/TNF co-production is only lost during high level 
viremic episodes and recovers rapidly after resolution of viremia. In contrast, co-production 
of IFNand IL-2 is lost during high and low level viremic episodes, does not recover rapidly 
after resolution of viremia, and even tends to be lost in immunocompromised patients 
without reactivation (Figure 4 and Figure 5). This loss of multifunctionality was paralleled by 
phenotypical changes, as the expression of the inhibitory T cell receptors PD-1, TIM-3 and 
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CTLA-4 was significantly increased during viremic episodes (Figure 6 and Figure 8). Combined 
analysis of CTLA-4, IFN and TNF in the same staining reaction indicated that increased 
CTLA-4 expression was directly linked to a loss in T cell multifunctionality (Figure 18).  
Our results are in line with those on other chronic viral infections such as HIV, HCV and HBV, 
where insufficient control of viral replication was marked by loss of T cell multifunctionality 
and an increase in inhibitory receptor expression (D'SOUZA et al., 2007; DAY et al., 2006; 
KASPROWICZ et al., 2008; KAUFMANN et al., 2007; PENG et al., 2008; PETROVAS et al., 2006; 
RADZIEWICZ et al., 2007; TRAUTMANN et al., 2006; URBANI et al., 2008). Likewise, we 
recently showed that a loss in T cell multifunctionality was also observed in renal transplant 
recipients with clinically relevant BK polyomavirus replication (SCHMIDT et al., 2014). Of 
note, increased inhibitory T cell receptor expression and dominance of IFN-only producing 
cells during primary infection per se should not necessarily be mistaken as a sign of impaired 
immunity, but rather a physiological response to down-regulate the primary immune 
response (BARBER et al., 2006; PANTALEO, HARARI, 2006). This is also emphasised by results 
derived from our vaccination study for pandemic H1N1 influenza, where we observed an 
increased CTLA-4 expression and dominance of IFN-only producing cells not only in patients 
with acute pandemic influenza, but also in the time period of acute induction of immune 
response to vaccination (SCHMIDT et al., 2012a). Yet, in vaccinated individuals, this anergic 
phenotype was only temporary, as CTLA-4 expression decreased and multifunctionality was 
fully restored at week ten after vaccination (SCHMIDT et al., 2012a). In contrast to 
vaccination and self-limiting infections, the anergic phenotype is sustained in chronic 
uncontrolled infection. This is illustrated in this thesis by longitudinal data from a patient 
with primary CMV viremia who maintained high levels of anergy marker expression for 
about 200 days post-infection and suffered from recurrent viremia during this period  
(Figure 7).  
Another feature of the observed anergic phenotype is a decreased CMV specific proliferation 
capacity (Figure 19 and Figure 20). Interestingly, it has been demonstrated for other chronic 
viral infections before that in vitro blockade of inhibitory pathways can at least partly 
reverse anergy (BARBER et al., 2006; BLACKBURN et al., 2009; DAY et al., 2006; KAUFMANN 
et al., 2007; SAKUISHI et al., 2010; TRAUTMANN et al., 2006; URBANI et al., 2008). Previous 
work from our group has shown that PD-1 mediated reversion of functional anergy also 
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occurred in CMV viremic patients (DIRKS, 2008; SESTER et al., 2008b). This thesis now further 
analysed the influence of in vitro blockade of other inhibitory pathways on proliferation and 
cytokine production. It was shown that blockade of PD-1, and to a lesser extent TIM-3 
signalling pathways enhanced proliferative capacity (Figure 19), similarly as demonstrated 
before in antigen-specific T cells from patients with chronic HIV and HCV infection (JONES et 
al., 2008; MCMAHAN et al., 2010). In addition to an increase in proliferation, multiplex 
analysis revealed that in vitro blockade of PD-1 signalling in peripheral blood mononuclear 
cells from patients with high levels of PD-1 on CMV specific T cells restored the production of 
cytokines such as IL-2, TNF, IFN, IL-6, IL-9 and IL-10 (DIRKS et al., 2013). As our assay also 
comprised cells from the myeloid lineage, blocking of PD-1 signalling additionally led to a 
recovery of the cytokines IL-1, G-CSF, or MIP-1(DIRKS et al., 2013).  
Therapeutic use of blocking antibodies towards inhibitory T cell receptors to restore anergic 
T cells in vivo is already accomplished in cancer therapy, with so far promising results 
(ARANDA et al., 2014; HAMID et al., 2013; RIBAS, 2012; TARHINI, IQBAL, 2010; TOPALIAN et 
al., 2012). Direct therapeutic use to treat chronic viral infections in vivo has not been 
explored in humans, as inhibitory receptor blockade may have severe side effects and might 
trigger a variety of autoimmune responses (CRANMER, HERSH, 2007; MOVVA, 
VERSCHRAEGEN, 2009). Yet, inhibitory receptor blockade might be an option to improve 
current protocols for in vitro expansion of antigen specific T cells for adoptive transfer 
(BLYTH et al., 2013; EINSELE et al., 2002; GERDEMANN et al., 2011; HAMID et al., 2013; 
RIBAS, 2012; TOPALIAN et al., 2012). This may be of particular practical relevance, as 
adoptive transfer of in vitro expanded T cells is presently used mainly as rescue therapy for 
severe CMV infections in organ or stem cell transplant recipients. As autologous T cells may 
likely be functionally anergic in this situation, blockade of inhibitory receptors during in vitro 
expansion may represent means to improve cell yield for therapeutic infusion.  
4.1.2 Features and applicability of T cell based assays for monitoring of CMV infection 
after organ transplantation 
Despite the clinical utility of the above described approach, the ultimate goal of CMV 
immune monitoring would be not only to detect viremia but also to predict its occurrence. 
As the expression of the inhibitory receptors PD-1, TIM-3 and CTLA-4 correlated with a 
decreased functionality and directly with episodes of viremia, the diagnostic potential of the 
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three markers to detect and to predict episodes of viremia was assessed. Therefore, we 
performed receiver operator characteristics (ROC) analyses of the fold increase in anergy 
marker expression at onset of viremia versus pre-transplant. All three markers discriminated 
well between patients with high level viremia and patients without viremic episodes, with 
TIM-3 showing the highest diagnostic power (Figure 9). The combined analyses of all three 
markers led to an increase in sensitivity at the cost of lower specificity. Of note, our analysis 
revealed that TIM-3 alone, or combined analyses of all three markers was able to predict 
viremic episodes at a median of 7 days (IQR: 4.8-12) before onset of viremia. Although 
sensitivity was rather low, this is to our knowledge the first study in the field of CMV 
immune diagnostics, which provides evidence that analysis of phenotypical changes in CMV 
specific immunity can actually predict episodes of viremia in CMV seropositive patients post-
transplant.  
Based on current recommendations, high level viremia is clearly indicative for initiation of 
antiviral therapy. In contrast, there is currently no consensus on how to deal with low level 
viremia (KOTTON et al., 2013b). Thresholds for defining high level viremia differ significantly 
between individual centers, as do therapeutic decisions based on low level viremia. 
Therefore, initiation of antiviral therapy is highly variable from center to center. Results from 
this thesis indicate that the analysis of inhibitory receptor expression and/or T cell 
functionality may have potential to early identify patients with viremia and to more 
specifically target antiviral therapy to patients at risk for uncontrolled viremia. Phenotypical 
T cell monitoring could therefore be of significant clinical value, as it may contribute to 
reduction of both direct and indirect effects of CMV infection on patient health and graft 
outcome (SAGEDAL et al., 2004). Monitoring CMV specific T cell anergy has meanwhile 
already been included in the pre-emptive monitoring regimen in our transplant center 
where decisions on antiviral therapy are based on both viral load as well as on analysis of 
inhibitory T cell receptor expression on CMV specific T cells.  
Current pre-emptive therapy approaches based on viral load monitoring only have been 
shown to be valuable in reducing treatment costs and potential side effects of antiviral 
therapy (BALFOUR, 1999; HELLEMANS et al., 2013). We postulate that efficacy of pre-
emptive monitoring can be further improved by guiding initiation and duration of antiviral 
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therapy via assessment of the quality and functionality of patients CMV specific immunity 
(SESTER et al., 2008a). 
4.1.3 Stimulation-independent approaches for CMV immunomonitoring 
As described above, stimulation based assays offer the unique opportunity to combine 
functional and phenotypical characterisation of antigen specific T cell responses and can be 
performed within one working day. Yet, one limitation of these assays is the need of live and 
fully functional T cells. Fresh blood samples have to be kept refrigerated and should not be 
stored longer than 24-32 hours before processing, thereby complicating sample shipment 
and batched analyses of stored sampled. Pre-treatment of blood samples with reagents like 
T cell Xtend (Oxford Immunotec) might also increase storage time for use in ELISPOT assays 
for up to 32 hours. Isolation and subsequent freezing of peripheral blood mononuclear cells 
(PBMC) allows even longer storage time but is more laborious (MILSON, KELLER, 1982). 
Furthermore, freezing and re-thawing of samples leads to a quantitative loss in antigen 
reactive T cells or functional and phenotypical changes and hence is unsuitable for clinical 
decision making.  
One approach to limit both the blood volume needed and sample processing time, is the use 
of HLA-peptide-multimers (ALTMAN et al., 1996; DAVIS et al., 2011). As they allow direct 
analysis of antigen specific T cells and can be combined with additional phenotypical 
characterisation, they might be a promising alternative to stimulation based assays 
(BROOIMANS et al., 2008; LA ROSA et al., 2008). Our results in kidney and stem cell 
transplant recipients showed that frequencies of CMV specific CD8 T cells after tetramer 
staining correlated with those observed after stimulation with the respective peptides and 
do not differ between healthy controls and immunosuppressed patient groups (Figure 10). 
We observed that PD-1 expression on CMV specific tetramer positive cells was increased 
during viremic episodes and correlated with both T cell functionality and viral load (Figure 
11), which is in line with results observed in liver transplant recipients (LA ROSA et al., 2008). 
Analysis of PD-1 or other inhibitory T cell receptors on tetramer positive cells might 
therefore be a rapid and elegant means to monitor CMV specific T cell anergy after 
transplantation. Despite its simplicity, the tetramer approach has several drawbacks. 
Tetramer staining requires the knowledge of patients MHC-status and the availability of 
suitable MHC-peptide combinations matched for every patient. For CMV immunomonitoring, 
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this precludes a priori patients with unknown or uncommon HLA antigens, as only the most 
common HLA-peptide combinations are commercially available. This is illustrated by the fact 
that with the combination of tetramers against HLA-A1, -A2 and -B7 used in this study 
(Glycotype Biotechnology) only about ~60% of CMV seropositive individuals could be 
analysed (RAHMEL, 2013). The tetramer approach is further limited by the fact that T cell 
responses towards a given epitope differ widely between patients. Therefore, a response 
against a single epitope is not necessarily representative of the total CMV specific immune 
response (WIDMANN et al., 2008). Indeed, 15.73% of the patients analysed in this thesis did 
not react to the available HLA-peptide-combination, despite being positive for the respective 
HLA subtype (Figure 10).  
Available literature and our own preliminary data suggested a specific loss of CD28 and CD27 
expression on CD4 T cells of CMV seropositive individuals (FLETCHER et al., 2005; LOONEY et 
al., 1999; POURGHEYSARI et al., 2007; VAN DE BERG et al., 2008; VAN LEEUWEN et al., 2006; 
VAN LEEUWEN et al., 2004). Thus, one aim of this thesis was to evaluate if CD28-CD27- CD4  
T cells can be used as a stimulation independent surrogate for CMV specific T cell immunity 
in transplant recipients, and if an increase in PD-1 and CTLA-4 expression on these cells over 
time was a specific indicator of viremia. Based on a cross-sectional analysis of healthy 
controls, hemodialysis-patients and renal transplant recipients, frequencies of more than 
0.44% of CD28-CD27- CD4 T cells were tightly associated with CMV-seropositivity and 
quantitatively correlate with the frequency of CMV specific CD4 T cells identified based on 
cytokine induction after specific stimulation (Figure 12). Association with CMV is in line with 
previous studies showing that a large fraction of CD28-CD27- CD4 T cells is able to produce 
cytokines and proliferate after CMV specific stimulation, but not after incubation with 
stimuli unrelated to CMV such as purified protein derivative (PPD), tetanus toxoid, or 
antigens from herpes simplex, Epstein Barr or varicella-zoster virus (DERHOVANESSIAN et al., 
2011; FLETCHER et al., 2005; VAN LEEUWEN et al., 2006; VAN LEEUWEN et al., 2004). We 
additionally showed that CD28-CD27- CD4 T cells were rapidly induced in 8 out of 10 patients 
with CMV primary infection, and their induction kinetics were largely comparable to those of 
CMV specific T cells. The two patients who did not develop CD28-CD27- CD4 T cells during 
the observation period were exceptional in that they inadvertently did not receive antiviral 
prophylaxis and experienced CMV primary infection very early after transplantation (Figure 
13). Of note, these patients also showed a delayed induction of CMV specific CD4 T cells that 
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remained at considerably low frequencies. Together with earlier work in patients with graft-
related primary infection (RENTENAAR et al., 2000; SESTER et al., 2002c), this further 
emphasizes that primary infection early after transplantation may adversely affect the 
induction of sufficient CMV specific CD4 T cell immunity, which may directly be related to 
higher levels of immunosuppressive drugs.  
Unlike dynamics in relative and absolute numbers of CD28-CD27- CD4 T cells, an increased 
PD-1 expression on this T cell subset was associated with viremia in both CMV primary 
infection and reactivation, which is in line with our results in CMV specific CD4 T cells 
identified after stimulation (Figure 6 and (SESTER et al., 2008b)) or in CMV specific CD8  
T cells after MHC-multimer staining (Figure 11 and (LA ROSA et al., 2008)). It is interesting to 
note that PD-1 expression also showed a slight but insignificant increase on CD28-CD27- CD4 
T cells in non-viremic patients, although the increase was less pronounced and kinetics were 
different from those in viremic patients. Whether this is due to a lower sample size of non-
reactivating patients deserves further study. It is unlikely that this is directly mediated by 
immunosuppressive drugs, as PD-1 expression was not generally increased on bulk CD4  
T cells. Rather, the initial increase in PD-1 expression may result from subclinical viral 
reactivation events in response to immunosuppressive drugs acting early after 
transplantation. As with other chronically persisting pathogens (DAY et al., 2006; 
TRAUTMANN et al., 2006; URBANI et al., 2006), a further increase in CMV-replication may 
lead to a more pronounced increase in PD-1 expression on specific T cells in a subset of 
patients. It thus seems that PD-1 expression dynamics over time show a direct association 
with the level of viremia, which is supported by a correlation between PD-1 expression-levels 
and viral load. Among patients with reactivation, there was no obvious difference in PD-1 
expression dynamics between patients with low and high viral loads and symptoms 
compatible with CMV infection were only mild or absent. This may be due to the fact that 
viral load generally remained rather low in both groups due to a stringent implementation of 
pre-emptive therapy based on viral load monitoring and to variable length of antiviral 
therapy. It is thus tempting to speculate whether the increase in PD-1 expression would be 
more pronounced in symptomatic patients with higher viral loads in the absence or delay of 
antiviral therapy, although this was not possible to address in the context of this study.  
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In contrast to our results after antigen specific stimulation, no differences in CTLA-4 
expression on CD28-CD27- CD4 T cells were found between viremic and non-viremic patients. 
One possible explanation might be a more transient cell surface expression of CTLA-4 
compared to PD-1 or TIM-3. In fact, CTLA-4 expression is up-regulated upon antigen 
stimulation and rapidly internalized thereafter by utilizing a mechanism of secretory 
lysosomes (IIDA et al., 2000). In line with this, we found that 6 hour stimulation with CMV or 
SEB antigen led to 1.25 or 2.60-fold increases, respectively, in CTLA-4 expression on total 
CD4 T cells compared to stimulation with control antigen (data not shown). In contrast, PD-1 
or TIM-3 on total CD4 T cells did not increase following stimulation (Figure 20D and data not 
shown). Even though not included in this thesis, we have preliminary evidence indicating 
that TIM-3 expression on CD28-CD27- CD4 T cells is up-regulated during viremic episodes in a 
similar fashion as on CMV specific T cells detected after stimulation. As with our results after 
antigen specific stimulation, an increase in PD-1 expression preceded the onset of viremia in 
longitudinally monitored patients, thus making it a possible tool to identify patients at risk 
for reactivation and/or to identify patients where the T cell anergy is too high to control 
viremia in the absence of antiviral therapy. Interestingly, an elevated PD-1 expression-level 
at the end of therapy correlated with recurrent episodes of viremia. Inability to control 
viremia was apparently reached, when the PD-1 expression on CD28-CD27- CD4 T cells was 
3.1-fold higher as compared to the remaining CD4 T cell subset (Figure 17B). Thus, this may 
be explored further as a highly specific parameter to identify recurrent episodes of viremia. 
Determination of CD28-CD27- CD4 T cells as surrogate for CMV specific T cells has a number 
of operational advantages compared to the currently used assays for analysis of CMV 
specific immunity, such as intracellular cytokine staining, ELISPOT assay or the ELISA-based 
QuantiFERON-CMV assay, which require higher blood volumes and necessitate antigen-
specific stimulation for at least 6 to 20 hours (KOTTON et al., 2013a; SESTER et al., 2008a). 
Hence, these methods are more time consuming and require a complex panel of reagents. In 
contrast, PD-1 expression on CD28-CD27- CD4 T cells may be determined directly from as 
little as 100µl of whole blood within 1 hour. Although we have used a sequential procedure 
for staining of molecules on the cell-surface and intracellularly in this study, the assay may in 
the future be simplified to a mere one-step surface staining procedure, as CTLA-4 expression 
was rather unrelated to viremia. Based on preliminary evidence, the cellular phenotype is 
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stable even after 2 days of sample storage which makes this technique amenable to 
shipment due to less critical pre-analytic time.  
Despite these operational advantages, this approach also has some limitations. Although it 
had a high sensitivity, the specificity of PD-1 expression for viremia in an individual patient at 
a given time point was limited by the fact that non-viremic patients also showed some slight 
increase. In addition, PD-1 expression dynamics may have been confounded by antiviral 
therapy or by infections other than CMV, but we did not find any evidence for differences in 
PD-1 expression dynamics on CD28-CD27- CD4 T cells in patients with and without BKV-
related or other herpesviral infections (data not shown). Clearly, as with other assays for 
analysis of cellular immunity, it is too early to recommend monitoring of cellular immunity as 
the only monitoring tool to guide antiviral therapy (KOTTON et al., 2013a).  
In conclusion, we have evaluated the clinical utility to directly analyse CD28-CD27- CD4 T cells 
as a surrogate of CMV specific CD4 T cells in patients after renal transplantation. Co-staining 
of PD-1 holds promise as a simple approach to specifically identify patients who may benefit 
from prolonged therapy.  
4.1.4 Comparison of available assays for CMV immunomonitoring post-tranplant and 
potential areas of clinical application 
Apart from flow cytometry, other stimulation-based interferon gamma release assays such 
as the ELISA technique or the ELISPOT assay exist that are in part available as commercial 
assay format and therefore better standardised. Nevertheless, these assays are not suited to 
predict the risk of subclinical reactivation or relapse in CMV seropositive transplant 
recipients (KOTTON et al., 2013b; SESTER et al., 2008a). This thesis provides evidence that 
functional and phenotypical analysis of CMV specific CD4 T cells after stimulation, as well as 
analysis of PD-1 on HLA-peptide-tetramers positive CD8 or CD28-CD27- CD4 T cells correlates 
with episodes of viremia post-transplant and might be used to identify patients at risk of 
CMV reactivation or relapse. Together with evidence discussed above, analysis of inhibitory 
T cell receptors on CD28-CD27- CD4 T cells might be best suited for implementation in clinical 
routine monitoring, as it is quick, easy to perform, does not rely on patients HLA status and 
is more likely to be representative of the overall CMV specific T cell response of an individual 
patient than T cell frequencies determined by HLA-peptide multimers. One limitation of 
CD28-CD27- CD4 T cells might be, that this population is not entirely CMV specific, as there is 
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to some degree a bystander effect in the CMV induced and IFN mediated differentiation 
process of this cell lineage (FLETCHER et al., 2005). Yet, this lower specificity might be 
negligible, as we observed a close correlation between frequencies of CD28-CD27- and CMV 
specific CD4 T cells determined after stimulation and similar PD-1 expression dynamics on 
both cell-populations post-transplant. Due to its technical ease and low sample volume, this 
assay may also be explored as a tool to identify CMV specific immunity in pediatric 
transplant recipients, or to determine the time of CMV specific T cell reconstitution in 
patients after stem-cell transplantation. The use of this approach for monitoring of CMV 
complications in pediatric transplant recipients is currently addressed in a collaborative 
project with Prof. Jutta Preiksaitis in Edmonton (Canada), who has complementary expertise 
in viral load monitoring of children in the setting of transplantation (PANG et al., 2003; 
PREIKSAITIS et al., 2005; PREIKSAITIS et al., 1988; PREIKSAITIS et al., 1997; VAUDRY et al., 
2010). 
An additional area of application for cell-mediated immunity assays is to correctly assign the 
CMV infection status in individuals where serology might be confounded by passively 
transferred antibodies, such as in children under 18 months of age or in patients after 
plasma transfusion. We have demonstrated before, that our stimulation based assay 
correlates closely with CMV serology in both healthy and immunocompromised individuals. 
As T cells are not transferred from mother to child during pregnancy or by plasma 
transfusion, we postulated that assessing CMV specific CD4 T cells will indicate the true 
infection status in individuals with passively transferred antibodies. A medical thesis by 
Marion Ritter in our department, to which I contributed in supervising and study design, 
revealed a perfect agreement between serostatus and CMV specific CD4 T cells in children 
over 18 months of age. In contrast, 16.7% of children under 18 months were antibody 
positive but T cell negative, indicating passively transferred immunity by their seropositive 
mothers (RITTER et al., 2013). Similarly, the case of a CMV seronegative kidney transplant 
recipient of a seropositive donor, who received human immunglobulins pre-transplant, 
revealed the dynamics of CMV specific IgG levels and CD4 T cells after plasma transfusion 
and primary CMV infection. Plasma transfusion led to a transient low-titer seroconversion in 
the first weeks post-transplant, whereas CMV specific CD4 T cells and CMV-DNA remained 
undetectable. At the time of CMV primary infection (week 25 post-transplant), CMV specific 
IgG were decreased to undetectable levels. CMV specific immunity after primary infection 
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was established by the successive onset of CMV specific T cells and IgG (SCHMIDT et al., 
2012b). This indicates that analysis of CMV specific T cells might be a valuable tool to 
correctly assign the CMV infection status in patients with presumed passively transferred 
CMV specific antibodies (EMERY, 2013; KOTTON et al., 2013b).  
If the results from this thesis were to be confirmed in larger studies, monitoring of inhibitory 
T cell receptor expression on CD28-CD27- and/or CMV specific CD4 T cells after stimulation 
might be a potent tool to assign the individual infection state, to personalise antiviral 
therapy post-transplant and to determine individual monitoring intervals during follow up.  
4.2 Immune-based assays for diagnosis of active M. tuberculosis infection  
Cell-mediated immunity assays such as the commercially available ELISA based QuantiFERON 
TB gold in tube test and the ELISPOT based T-SPOT.TB assay are superior to the classical 
tuberculin skin test by their ability to discriminate between BCG vaccination response and 
actual infection with M. tuberculosis bacteria (HINKS et al., 2009; LALVANI, 2007; SESTER et 
al., 2011a). Yet at present, they are not able to distinguish between patients with active  
M. tuberculosis infection and those with latent or successfully treated infection (SESTER et 
al., 2011a). We and others demonstrated before that a shift in cytokine profiling and a loss 
of CD27 expression on M. tuberculosis specific T cells correlate with disease activity (HARARI 
et al., 2011; NEMETH et al., 2012; SCHUETZ et al., 2011; SESTER et al., 2011b; STREITZ et al., 
2012; STREITZ et al., 2007). As the expression of inhibitory T cell receptors correlates closely 
with disease activity in CMV and other chronic viral infections, we compared cytokine 
profiling and CD27 expression analysis with analysis of CTLA-4 expression on M. tuberculosis 
specific T cells. Indeed, similar to our observations in CMV viremic patients, we observed an 
increased CTLA-4 expression in patients with active disease.  
ROC analyses indicate that determination of CD27 expression alone is superior to cytokine 
profiling or CTLA-4 analysis for diagnosing active M. tuberculosis infection (Table 13). Of note, 
the combined analysis of CD27 with CTLA-4 but not with cytokine profiling further increased 
diagnostic power (Table 13). To our knowledge, we are the first to show that an increased 
CTLA-4 expression is indicative of active M. tuberculosis infection. Even though being limited 
by small patient numbers, our data indicate that the combined analysis of CD27 and CTLA-4 
expression may serve as a potent diagnostic marker to identify patients with active  
M. tuberculosis infection with notably higher diagnostic power than other biomarkers 
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reported before (HARARI et al., 2011; NEMETH et al., 2012; SCHUETZ et al., 2011; SESTER et 
al., 2011b; STREITZ et al., 2012; STREITZ et al., 2007). The combinatorial effect might be in 
part explained by the different physiological roles of both markers. Whereas CD27 is a co-
stimulatory receptor that is needed for the activation of naïve or central memory T cells, it is 
lost on cells with an effector-memory phenotype (HASHIMOTO-OKADA et al., 2009; KOBATA 
et al., 1994; MAHNKE et al., 2013). Interestingly, studies in mice and men showed that CD27 
expression on M. tuberculosis specific T cells was lost at the site of infection (KAPINA et al., 
2007; LYADOVA et al., 2004; NEMETH et al., 2012; NIKITINA et al., 2012). Whereas CD27 
negative M. tuberculosis specific T cells remain in the lungs in controlled infection, they are 
detectable in peripheral blood in active disease and their frequency correlates with the 
degree of tissue destruction (NIKITINA et al., 2012). Unlike CD27, CTLA-4 as an inhibitory  
T cell receptor has the physiological role to down-regulate T cell responses after antigen 
encounter (KRUMMEL, ALLISON, 1995; ODORIZZI, WHERRY, 2012). CTLA-4 expression seems 
to be induced at higher levels in primary immune responses compared to boosting of pre-
existing immunity in response to reactivations, as was also shown for CMV primary infection 
and reactivation. Hence, one might speculate that CTLA-4 expression in patients with 
primary M. tuberculosis infection may be higher as compared to patients suffering from 
reactivation of a latent infection. Interestingly, among the patients with active M. 
tuberculosis infection analysed during this thesis, there was only one seven-year-old child 
who was assumed to have contracted M. tuberculosis by its uncle diagnosed with active 
tuberculosis before. This child was distinct, as its PPD-reactive T cells not only expressed high 
levels of CTLA-4 but also of CD27, which might be due to a primary infection with  
M. tuberculosis. In contrast, reactivation from latent infection and more chronic infection 
stages might rather be characterised by a loss in CD27 expression. It is thus tempting to 
explore the use of CTLA-4 as a marker of primary infection in combination with CD27 as a 
marker of disease chronicity. The benefit of combined analyses of CTLA-4 and CD27 
expression on PPD-reactive CD4 T cells would need to be addressed by future studies, where 
the time of infection can be determined precisely and pre-existing immunity is taken into 
account. However, as it is generally difficult to determine the exact time point of primary  
M. tuberculosis infection in humans, one might have to look at alternative approaches. One 
possible approach could be to longitudinally monitor the induction of primary immune 
responses in bladder cancer patients before and after treatment with live bacillus Calmette-
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Guérin (BCG) instillation. The antitumor effect of BCG instillation is mediated by a strong 
innate immune response in the bladder, followed by infiltration of T cells (BOHLE, BRANDAU, 
2003; BRANDAU, SUTTMANN, 2007; HIGUCHI et al., 2009). Although the therapeutic activity 
is restricted to the bladder, mouse models indicate that live bacilli enter bladder-draining 
lymph nodes where T cell priming is initiated (BIOT et al., 2012). This suggests that local BCG-
instillation may be associated with a systemic induction of specific T cells and serve as a 
model to study the induction of mycobacterial immunity after defined antigen contact in 
humans. Indeed, our group recently demonstrated that therapy-induced PPD specific CD4  
T cells in patients with and without pre-existing immunity showed functional differences. 
Patients without pre-existing immunity which may be considered as individuals with BCG-
primary infection showed a dominance of IL-2 single producing over IFN single producing 
cells, whereas this relation was inverted in patients with pre-existing immunity (ELSASSER et 
al., 2013). It is tempting to speculate, whether this difference in cytokine profiles is also 
associated with differences in CD27 and CTLA-4 expression and if those markers correlate 
with progression to active disease. 
As the progression to active M. tuberculosis infection only occurs in 5 to 10 percent of 
individuals with latent infection, chemoprophylaxis and chemoprevention of latent infection 
are only recommended in situations of increased risk, such as close contact to a patient with 
active disease or relevant degree of immunosuppression (DIEL et al., 2009; DIEL et al., 2011). 
Up to now, current measures to estimate the individual risk of a patient to progress from 
latent infection to active tuberculosis only have considerably low positive predictive values, 
and therefore it is unclear who will specifically benefit from preventive chemotherapy. In 
tuberculosis contact tracing it is recommended to treat every contact person with immunity 
towards M. tuberculosis specific antigens, even though in many cases the measured immune 
response might not represent a de novo infection but rather a pre-existing immune response 
towards an immunological well contained previous infection. This suggests that currently 
considerably more patients are treated than actually needed. Indeed, a study by Diel et al 
showed that in TB contact tracing the number of patients treated to prevent one TB case 
was 22 for the ELISA-based QuantiFERON assay, and 40 for the tuberculin skin test at a 
cutoff induration size of 10 mm (DIEL et al., 2007). These low positive predictive values of 
both skin test and IFN based assays emphasise the need for alternative biomarkers to 
minimize unneeded treatment and treatment costs. Potential biomarkers would be the 
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above described T cell cytokine profiles and cell surface markers (HARARI et al., 2011; 
NEMETH et al., 2012; SCHUETZ et al., 2011; SESTER et al., 2011b; STREITZ et al., 2012; 
STREITZ et al., 2007) as well as chemokines such as IP-10 or MCP-2 which are produced by 
cells of the myeloid lineage after M. tuberculosis specific stimulation (RUHWALD et al., 2009). 
Another promising approach is the use of novel M. tuberculosis antigens or peptide pools 
which seem to correlate with different M. tuberculosis infection states (DEMISSIE et al., 
2006; DOSANJH et al., 2011; VINCENTI et al., 2003). Yet, all these markers still need 
validation in larger clinical studies and to date there is no biomarker which can predict 
progression from latent to active M. tuberculosis infection with a satisfyingly high positive 
predictive value.  
To further address this issue, we performed IFN/IL-2 cytokine profiling in parallel with  
CTLA-4 and CD27 expression analyses on PPD specific CD4 T cells in a subset of latently 
infected individuals with known recent exposure to M. tuberculosis or clinical risk factors for 
progression. Our analysis revealed that more than half (52%) of these individuals were below 
the threshold for active disease for all three markers analysed (Figure 26). Although, we do 
not have any clinical follow-up data of these individuals, it is tempting to speculate whether 
preventive chemotherapy might not have been necessary for these individuals, yet 
immunological and radiological monitoring would be advisable. Because of therapy duration, 
costs and possible side effects of preventive chemotherapy, biomarkers with higher positive 
predictive values would be of great benefit to the individual patient as well as the healthcare 
system in general. If future studies confirmed that immunological markers such as cytokine 
profiling, CTLA-4 and CD27 indeed were able to more precisely assess the risk for 
progression to active disease, they would be powerful tools to facilitate clinical decision 
making on initiation of preventive chemotherapy in the setting of contact tracing. 
4.3 Influence of pathogen prevalence on antigen specific immunity in 
immunocompromised patients 
In HIV infected individuals, the ongoing HIV replication and virus induced cell death during 
acute HIV-infection results in massive depletion of memory CD4 T cells at mucosal sites that 
can be partially restored, in particular under antiretroviral therapy (ART) (GELDMACHER et 
al., 2008; GUIHOT et al., 2011). Similarly, an increased turnover in the patients T cell pool 
occurs in stem cell transplant recipients or in solid organ transplant recipients after anti-
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thymocyte-globulin (ATG) induction therapy (CHANG et al., 2014; GUILLAUME et al., 1998; 
PAGE et al., 2013). We have assessed the frequencies of antigen specific T cells towards CMV 
and M. tuberculosis in HIV infected individuals in tuberculosis high and low endemic 
countries to elucidate the influence of exogenous and endogenous antigen re-challenge on 
replenishment of antigen specific immune responses after initial HIV mediated T cell 
depletion. Our results showed that PPD reactive T cell frequencies were higher in 
tuberculosis high than low endemic countries (Figure 29). In line with this evidence and with 
results from immunocompetent individuals (SESTER et al., 2011b), an even stronger 
mycobacterial challenge during active tuberculosis was associated with a further increase in 
PPD specific CD4 T cell frequencies. Consequently, immunity towards a persistent pathogen 
such as CMV that poses a constant antigenic challenge to the immune system should not 
differ in magnitude between the two groups. Indeed, T cell immunity toward CMV or the 
bacterial superantigen SEB was detectable in patients and controls from both low and high 
tuberculosis endemic areas (Figure 29). Together, these data suggest a constant skewing and 
restriction of specific T cell immunity toward environmental antigens in HIV infected 
individuals, where either endogenous or exogenous antigen re-challenge is needed to 
expand T cells with defined specificities from few pre-existing memory T cell clones.  
In general, PPD specific immunity wanes in the absence of re-exposure, but this is rather a 
slow process that occurs over decades (GUIHOT et al., 2011). Hence, the relative 
maintenance of PPD specific immunity in healthy controls is a common observation even in 
low endemic countries such as Germany where frequent exposure to M. tuberculosis is 
unlikely. Measurable PPD specific immunity is observed not only in immunocompetent 
controls but also in patients with other types of immunodeficiency such as chronic renal 
failure or renal transplant recipients (SESTER et al., 2004; SESTER et al., 2006). Thus, given 
that HIV infection is usually acquired later in life and that HIV infected individuals were 
recruited from the same geographic region as controls, one would primarily expect similar 
levels of PPD specific T cells as in controls or other immunocompromised groups. As there 
were no differences in ethnicity and countries of origin between controls and HIV infected 
individuals in Germany, the lower frequency of PPD specific T cells is a particular feature of 
HIV related immunosuppression in low-prevalence regions and generally indicates a loss of  
T cell specificities that are not urgently needed to control environmental or persistent 
pathogens. In line with this evidence, results from HIV infected patients in Tanzania show 
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that PPD reactive T cells are maintained in areas of higher M. tuberculosis endemicity. Our 
observations are compatible with current views of HIV-pathogenesis and maintenance of 
antigen specific memory CD4 T cells in long-term HIV infected patients under antiretroviral 
therapy (GUIHOT et al., 2011). While HIV infection leads to a profound depletion of CD4  
T cells already during the primary infection phase (BRENCHLEY et al., 2004; MEHANDRU et 
al., 2004), subsequent treatment restores antigen specific responses that mediate protection 
against opportunistic agents (GUIHOT et al., 2011). The trigger that determines the antigen 
specificity of the recovering immunity seems to be environmental exposure to the antigen 
itself or other cross-reacting antigens. In support of this, antiretroviral therapy in vaccinia 
vaccinated patients did not lead to a full recovery of memory T cells specific for smallpox, a 
now eradicated virus (PUISSANT-LUBRANO et al., 2009), whereas T cell responses against 
CMV, a persistent viral pathogen, were readily restored (PUISSANT-LUBRANO et al., 2009; 
SESTER et al., 2007). A similar dependence on antigen has been shown for specific T cell 
responses recovering after profound lymphopenia in allogeneic stem-cell transplant 
recipients, where early expansion of donor-derived CMV specific T cell clones in a recipient 
was observed only when the recipient was CMV seropositive (GANDHI et al., 2003). Thus, 
exposure to antigen is the key determinant of a measurable T cell response in HIV 
seropositive individuals. 
In conclusion, the antigen specific T cell repertoire in chronically HIV infected individuals 
seems to be skewed towards environmentally present antigens. Thus, pathogen prevalence 
may critically influence the specificity of this recovering repertoire in HIV infected individuals. 
This could have important implications for future vaccination strategies and risk assessment 
of infectious complications in HIV patients and other immunocompromised patient groups. 
Whether the observed differences in the levels of PPD specific immunity in HIV infected 
individuals from low and high endemic regions may translate into differences in the control 
of M. tuberculosis after re-exposure merits further study. 
4.4 Concluding remarks on chances and limitations of flow cytometry based 
phenotypical and functional characterisation of antigen specific immune responses 
The exclusive quantitation of antigen specific immunity has proven valuable in assigning the 
infection status in several chronic infections, yet it is only of limited value to determine 
disease activity or predict reactivation episodes. As demonstrated in this thesis, phenotypical 
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and functional characterisation of antigen specific T cells allows assessment of the quality of 
the patients’ pathogen specific immunity. It can be applied not only to determine the 
patients’ infection state but also to assess disease activity and severity. This may in future be 
exploited to improve diagnosis of infectious diseases, to identify patients with increased risk 
for complications and to monitor therapy response and success. Our data show that a 
meaningful combination of phenotypical and functional biomarkers on antigen specific  
T cells may considerably improve power to diagnose active disease, compared to mere 
quantitative analysis. Additionally, our 6 hour stimulation-based assay needs less time and 
blood volume than the commercially available ELISA and ELISPOT assays, which makes it 
attractive for routine diagnostics. Apart from specific immunity towards CMV and  
M. tuberculosis, the assay principle can also be applied to monitoring immunity towards 
other pathogens such as HIV, adenovirus, human herpesvirus-8, varicella zoster virus, 
seasonal and pandemic influenza, and BK polyomavirus (LÖNARD et al., 2007; SCHMIDT et al., 
2014; SCHMIDT et al., 2012a; SCHUB et al., 2012; SESTER et al., 2002a; SESTER et al., 2000) 
or vaccine antigens (SCHMIDT et al., 2012a; SESTER et al., 2013). The phenotypical 
characterisation of CD28-CD27- CD4 T cells for assessment of CMV associated T cell immunity 
further reduces assay complexity, costs, sample volumes and logistical limitations, which 
should facilitate a broader, multicentre application.  
One possible limitation of using multiparameter analyses for widespread clinical application 
is the need for access to a flow cytometer, yet in most university hospitals and diagnostic 
laboratories flow cytometry is already used since decades for diagnostics of hematologic 
diseases (ORFAO et al., 1995). Another possible limitation of flow cytometry often discussed 
is the assumed lack of standardisation between centres and individual devices. However, the 
development of fluorophore-coated calibration beads, together with standard operating 
procedures enable standardisation between different sites and virtually all available 
cytometer platforms (MAECKER et al., 2010; PERFETTO et al., 2012). Furthermore, recently 
available software tools for automated data analysis may prove helpful to facilitate analyses 
of multicolour experiments across several centers and avoid operator bias (COSTA et al., 
2010; QIU et al., 2011). A combination of the above was used by the “EuroFlow” consortium 
aimed at standardising flow cytometric diagnostics in the area of hematologic diseases. The 
consortium achieved standardisation of staining protocols and instrument setups in 18 
diagnostic research groups to a level that allowed storage, management and subsequent 
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analysis of flow cytometry raw data in a shared data base (KALINA et al., 2012; VAN DONGEN 
et al., 2012a; VAN DONGEN et al., 2012b). In the future the described or similar approaches 
can be used to synchronize multicentre studies to define universal diagnostic thresholds or 
detection limits, and to facilitate the exchange of scientific outcome between laboratories.  
In conclusion, this thesis highlights the potential of combined functional and phenotypical 
analysis of pathogen specific T cell immunity via flow cytometry to improve diagnostics of 
active infections and to facilitate clinical decision making by monitoring treatment response 
and success. As a future perspective, the diagnostic value of the presented results needs to 
be validated by multicentre clinical trials where clinical decisions will be based upon the 
results of the presented assays. 
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active tuberculosis from successfully treated disease 
Poster presentation at the Annual meeting of the Society of Internal Medicine in 
Saarland and Rhineland-Palatinate in Neustadt, Germany, 03.2009 
2. Dirks, J., Sester, U., Gärtner, B., Sester, M. 
Novel phenotypical and functional markers on CMV specific T cells as predictors of CMV 
viremia after renal transplantation 
Poster presentation at the American Transplant Congress in San Diego, USA, 05.2010 
3. Dirks, J., Schuetz, A., Sester, A., Haule, A., Geldmacher, C., Elias, N., Schindler, K., Sanga, 
E., Maboko, L., Minja, F., Samky, E., Reither, K., Hoelscher, M., Meyerhans, A., Sester, M. 
Pathogen prevalence may determine maintenance of antigen specific T cell responses in 
HIV infected individuals 
Oral presentation at the annual meeting of the European Respiratory Society in 
Barcelona, Spain, 09. 2010 
4. Dirks, J., Tas, H., Schmidt, T., Kirsch, S., Gärtner, B,. Sester, U., Sester, M. 
Combined analysis of multiple inhibitory T cell receptors on cytomegalovirus specific CD4 
T cells allows identification of patients at risk for viral reactivation after transplantation 
Oral presentation at the 24th International Congress of the Transplant Society in Berlin, 
Germany, 07.2012 
5. Dirks, J., Tas, H., Schmidt, T., Kirsch, S., Gärtner, B., Sester, U., Sester, M. 
PD-1 analysis on CD28-CD27- CD4 T cells allows rapid stimulation-independent 
assessment of CMV-viremic episodes in transplant recipients 
Plenary session talk at the American Transplant Congress in Seattle, USA, 05.2013
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Upcoming presentation 
6. Dirks, J., Fousse, M., Sester, U., Sester, M. 
Combined phenotypical and functional analysis of M. tuberculosis specific immunity for 
diagnosing active infection and risk assessment in latently infected individuals 
Oral presentation at the Annual Meeting of the European Respiratory Society in Munich, 
Germany, 09.2014 
 
6.4 Scientific awards 
03.2009: Poster award 
Flow cytometric analysis of antigen-specific CD4 T cell cytokine profiles 
distinguishes active tuberculosis from successfully treated disease  
Annual meeting of the society of internal medicine in Saarland and Rhineland-
Palatinate 
09.2010: Young investigator award  
Pathogen prevalence may determine maintenance of antigen-specific T cell 
responses in HIV-infected individuals 
Annual meeting of the European Respiratory Society (ERS) in Barcelona, Spain 
06.2011: Invited as a young researcher to the Lindau Nobel Laureate Meeting dedicated 
to Physiology or Medicine, Lindau, Germany 
05.2013: Young investigator award and oral presentation in plenary session 
PD-1 analysis on CD28-CD27- CD4 T cells allows rapid stimulation-independent 
assessment of CMV-viremic episodes in transplant recipients  
Annual meeting of the American Transplantation Society (ATC) in Seattle, USA 
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